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1.0 ABSTRACT 
Growth differentiation factor-5 (GDF-5) is a member of the transforming growth factor-
 superfamily, a family of proteins that play diverse roles in many aspects of cell 
growth, proliferation and differentiation.  GDF-5 has also been shown to be a trophic 
factor for embryonic midbrain dopaminergic neurons in vitro (Krieglstein et al. 1995) 
and after transplantation to adult rats in vivo (Sullivan et al. 1998).  GDF-5 has also been 
shown to have neuroprotective and neurorestorative effects on adult dopaminergic 
neurons in the substantia nigra in animal models of Parkinson’s disease (Sullivan et al. 
1997, 1999; Hurley et al. 2004).  This experimental evidence has lead to GDF-5 being 
proposed as a neurotrophic factor with potential for use in the treatment of Parkinson’s 
disease.  However, it is not know if GDF-5 is expressed in the brain and whether it plays 
a role in dopaminergic neuron development.  The experiments presented here aim to 
address these questions.  To that end this thesis is divided into five separate studies each 
addressing a particular question associated with GDF-5 and its expression patterns and 
roles during the development of the rat midbrain. 
Expression of the GDF-5 in the developing rat ventral mesencephalon (VM) was 
found to begin at E12 and peak on E14, the day that dopaminergic neurons undergo 
terminal differentiation.  In the adult rat, GDF-5 was found to be restricted to heart and 
brain, being expressed in many areas of the brain, including striatum and midbrain. This 
indicated a role for GDF-5 in the development and maintenance of dopaminergic 
neurons.   
The appropriate receptors for GDF-5 (BMPR-II and BMPR-Ib) were found to be 
expressed at high levels in the rat VM at E14 and BMPR-II expression was 
demonstrated on dopaminergic neurons in the E13 mouse VM.  GDF-5 resulted in a 
three-fold increase in the numbers of dopaminergic neurons in cultures of E14 rat VM, 
without affecting the numbers of neurones or total cells.  GDF-5 was found to increase 
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the proportion of neurons that were dopaminergic.  The numbers of Nurr1-positive cells 
were not affected by GDF-5 treatment, but GDF-5 did increase the numbers of Nurr1-
positive cells that expressed tyrosine hydroxylase (TH).  Taken together this data 
indicated that GDF-5 increases the conversion of Nurr1-positive, TH-negative cells to 
Nurr1-positive, TH-positive cells.  In GDF-5 treated cultures, total neurite length, 
neurite arborisation and somal area of dopaminergic were all significantly increased 
compared to control cultures.  Thus this study showed that GDF-5 increased the 
numbers and morphological differentiation of VM dopaminergic neurones in vitro. 
In order to examine if GDF-5 could induce a dopaminergic phenotype in neural 
progenitor cells, neurosphere cultures prepared from embryonic rat VM were 
established.  The effect of the gestational age of the donor VM on the proportion of cell 
types generated from neurospheres from E12, E13 and E14 VM was examined.  
Dopaminergic neurons could only be generated from neurospheres which were prepared 
from E12 VM.  Thus in subsequent studies the effect of GDF-5 on dopaminergic 
induction was examined in progentior cell cultures prepared from the E12 rat VM.   
In primary cultures of E12 rat VM, GDF-5 increased the numbers of TH-positive 
cells without affecting the proliferation or survival of these cells.  In cultures of 
expanded neural progenitor cells from the E12 rat VM, GDF-5 increased the expression 
of Nurr1 and TH, an action that was dependent on signalling through the BMPR-Ib 
receptor. 
Taken together, these experiments provide evidence that GDF-5 is expressed in 
the developing rat VM, is involved in both the induction of a dopaminergic phenotype in 
cells of the VM and in the subsequent morphological development of these 
dopaminergic neurons.  
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2.0 ABBREVIATIONS 
 
AA  ascorbic acid 
Act  activin 
ActR  activin receptor 
AM  adrenal medulla 
ANOVA analysis of variance 
APS  ammonium persulphate 
BDNF  brain derived neurotrophic factor 
BMP  bone morphogenetic protein  
BMPR bone morphogenetic protein 
BMSC  bone marrow stromal cells 
bp  brachypodism 
Brd-U  5-Bromo-2-deoxyuridine 
BSA  bovine serum albumin 
ca  constitutively active 
CB  carotid body 
CHO  chinese hamster ovary 
Co-smad common mediator smad 
CREB  cAMP responsive element binding 
CBP  cAMP responsive element binding-binding protein 
DIV  days in vitro 
DMEM dulbecco's minimal essential medium 
DVR  Dpp-Vgr1-related 
E  embryonic day 
EGF  epidermal growth factor 
EMEM eagle minimum essential medium  
FCS  foetal calf serum 
FGF-2  fibroblast growth factor 
GABA  gamma-amino-butyric acid 
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GDF  growth differentiation factor  
GDNF  glial cell line-derived neurotrophic factor  
GFAP  glial fibrillary acidic protein 
GPe  Globis pallidus external segment 
GPi  Globis pallidus internal segment 
h  hour 
HBSS  Hank's balanced salts solution  
HLH  helix-loop-helix 
HRP  horseradish peroxidase 
I-smad inhibitory smad 
IL  interleukin 
LIF  leukemia inhibitory factor 
M  molarity 
MAO  monoamine oxidase 
MBP  myelin basic protein 
MH  mad homology 
MIC  macrophage inhibiting cytokine 
min  minute 
MPP
+
  n-methyl-4-phenylpyridinium ion  
MPTP  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MRI  magnetic resonance imaging 
N  number 
NGS  normal goat serum 
nNOS  neuronal nitric oxide synthase 
NO  nitric oxide 
NPC  neural progenitor cells 
NSC  neural stem cells 
6-OHDA 6-hydroxydopamine 
p  probability 
P  postnatal day 
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PD  parkinson’s disease 
PBS  phosphate buffered saline 
PBS-T  phosphate buffered saline with Tween-20  
PVDF  polyvinylidene difluoride 
R-smad receptor activated smad 
rh  recombinant human 
RPE  retinal pigmented epithelium 
SD  standard deviation 
SDS  sodium dodecyl sulphate 
SE  standard error  
Shh  sonic hedgehog 
SN  substantia nigra 
SOD  superoxide dismutase 
STN  subthalamic nucleus 
SVZ  subventricular zone 
TGF- transforming growth factor- 
TH  tyrosine hydroxylase 
VM  ventral mesencephalon 
VZ  ventricular zone 
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3.0 INTRODUCTION 
 
3.1 Parkinsons Disease 
First described by James Parkinson in 1817, the disease has since come to bear his name 
(Parkinson 2002).  Parkinson’s disease (PD) is a slowly progressing neurodegenerative 
disorder, the pathological hallmark of which involves degeneration of dopaminergic 
neurons in the substantia nigra (SN) of the midbrain (A9 group of neurons)  (Jellinger et 
al. 1991).  The disease has been reported to affect 0.1% of the total population and 
approximately 1% of the population over 65 years of age (for review see Marsden 
1994).  The degeneration of these neurons leads to a loss of dopaminergic innervation of 
the striatum and consequently reduced dopamine levels in the striatum (Llyod and 
Hornykiewicz 1970).  The SN is part of a group of subcortical nuclei called the basal 
ganglia, comprising the striatum (or caudate/putamen), the globus pallidus (internal 
(GPi) and external (GPe) segments), the subthalmic nucleus (STN), the thalamus, the 
pedunculopontine nucleus and the SN (Alexander and Delong 1990).  The basal ganglia 
can be viewed as part of a larger cortico-basal gangli-thalmo-cortical pathway that is 
responsible for mediating voluntary movement (Alexander and Delong 1990).  In PD, 
the loss of dopaminergic neurons in the SN results in overactivity of the output nuclei of 
the basal ganglia, the STN and the GPi.  As these structures use the inhibitory 
neurotransmitter gamma-amino-butyric acid (GABA), the overactivity of these nuclei 
leads to excessive inhibition of thalamic nuclei, which leads to inhibition of the cortical 
motor system, resulting in the three classical symptoms of PD, bradykinesia (slowness 
of movement), akinesia (difficulty to initiate movement) and resting tremor (for reviews 
see Alexander and Delong 1990, Bonnet and Houeto 1999).  It is believed that inhibitory 
descending projections to the brainstem nuclei, namely the pedunculopontine nucleus, 
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the superior colliculus and the mesopontine tegmentum is responsible for abnormalities 
in posture and gait (Parent and Cicchetti 1998). 
 
3.1.1 Etiology  
Although the pathology of PD has been well characterised, the etiology of this disease is 
unknown.  However, a number of factors have been shown to increase the risk of 
developing PD.  These include exposure to well water, herbicides, pesticides, industrial 
chemicals, wood pulp mills farming and rural environments (for review see Tanner and 
Langston 1990).  However, no specific environmental or chemical agents can be directly 
attributed as the causative agent for PD.  The argument that exogenous toxins are 
responsible for PD was strengthened by the discovery of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP).  MPTP is a byproduct of the chemical synthesis of an 
analogue of the opiate, meperidine (Langston et al. 1983).  Drug addicts who took opiate 
preparations containing MPTP developed a condition that strikingly resembled PD at the 
clinical and pathological level (Langston et al. 1983).  In recent years it has emerged 
that MPTP crosses the blood brain barrier and is converted to N-methyl-4-
phenylpyridine (MPP+) by monoamine oxidase B (MAO-B) in astrocytes (Singer et al. 
1987).  It is selectively taken up by dopamine neurons in the SN, where it causes a 
defect in complex I of the mitochondrial respiratory chain, which is similar to that found 
in PD (Nicklas et al. 1985, Singer et al. 1987, Schapira et al. 1990).  MPP+ has been 
shown to induce apoptotic neuronal death in cultures of the embryonic rat midbrain 
(Mytilineou et al. 1985) and in the human dopaminergic cell line SH-SY5Y (Itano and 
Nomura 1995).  As apoptosis has been detected in the SN of PD patients (Mochizuki et 
al. 1996, Anglade et al.  1997), it is now thought that MPP+ induced parkinsonism 
results from apoptosis of dopaminergic neurons of the SN through a blocakage of 
complex I of the mitochondrial respiratory chain (Fall and Bennett 1999).  These 
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findings suggest that certain environmental toxins may mimic the action of 
MPTP/MPP+ and be responsible for at least some cases of idiopathetic PD (for review 
see Di Monte et al. 2002, for detailed review of mechanisms of MPTP neurotoxicity see 
Przedborski and Vila 2001).    
 
3.1.2 Genetic factors 
Although the majority of PD cases are idiopathetic, it has emerged that approximately 5-
10% of all cases are genetic in origin (for review see Pankratz and Foroud 2004).  A 
large number of DNA polymorphisms have been studied in the search for a genetic risk 
factor for PD.  However, polymorphisms in many genes found in some PD cases have 
been shown not to confer an increased risk of PD, while others do confer an increased 
risk (for a complete list, see Mizuno et al. 1999, Pankratz and Fourod 2004).  Because a 
defect in complex I of the mitochondrial respiratory chain has been found in PD 
(Nicklas et al. 1985), extensive searching of the mitochondrial genome for mutations 
associated with the disease was performed.  A polymorphorism in manganese-
containing superoxide dismutase was found to be a risk factor for PD (for review see 
Mizuno et al. 1999, Pankratz and Fourod 2004), but no disease-specific mutation in the 
mitochondrial genome has been identified.  Although a large number of families have 
been identified in which members in different generations suffer from PD (for review 
see Duvoisin et al. 1998, Mizuno et al. 1999, Pankratz and Fourod 2004), disease-
causing mutations in specific genes of known function have been difficult to identify.  A 
few exceptions have been the identification of mutations in genes encoding -synuclein 
(Polymeropoulos et al. 1997), parkin (Kitada et al. 1998), UCH-L1 (Leroy et al 1998) 
and tau (Hutton et al. 1998), which have been shown to be responsible for PD in certain 
families (for review see Olanow and Tatton 1999, Skipper and Farrer 2002). 
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3.2 Pathogenesis of Parkinson’s disease 
While in most cases the causes of idiopathetic PD are unknown, a number of different 
mechanisms have been shown to be involved in the pathogenesis of PD.  These include 
oxidative stress, mitochondrial dysfunction and excitotoxicity. 
 
3.2.1 Oxidative stress 
Oxidative stress was proposed as a major factor in the pathogenesis of PD after it 
became known that the metabolism of dopamine can generate hydrogen peroxide. 
Hydrogen peroxidase can interact with iron, generating reactive oxygen species and lead 
to oxidative damage and cell death (for review see Olanow and Tatton 1999).  Free 
hydrogen peroxidase is normally cleared by reduced glutathione.  A role for oxidative 
stress in the pathogenesis of PD was strengthened when it was shown that free iron 
levels are increased in the SN of PD patients (for review see Olanow and Youdim 1996).  
Furthermore when infused into the SN of rodents it caused progressive degeneration of 
SN dopaminergic neurons (Sengstock et al. 1993).  Reduced glutathione levels and 
evidence of oxidative damage have also been found in the SN of PD patients (for review 
see Olanow and Tatton 1999), suggesting that oxidative damage is a contributing factor 
in the pathogenesis of PD.  Whether is it the primary causative agent or it occurs 
secondary to an alternate etiology remains to be determined. 
 
3.2.2 Mitochondrial dysfunction 
A decrease in complex I activity of the mitochondrial respiratory chain has been found 
in the SN of PD patients (Nicklas et al. 1985, Schapira et al. 1990).  It has been shown 
that blockage of complex 1 of the mitochondrial electron transport chain by MPP+ leads 
to depletion of cellular ATP levels, ultimately leading to apoptosis (Song et al. 1997).  It 
has also been proposed that inhibition of the mitochondrial electron transport chain by 
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MPP+ leads to the leakage of the superoxide anion, O2¯ (Przedborski et al. 1996) and of 
Ca
2+
 (Packer et al. 1996).  This Ca
2+ 
rise inside the cell may lead to the activation of 
Ca
2+
 -dependent enzymes, such as neuronal nitric oxide synthase (nNOS), leading to the 
production of nitric oxide (NO).  It has also been shown that O2
-
 reacts with NO
-
, 
generating peroxynitrite (Packer et al 1996, for review see Schulz et al. 1997).  The key 
role that Ca
2+
 and nNOS play in the toxicity of MPP+ was shown in a study that 
demonstrated that pretreatment with nitro-L-arginine (an nNOS inhibitor) or the NMDA 
channel blocker, MK-801 (which prevents Ca
2+
 efflux), blocked the increase of 
hydroxyl radicals (OH
-
) induced by MPTP administration to mice (Smith and Bennett 
1997).  These studies on MPP+ supported the theory that a defect in complex I, as has 
been found in PD patients (Nicklas et al. 1985, Schapira et al. 1990), can cause cell 
death and is likely to be involved in the pathogenesis of PD. 
 
3.2.3 Excitotoxicity 
The SN receives extensive glutamatergic innervation from the STN (Alexander and 
Delong 1990).  Lesions of the STN have been shown to increase the firing rate of 
glutamatergic neurons to the SN (for review see Delong 1990), leading to direct 
excitotoxic damage.  A second mechanism proposed to be involved in excitotoxic 
damage in PD is that a defect in mitochondrial energy metabolism could secondarily 
lead to slow excitotoxic neuronal death by making SN dopaminergic neurons more 
vulnerable to endogenous glutamate.  It has been shown that NMDA antagonists can 
block the neurodegeneration induced by MPP+ in dopaminergic neurons (for review see 
Beal 1992).  These studies suggest that excitotoxicity is likely to play a role in the 
pathogenesis of PD, but whether it is the primary causative agent or a secondary process 
remains to be determined (for review see Olanow and Tatton 1999). 
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3.3 Existing treatments for PD 
Current treatments for PD treat the symptoms of the disease.  They do not affect the 
pathological process, which continues unabated while the treatments are being taken.  
Existing treatments can be defined into two broad classes; drug treatment and surgical 
treatment. 
 
3.3.1 Drug treatment 
The main therapeutic drug used to control the symptoms of PD is L-dopa, the precursor 
of dopamine.  Unlike dopamine, L-dopa crosses the blood brain barrier and is converted 
to dopamine within dopaminergic nerve terminals in the striatum (Adams and Victor 
1993).  In the early stages of PD, L-dopa treatment results in substantial improvements 
in symptoms, with most patients displaying a reduction in the severity of their 
symptoms (Cedarbaum et al. 1990).  It has been calculated that only approximately 1% 
of orally administered L-dopa actually crosses the blood brain barrier, with much of it 
being broken down by peripheral decarboxylases.  Thus L-dopa is usually administered 
in conjunction with a peripheral decarboxylase inhibitor (Sinemet) (Cedarbaum et al. 
1990).  Compounds which cause the release of dopamine, such as amatidine, have also 
been tested (for review see Stocchi and Olanow 2003).  Because dopaminergic nerve 
terminals continue to degenerate, dopamine agonists such as bromocryptine are now 
being used as an alternative to L-dopa (for review see for review see Stocchi and 
Olanow 2003).  Anticholinergic drugs such as Benzhexol are also used in  an attempt to 
control the increased striatal cholinergic output which results from dopaminergic 
neuronal degeneration (for review see Stocchi and Olanow 2003).  MAO-B inhibitors 
such as deprenyl and anti-oxidants such as have also been considered for future use in 
PD as MAO-B plays a role in MPP+ toxicity, thus it may be involved in the contributing 
to the ongoing degeneration seen in PD (for review see Stocchi and Olanow 2003). 
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3.3.2 Surgical treatment 
Surgical treatment for PD can be divided into ablative procedures (which involves the 
lesioning of particular brain nuclei), deep brain stimulation (use of electrical stimulation 
to mimic the effect of a lesion but without causing damage) and restorative procedures 
(which aim to replace the lost cells and address the pathological process, see below).  As 
discussed above, l-dopa therapy has been the mainstay of treatment for PD, however this 
is associated with disabling side-effects in a large number of patients (for review see 
Lang and Lozano 1998).  In patients displaying severe functional impairment with 
resting tremor that does not respond to conventional drug therapy, three ablative 
procedures can be performed, thalamotomy, pallidotomy and subthalamotomy (for 
review see Olanow 2002).  In general, thalamotomy has been used to improve unilateral 
resting tremor of the hand and involves lesioning the ventrointermediate nucleus of the 
thalamus (for review see Kupsch and Earl 1999, Olanow 2002).  It has been reported 
that thalamotomy results in improvements in resting tremor in up to 90% of cases, but 
due to adverse side effects and morbidity due to haemorrhaging at the lesion site, this 
procedure is rarely used in the present day (for review see Kupsch and Earl 1999, 
Olanow 2002).  Pallidotomy is favoured over thalamotomy because of the reported 
superior results obtained by placing lesions in the posteroventral portion of the GPi 
(Laitinen et al. 1992).  Lesions of the STN remove the hyperactive output of this nucleus 
and studies have been carried out using this technique (Gill and Heywood 1997).  Deep 
brain stimulation uses an electrical current to mimic the effects of ablative procedures.  
Its advantage over these procedures is that it does not involve permanent brain damage 
to the brain region, it is a reversible procedure and the degree and frequency of 
stimulation can be adjusted (for review see Koller et al. 1999). 
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3.4 Experimental therapies proposed for PD 
As mentioned above, existing treatments for PD provide symptomatic relief but do not 
stop the pathogenic progress or aim to replace the cells that are lost in PD.  In recent 
years extensive work has focused on addressing the above issues.  Proposed 
experimental therapies can be broadly classified into two groups;  
1. Replacing the lost dopaminergic neurons by transplantation of a population of 
dopaminergic neurons. 
2. Preventing or at least slowing the loss of dopaminergic neurons in the SN by the 
use of neurotrophic factors. 
 
3.4.1 Neural transplantation  
As previously discussed, current pharmacological and surgical therapies for PD aim to 
provide symptomatic relief for the patient and do not aim to reconstruct the damaged 
circuitry as a result of dopaminergic degeneration in the SN.  Neural transplantation 
aims to do just this, by replacing the missing dopamine neurons to restore the missing 
cells and hopefully lead to circuit reconstruction.  The idea that neural transplantation 
might be a suitable therapy for the treatment of PD emerged when it was shown that 
grafts of embryonic rat ventral mesencephalon (VM – the embryonic SN) placed in 
either the lateral ventricle (Perlow et al. 1979) or a cortical cavity of adult rats 
(Bjorklünd and Stenevi 1979) resulted in improvements in tests of motor function and 
that surviving dopaminergic neurons were present within the grafts.  It has subsequently 
been shown that the age of donor tissue (Barker et al. 1999) and the site of implantation 
of the graft within the host striatum (Dunnett et al. 1983) is critical for a functional 
effect to occur.  However although a functional improvement was seen in these initial 
grafting studies, it has subsequently emerged that the survival of the grafted neurons is 
low, with only 2-5% of the implanted cells surviving the procedure (for review see 
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Barker and Dunnett 1999).  A variety of methods have been employed in an attempt to 
increase the numbers of surviving dopaminergic neurons in transplants in animal 
studies, including optimising the tissue preparation prior to grafting (Emgard et al. 
2002), and treating the graft with a variety of agents designed to prevent cell death.  
These agents have included anti-oxidants such as the lazaroids (Nakao et al. 1994), 
caspase inhibitors (Schierle et al. 1999), calcium channel blockers (Kaminski-Schierle et 
al. 1999) and a variety of neurotrophic factors (for review see Brundin et al. 2000), one 
of the most notable being glial cell line-derived neurotrophic factor (GDNF), as 
discussed below (Lin et al. 1993, Sinclair et al. 1996). 
 
3.4.2 Adrenal medullary grafts 
The first source of tissue considered for clinical transplantation in PD was the adrenal 
medulla (AM), due to the relatively high cathecholamine content of this tissue, which 
also contains dopaminergic neurons.  The first clinical trials that were undertaken 
showed that although the grafted AM tissue resulted in an initial improvement in motor 
function, this effect was not permanent and the benefit usually disappeared after 18 
months (Cahill and Olanow 1990).  The technique was also found to cause high 
morbidity due to the two surgical procedures which were necessary; an abdominal 
procedure to obtain the AM tissue, followed by a neurosurgical approach to graft the 
tissue to the patients brain (for review see Quinn 1990).  This finding, along with 
postmortem data that showed minimal graft survival of the AM tissue (Quinn 1990), 
have lead to the technique being discontinued due to the minimal beneficial effect to the 
patient and the risk involved. 
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3.4.3 Embryonic ventral mesencephalic grafts 
The success of early grafting experiments using embryonic VM in rats (Bjorklünd and 
Stenevi 1979; Perlow et al. 1979) suggested that grafts of embryonic human VM might 
be a suitable donor tissue to use for clinical transplantation in PD.  In the first trials 
carried out, the patients showed little clinical benefit (Lindvall et al. 1989).  However, 
following refinement of the surgical techniques, studies have shown that grafted 
embryonic VM can survive in the human PD brain and integrate into the host striatum 
neural network (Lindvall et al. 1994) as well as providing long lasting relief of 
symptoms (Kordower et al. 1998).  However these did not include a placebo group, 
which was suggested to be ethically unacceptable, and this sparked a debate that still 
continues (for review see Dekkers and Boer 2001).  Results from the first double-blind 
placebo-controlled trial of transplantation of embryonic VM in PD were published in 
2001 and showed that younger patients (<60 years) improved in the years following the 
transplant while the older group (>60years) did not (Freed et al. 2001).  This trial 
provided conclusive evidence that the beneficial effect of grafting embryonic VM to the 
human PD brain was mediated by the grafted tissue.  However as shown by 
experimental studies (for review see Barker and Dunnett 1999), few of the grafted 
neurons survive the transplantation procedure.  The result of this is that approximately 
8-10 embryos are required to complete a bilateral transplant in a PD patient (Olanow et 
al. 1996) making it logistically very difficult.  Also the use of embryonic foetal tissue 
has raised ethical issues (Ferguson 1994, for review see Dekkers and Boer 2001).  As a 
result of these practical and moral difficulties, the widespread adoption of clinical 
neurotransplantation for PD is unlikely unless alternative sources of donor tissues are 
found. 
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3.4.3 Neurotrophic factor application 
A wide number of neurotrophic factors have been examined for potential use in PD.  
GDNF was initially purified from a rat glioma cell-line supernatant (Lin et al. 1993) and 
is a distant member of the transforming growth factor (TGF)-β superfamily (Krieglstein 
et al. 2002).  GDNF plays numerous roles during development outside the nervous 
system.    It acts as a morphogen in kidney development and regulates the differentiation 
of spermatogonia (for review see Airaksinen et al. 2002).  GDNF has also been shown 
to be widely expressed in the adult brain, including the striatum and SN (Springer et al. 
1994, Kawamoto et al. 2000).  Although GDNF mRNA has not been detected in the 
developing rat VM at E14 (Krieglstein et al. 1995a), GDNF has been shown to be 
crucial for the survival of post-natal midbrain dopaminergic neurons (Granholm et al. 
2000).  Also, numerous studies since the initial characterisation of GDNF have shown it 
to be a potent dopaminergic neurotrophin in vitro for E14 VM dopaminergic neurons 
(Lin et al. 1993, Krieglstein et al. 1995a, 1995b).  GDNF also improves the 
morphological development of these neurons (Widmer et al. 2000).  Subsequently it was 
shown that intrastriatal administration of GDNF in a rat model of PD partially protected 
the degenerating dopaminergic neurons and spared their terminals in the striatum 
(Sullivan et al. 1997, 1999, Hurley et al. 2004).  In non-human primates, GDNF 
administration to the striatum was shown to improve motor disabilities following MPTP 
administration (Costa et al. 2001).  As such, GDNF has been proposed as a potential 
therapeutic agent for use in the treatment of PD.  Initial results from a human trial 
showed GDNF to have no beneficial effect (Kordower et al., 1999).  However more 
recent studies have shown a clear improvement in motor functions of PD patients after 
continuous intrastriatal infusions of GDNF (Gill et al. 2003).  Use of GDNF as an 
adjunct to neural grafting, has shown that GDNF improves graft survival in animal 
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models of PD (Rosenblad et al. 1996, Sinclair et al. 1996, Wang et al. 1996, Sullivan et 
al. 1998). 
 
3.5 Alternative cell sources for PD 
Alternative sources of cells that have been considered for use in PD can be divided into 
those cells that are genetically engineered to provide molecular replacement of lost 
dopamine and those that aim to replace the lost dopaminergic neurons.   
 
3.5.1 Embryonic neural stem/progenitor cells (NPCs) 
In the developing and adult brain, neural stem cells exist which give rise to progenitor 
cells which are capable of differentiating into the major cell types of the nervous 
system- neurons, astrocytes and oligodendrocytes (for review see Gage 2000; see Figure 
3.1).  These neural stem cells have been isolated from the embryonic mouse (Reyonlds 
et al. 1992), rat (Svendsen et al. 1995) and human (Carpenter et al. 1999).  CNS stem 
cells can proliferate in culture in response to epidermal growth factor (EGF) and basic 
fibroblastic growth factor-2 (FGF-2), generating structures called “neurospheres”, which 
are free-floating spherical aggregates.  Cells in these neurospheres express the 
intermediate filament protein nestin, which is used as a marker of multipotential stem 
cells (Frederiksen et al. 1988).  Cells derived from these neurospheres can subsequently 
give rise to neurons, astrocytes and oligodendrocytes (for review see Gage 2000).  Thus 
these cells can be used to study lineage specification from neural stem cells and have the 
potential to generate cells for transplantation approaches to the treatment of 
neurodegenerative disease, including PD (for reviews see Rossi and Cattaneo 2002, 
Svendsen and Smith 1999). 
NPCs from the developing mouse (Studer et al. 1998), rodent (Ostenfeld et al. 
2002) and human (Carpenter et al. 1999, Ostenfeld et al. 2002) midbrain have been 
Figure 3.1:  
Schematic representation showing the lineage tree of a neural stem cells as it 
self-reviews to give rise to itself and lineage restricted progeny. These lineage 
restricted progeny then differentiate to generate the major cell types of the 
nervous system, that is neurons, astrocytes and oligodendrocytes.  
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shown to have the potential to differentiate into tyrosine hydroxylase (TH; the rate-
limiting enzyme involved in the synthesis of dopamine)-expressing dopaminergic 
neurons in vitro.  As such, it was proposed that transplantation of these cells to the PD 
brain would result in functioning grafts containing dopaminergic neurons.  Expanded 
human NPCs were shown to differentiate into mature neuronal and glial phenotypes 
when transplanted to the striatum of 6-hydroxydopamine (6-OHDA) lesioned rats, with 
a small number of dopaminergic neurons also being generated (Svendsen et al. 1997).  
Subsequently a number of groups have tried to enhance dopaminergic differentiation 
from NPCs.  Riaz et al. have shown that expanded human NPCs from VM of 7-8 week 
old foetuses generate approximately 12% dopaminergic neurons when induced to 
differentiate (Riaz et al. 2002).  It was shown that treatment of the cells during their 
differentiation with a combination of brain derived neurotrophic factor (BDNF; 
10ng/ml), dopamine (10M) and forskolin (10M) increased the numbers of cells 
expressing TH to approximately 60% of total cells (Riaz et al. 2002).  It has also been 
shown that BDNF, dopamine, forskolin and GDNF can induce the expression of TH in 
rat cortical NPCs (Theofilopoulos et al. 2001). Ling et al. showed that efficient 
generation of dopaminergic neurons from expanded mesencephalic rat NPCs could be 
achieved by treating the differentiating cells with interleukin (IL)-1, IL-11, leukima 
inhibitory factor (LIF) and GDNF.  Addition of this cytokine mixture, along with 
mesencephalic membrane fragments and conditioned medium from striatal cultures, 
resulted in 20-25% of the overall population being immunopositive for TH (Ling et al 
1998).  Similar cytokine mixtures have also been used to induce TH expression in 
expanded human mesencephalic NPCs, although in this study TH neurons represented 
only 1% of the total cell population (Storch et al. 2001).  Co-treatment of mouse 
embryonic striatal NPCs with FGF-2 and conditioned medium from the B49 glial cell 
line resulted in approximately 20% of the neurons expressing TH (Daadi and Weiss 
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1999).  It has also been shown that dopaminergic neurons generated from expanded rat 
NPCs exhibit the morphological and functional characteristics of embryonic VM 
dopaminergic neurons (Storch et al. 2003). 
Although previous work reporting the grafting of expanded undifferentiated 
NPCs to the striatum has shown that dopaminergic neurons can be generated in vivo 
(Svendsen et al. 1997), differentiation of the NPCs in vitro prior to grafting may be a 
more logical approach to generate large numbers of dopaminergic neurons.  One report 
documenting such an approach was published in 1998 by Studer et al., who expanded 
E12 NPCs from the rat VM for 8 DIV with 10ng/ml FGF-2 and 1% N2 before 
differentiating the cells prior to transplantation (Studer et al. 1998).  Removal of bFGF-2 
and differentiation for 7 DIV resulted in 18.7% of the total cell population expressing 
TH.  Grafting of these pre-differentiated cells to the 6-OHDA lesioned striatum of rats 
resulted in a partial amerlioration of drug-induced rotation, a test of motor function 
(Studer et al. 1998).  Wagner et al. showed that a Nurr1-overexpressing a neural stem 
cell line (c17.2) gave rise to significant amounts of dopaminergic neurons in vitro 
(Wagner et al. 1999).  Nurr1 is an orphan nuclear receptor essential for the development 
of midbrain dopaminergic neurons (Zetterstrom et al. 1997, Saucedo-Cardenas et al. 
1998).  Nurr1 overexpressing C17.2 cells co-cultured with type 1 astrocytes from the 
ventral midbrain resulted in 40-60% of the cells expressing TH (Wagner et al. 1999).  
E12 rat VM neural stem cells differentiated in low oxygen (3%) also gave rise to 
significantly higher numbers of dopaminergic neurons than cells differentiated in 
atmospheric oxygen (20%) (Studer et al. 2000).  Expanded mouse mesencephalic NPCs 
have also been shown to differentiate into dopaminergic neurons and to mediate 
behavioural recovery when transplanted to a rat model of PD (Sawamoto et al. 2001).  
These studies have shown that dopaminergic neurons generated from expanded NPCs 
could provide a realistic alternative source of tissue for transplantation in PD. 
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3.5.2 Embryonic stem (ES)- cells 
ES cells are pluripotent cells derived from the inner cell mass of the embryonic 
blastocyst.  They can be propagated in vitro and can differentiate into representative 
derivatives of all three embryonic germ layers both in vitro and in vivo (for review see 
Conley et al. 2004).  Since the demonstration that ES cells could be differentiated into 
neurons and glia (Fraichard et al. 1995, Schuldiner et al. 2001), these cells have been 
proposed as an alternative source of cells to generate dopaminergic neurons for 
transplantation approaches to PD  (Bjorklund et al. 2002).  Subsequently it has been 
shown that ES cells can generate functional dopaminergic neurons in vitro (Lee et al. 
2000).  In this study, 71% of the total cell population were neurons, with 7% of these 
neurons being TH-immunopositive.  Treatment of the differentiating ES cells with sonic 
hedgehog (Shh), FGF-2-8 and ascorbic acid (AA) increased the percentage of TH-
positive neurons to 34% (Lee et al. 2000).  Efficient generation of hindbrain 
serotonergic neurons was also reported in this study (Lee et al. 2000).  Efficient 
generation of dopaminergic neurons has also been reported by culturing ES cells on a 
layer of stromal cells (PA6), which result in 16% of the total cell population expressing 
TH (Kawasaki et al. 2000).  It has also been shown that when undifferentiated ES cells 
are transplanted to the 6-OHDA-lesioned striatum in a rat model of PD, they develop 
into functional dopaminergic neurons and serotonergic neurons (Bjorklund et al. 2002).  
The ES cell-derived dopaminergic neurons reinnervate the host brain, reduce motor 
defects and restore physiological functional magnetic resonance imaging (MRI) 
response to dopamine-releasing agents (Bjorklund et al. 2002).  However in 20% of 
cases recipient animals developed teratoma-like structures at the implantation site 
(Bjorklund et al. 2002).  An ability to control the development of these teratomas is an 
essential pre-requisite before these cells can be used in a clinical setting. One possible 
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way to circumvent this problem would be to fully differentiate the cells in vitro before 
transplantation.  Lee et al. used ES cells stably over-expressing Nurr-1 to generate 
differentiated dopaminergic neurons for transplantation to a rat model of PD (Kim et al. 
2002).  Approximately 78% of the total cell population were positive for TH when the 
Nurr-1 ES cells were treated with Shh and FGF-2-8.  These differentiated cells were 
transplanted into the striatum of 6-OHDA lesioned rats, where they innervated the host 
brain, showed electrophysiological properties expected of neurons from the midbrain 
and induced significant improvements in tests of motor defects in an eight-week period 
following transplantation (Kim et al. 2002).  Importantly, no teratomas were observed in 
this study, in contrast to that of Bjorklund et al. as described above.  However, the long-
term effects of these grafts must be established, in particular with respect to tumour 
formation. 
 
3.5.3 Adult neural stem cells 
One of the long-held beliefs was that the adult brain did not generate new neurons.  
However the demonstration that neurogenesis occurs in the adult rat hippocampus 
(Khun et al. 1996) and sub-ventricular zone (Luskin 1993), meant neural stem cells 
existed in the adult brain, which are capable of generating neurons and glia.  It has been 
shown that cells isolated from the adult rat forebrain can be proliferated in culture and 
generate neurons and glia when induced to differentiate (Lois and Alvarez-Buylla 1993).  
NPCs can also be isolated from the adult rat SN, propagated in vitro in response to FGF-
2 and generate neurons, astrocytes and oligodendrocytes in vitro In vivo these cells only 
generate glial cells in the SN (Lie et al. 2002).  However when such NPCs from the SN 
were transplanted to the adult rat hippocampus they differentiated into neurons and glia 
(Lie et al. 2002).  This suggests that appropriate neurogeneic signals do not exist in the 
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adult SN to induce these cells to follow a neuronal lineage.  These findings, along with 
the demonstration that neurogenesis occurs in the adult human hippocampus (Eriksson 
et al 1998) and the fact that human NPCs have been isolated and propagated in vitro 
from the adult subventricular zone (Kukekov et al 1999), hippocampus (Kukekov et al 
1999), cortex and amygdala (Arsenijevic et al 2001), lead to the proposal that adult 
human neural stem cells could be use in autologus transplantation in PD.  This approach 
would circumvent the logistical, ethical and safety issues associated with transplantation 
of various other cell types, as mentioned above.   
 
3.5.4 Retinal pigment epithelial (RPE) cells 
The RPE forms part of the retina and consists of dopamine-producing support cells.  It 
has been shown that transplantation of human RPE cells to the striatum in a 6-OHDA rat 
model of PD induces a minimal host immune response and improvements in motor 
deficits (Subramanian et al. 2002).  Phase I clinical trials of transplantation of RPE in 
patients with PD has been carried out and the results are promising (for review see 
Watts et al. 2003). 
 
3.5.5 Carotid body (CB) cells 
The CBs contain neural crest-derived, highly dopaminergic glomus cells which function 
as arterial oxygen sensors, releasing dopamine in response to hypoxia (for review see 
Lopez-Barneo et al. 2003).  These have been proposed as an alternative cell source for 
transplantation in PD, due to the possibility of because autologus transplantation.  
Transplantation of CB cells in the 6-OHDA rat model has proved that these grafts 
survive well and improve motor deficits (Espejo et al. 1998).  The mechanism behind 
the functional recovery is unknown, however recent work has shown that the CBs 
contain high levels of GDNF, which may contribute to the trophic actions of CB 
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transplants on nigrostriatal dopaminergic neurons (Toledo-Aral et al. 2003).  However 
information on the mechanism of action of these transplants is needed (for review see 
(Toledo-Aral et al. 2002). 
 
3.5.6 Mesenchymal stem cells 
These cells are generated from bone marrow and thus are also known as bone marrow 
stromal cells (BMSCs) (for review see Prockop 1997).  These cells attracted much 
attention when it was shown that they could differentiate into neurons, astrocytes and 
oligodendrocytes in vitro (Sanchez-Ramos et al. 2000).  When these cells were 
transplanted into rat brains, they engrafted and migrated into the host brain and 
developed many of the characteristics of astrocytes (Azizi et al. 1998; Kopen et al. 
1999).  As such it has been proposed that genetically engineered BMSCs could be used 
to deliver trophic factors such as GDNF.  Human BMSCs transfected with the gene for 
TH were transplanted into a rodent model of PD and mediated significant functional 
recovery (Schwarz et al. 1999).  The use of BMSCs as an alternative source of cells to 
deliver trophic factors is attractive because these cells could be used in autologus 
transplantation, since they could be isolated from the patient’s own bone marrow. 
 
3.6 The transforming growth factor- superfamily 
The TGF- superfamily is a group of multifunctional cytokines that play diverse roles in 
many different tissues during development and in adulthood (for reviews see Sporn and 
Roberts 1990, Kingsley 1994, Herpin et al. 2004).  The TGF- superfamily is made up 
of a number of structurally-related molecules that are grouped into subfamilies based on 
sequence similarities (See Figures 3.2, 3.3, 3.4, 3.5).  Some examples include the 
GDNF, TGF, activin (Act), and the Dpp-Vgr1-related (DVR) subfamilies (for reviews 
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see Krieglstein et al. 2002, Herpin et al. 2004).  The DVR subgroup is further divided 
into the GDF-5 group, the bone morphogenetic (BMP)-2 group and the 60-A group, 
containing BMP-5, BMP-6, BMP-7 and BMP-8 (for reviews see Roberts and Sporn 
1990, Kingsley 1994, Krieglstein et al. 2002, Herpin et al. 2004).  Members of the 
TGF- superfamily are synthesised as large precursor proteins that contain a 
hydrophobic N-terminal signal sequence, a prodomain of varying size and a C-terminal 
peptide. The precursor proteins are cleaved at a [RK]-X-X-[RK] site to release a mature 
C-terminal segment of 110-140 amino acids.  The active signalling molecules are made 
up of hetero- or homodimers of this C-terminal region (for review see Kingsley 1994, 
Venkataraman et al. 1995, Herpin et al. 2004; see Figure 3.6A).  All members of the 
TGF- superfamily contain seven highly conserved cysteine residues in their C-terminal 
(Venkataraman et al. 1995), and all but one of the cysteine residues are involved in 
intramolecular disulphide bonds which result in a characteristic three-dimensional 
structure known as a cysteine knot motif (Venkataraman et al. 1995).  The remaining 
cysteine residue is involved in intermolecular disulphide bond formation, allowing the 
formation of active dimers (Daopin et al. 1992).  However some members, namely, 
GDF-3, GDF-9 (McPherron et al. 1993) and BMP-15 (see below) lack this cysteine 
residue and are thought to function as active monomers (see Figure 3.6B). 
   
3.6.1 Transforming growth factor-  superfamily receptors  
TGF- superfamily members act through two different types of serine-threonine kinase 
receptors, which have been classified as type-I and type-II receptors, based on their 
structural and functional properties (for review see Massague 1996; see below).  In the 
absence of ligand, these receptors exist as homodimers at the cell surface.  On ligand 
binding, a functional tetrameric receptor complex is assembled which consists of two 
  
Figure 3.2: Alignment of known protein sequences of human BMP and GDFs 
beginning from the first conserved cysteine residue in the mature C-terminal 
protein. Alignment shows the classical seven conserved cysteine (C) residues 
that form the structure known as the “cysteine-knot motif”. Protein sequences 
were obtained from www.ncbi.nih.gov and the alignment was performed using a 
web-based version of Clustal WTM from EMBL (http://www.ebi.ac.uk/clustalw/)  
  
Figure 3.3: Phylogeny tree showing the evolutionary relationship between human 
BMPs and GDFs. Phylogeny tree was generated from data obtained from Clustal 
WTM alignment of the protein sequences shown in figure 3.2. Line length 
represents evolutionary distance. Numbers in brackets represent how similar the 
sequence in question is to the GDF-5 sequence (for example, “GDF10 (48)” 
means that the human GDF10 sequence is 48% similar to the human GDF-5 
sequence). GDF6 and GDF7 share a high sequence similarity with GDF-% (86% 
and 80% respectively), showing that they belong to a subgroup within the DVR 
subfamily.  
 
  
Figure 3.4: Cysteine residues are normally encoded by either TGT or TGC. This 
nucleotide sequence alignment of the cDNA encoding the C-terminal end of the 
GDF-5 protein shows the position of nucleotides encoding the cysteine residues. 
In general there is conservation of codon usage (either TGT or TGC) encoding 
for the conserved cysteine residues. However, differential codon usage is evident 
in the codon encoding the first conserved cysteine residue, with TGT present in 
the chicken sequence, while TGC is used in the human and mouse sequence. 
cDNA sequences were obtained from www.ncbi.nih.gov and the alignment was 
preformed using a web-based version of Clustal WTM from EMBL 
(http://www.ebi.ac.uk/clustalw/)  
  
Figure 3.5: Alignment of known protein sequences of GDF-5 of various species 
beginning from the first conserved cysteine residue (C) in the mature C-terminal 
protein. The rabbit sequence was assumed to be 100% identical to the human 
sequence as previously reported (Sanyal et al. 2000). All sequences are identical 
expect for an amino acid substitution in the chick sequence from phenylalanine 
(F) to tyrosine (Y). Cysteine residues shown in green in the rat sequence are 
predicted. Protein sequences were obtained from www.ncbi.nih.gov and the 
alignment was performed using a web-based version of Clustal WTM from EMBL 
(http://www.ebi.ac.uk/clustalw/)  
 
  
Figure 3.6: (A) Schematic showing the generation of a typical TGF-β ligand. 
Although most TGF-β ligands function as dimers, exceptions are GDF3 and 
GDF9 and BMP-15, which lack the cysteine residue required to form dimmers. 
(B) The mature protein of GDF3, GDF9 and BMP15, which are thought to 
function as active monomers. The cysteine residue (C) is replaced by a serine (S) 
in GDF9 and BMP15 and by a valine (V) in GDF3. (SP=signal peptide)  
Part (A) of figure was adapted from (Herpin et al. 2004)  
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type-II receptors and two type-I receptors (for reviews see Massague 1996, Herpin et al. 
2004).  In mammals, only five type-II receptors and seven type-I receptors have been 
identified, whereas twenty nine ligands have been found (for review see Derynck and 
Zhang 2003).  These receptors mediate a diverse array of signals from TGF- 
superfamily members, by combining different type-I and type-II receptors in the 
tetrameric receptor complex to allow differential ligand binding or differential signalling 
in response to the same ligand (Derynck and Feng 1997).  For example, interaction of  
Act receptor (ActR)-II with ActR-Ib mediates Act signalling, whereas interaction of 
ActR-II with BMP receptor (BMPR)-Ia or BMPR-Ib can mediate signalling by certain 
BMPs or GDFs (Nishitoh et al. 1996, Derynck and Zhang 2003).  In the mouse, 
mutations in BMPR-Ia and BMPR-Ib as well as in ActR-Ib result in defects in 
gastrulation and mesoderm formation (Mishina et al. 1995, Gu et al. 1998, 1999).  Type-
II receptors are also required for gastrulation and mesoderm development, as 
demonstrated by mice with mutations in ActR-IIa and ActR-Ib (Song et al. 1999) or 
BMPR-II (Beppu et al. 2000), which fail to gastrulate or generate mesoderm.  All three 
BMP receptors are expressed during brain development (Zhang et al. 1998, Panchision 
et al. 2001).  
 
3.6.2 Signalling by transforming growth factor- superfamily members 
The BMPs, GDFs and Acts, along with the TGF-s all act through a similar mechanism.  
Ligand binding to the type-II receptors causes these receptors to phosphorylate the 
cytoplasmic domains of the type-I receptors.  Through a series of phosphorylations and 
protein interactions, these activate the smad effector proteins which move into the 
nucleus and affect transcription (for review see ten Dijke et al. 2000).  Smads have been 
divided into three different categories based on their function in the cell: receptor 
 36 
activated smads (R-smads), common mediator smad(s) (co-smad(s)) and inhibitory 
smads (I-smads)  (for review see Roberts 1999). R-smads are numbered 1,2,3,5 and 8 
and of these, smad 2 and 3 have been shown to mediate signals from the Act and TGF- 
receptors, while smads 1,5 and 8 mediate signals from the BMP receptors (for review 
see Roberts 1999).  Specificity of TGF- and BMP signalling is determined by the "L3 
loop" , a 17 amino acid region that protrudes from the core of the conserved MH-2 
domain of the R-smads (Lo et al. 1998).  The L3 loop is present in all R-smads, but 
differs in amino acid composition in smads 2 and 3 compared to smads 1, 5 and 8 (Lo et 
al. 1998).  After phosphorylation of an R-smad by an activated type I receptor, the R-
smads dissociate from the receptor and interact with smad 4 to form hetero-oligomeric 
complexes that undergo nuclear translocation, a critical event in the functioning of the 
smad proteins (for review see Miyazono et al. 1999).  In the nucleus, smad proteins 
interact with DNA by directly binding to it and also indirectly by their associations with 
other DNA binding proteins (for review see Miyazono et al. 1999). The co-smad (smad 
4) was first identified as a tumour supressor gene for pancreatic cancer that is either 
mutated or deleted in a significant percentage of pancreatic cancers as well as in a 
smaller number of colon cancers and breast cancers (Hahn et al. 1996).  It has been 
demonstrated that smad4 specifically associates with each of the R-smads following 
their ligand dependant phosphorylation (Lagna et al. 1996).  Inhibitory smads (Smads-6 
and –7) lack the L3 loop and the C-terminal phosphorylation site of the R-smads and 
interact with both type 1 receptors and other smads (Roberts 1999).  A rise in smad-6 
and -7 mRNA occurs after TGF- stimulation (Afrakhte et al. 1998) and it is thought 
that they act as in a negative feedback role, limiting the effects TGF superfamily 
members (Afrakhte et al. 1998, for review see Roberts 1999). 
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3.6.3 The bone morphogenetic proteins and the nervous system 
As part of the DVR subgroup, BMPs represent the largest subfamily of the TGF- 
superfamily (for review see Mehler et al. 1997).  Initially identified due to their ability 
to induce bone, cartilage and bone marrow formation (Wozney et al. 1988), more 
recently these factors have been shown to play diverse roles in the development of the 
nervous system (for review see Mehler et al. 1997).  One of the earliest events in which 
BMPs are involved is the regulation of neuralation during gastrulation.  It has been 
shown that BMP-4 and BMP-7 are expressed by the ectoderm surrounding the dorsal 
blastopore lip and that they induce epidermal cell fate in the early embryo, while 
inhibiting neuralation (for reviews see Tanabe and Jessell 1996, Hemmati-Brivanlou and 
Melton 1997).  Once gastrulation has been completed, BMPs act as key regulators in 
dorso-ventral patterning along the neuraxis (for review see Mehler et al. 1997).  Various 
BMPs have been shown to be expressed along the dorsal midline of the neuraxis 
(Tanabe and Jessell 1996) and induce the expression of dorsal identity genes Pax1 and 
Msx1 in proliferating ventral precursor cells (Tanabe and Jessell 1996, Panchision et al. 
2001).  It is hypothesised that a dorso-ventral gradient is established along the 
neuroaxis, with BMPs expressed dorsally and various factors, the most important of 
which is Shh, which is secreted from the notochord, expressed ventrally (Ye et al. 1998, 
for review see Mehler et al. 1997).  This gradient provides positional information for 
migrating cells (for review see Mehler et al. 1997).  
BMPs have been shown to play diverse roles in determining cell fate during 
nervous system development (for review see Mehler et al. 1997).  The cellular response 
to BMP treatment is diverse and ranges from apoptosis in early CNS precursors (Furuta 
et al. 1997, Mehler et al. 2000), neurogenesis or gliogenesis in mid-gestation CNS 
precursors depending on the time of addition of BMPs (Kalyani et al. 1998, Li et al. 
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1998, Mabie et al. 1999, Mehler et al. 2000), and glial differentiation in later embryonic 
or adult CNS precursors (Gross et al. 1996, Mabie et al. 1999, Mehler et al. 2000).  In 
explant cultures of E13 mouse dorsal telencephalon, BMP-2, 4, 5, 7 treatment all caused 
mitotic arrest and increased the numbers of neurons, suggesting that they caused 
premature differentiation to a neuronal fate (Li et al. 1998).  BMP-4 was also shown to 
increase neuritogenesis in these cultures; this required the presence of BMPR-Ia (Li et 
al. 1998).  In agreement with this finding, BMP-2 has also been shown to promote 
neuronal differentiation from neural-restricted precursors isolated from the rat E13.5 
spinal cord (Kalyani et al. 1998).  In cultures of E16 rat proliferating cortical cells, 
BMP-2 caused cell cycle arrest and enhanced the numbers of neurons while decreasing 
the numbers of oligodendrocytes generated (Mabie et al. 1999).  However, delayed 
addition of BMP-2 favoured the generation of astrocytes, while at the same time 
suppressing the generation of oligodendrocytes (Mabie et al. 1999), which suggests that, 
as precursors cells mature, the effect of BMP treatment can be different depending on 
the age of the cultured cells and on which precursor cells are present (Mehler et al. 
2000).  This fact is highlighted by studies showing enhanced generation of astrocytes as 
a result of BMP treatment.  Proliferating O2A cells express the full complement of BMP 
receptors (Mabie et al. 1997).  BMP-2, 4, or 7 treatment of these cells caused mitotic 
arrest and dramatically increased the numbers of astrocytes, while reducing the numbers 
of oligodendrocytes generated (Mabie et al. 1997).  This effect was seen after a one h 
exposure to BMP-2, whereas if BMP-2 was added at a later stage, the cells were 
unresponsive (Mabie et al. 1997).  This suggests that the role of BMPs is in the 
establishment of an astroglial phenotype and not in its maintenance.  BMPs have been 
shown to act in synergy with LIF to induce differentiation of neuroepithelial precursor 
cells into astrocytes (Nakashima et al. 1999a).  LIF is a member of the IL-6 family of 
cytokines which consists of IL-6, IL-11, ciliary neurotrophic factor (CNTF), oncostatin 
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M and cardiotrophin-1 (for review see Taga and Kishimoto 1997).  Members of this 
family of cytokines signal through the membrane receptor gp130, which activates 
cytoplasmic Janus kinases, which lead to downstream activation of a transcription 
factor, STAT-3 (for review see Taga and Kishimoto 1997).  BMP-2 and LIF co-
treatment have been shown to stimulate a high transcriptional activation of the glial 
fibrillary acidic protein (GFAP) promoter (Nakashima et al. 1999a), agreeing with 
previous suggestions that the role of BMPs in astrogenesis is the induction of a 
phenotype rather than maintenance of the phenotype (Mabie et al. 1997).  This 
synergism is mediated by a transcriptional activating complex consisting of STAT3 and 
Smad1, which is bridged by p300, a member of the cAMP responsive element-binding 
(CREB)-binding protein (CBP) family of transcriptional co-activators that have been 
previously shown to bind smad proteins (Nakashima et al. 1999b, Nishihara et al. 1998).  
Although BMP2 alone induces astrocytes from neuroepithelial precursors, LIF can 
accelerate this differentiation if the cells are cultured for longer time periods, (for 
example 3-7 days Gross et al. 1996 or 2 days Nakashima et al. 1999a).  It has 
subsequently been found that gp130 activation is essential for BMP-2 induction of 
astrocytes from neuroepithelial precursors, as cells cultured from gp130 null mice, failed 
to generated any astrocytes in response to BMP-2 alone or in combination with LIF 
(Nakashima et al. 1999a).  More recently, it has been shown that BMP-2 induces a 
switch in cell fate in proliferating telencephalic progenitors (Nakashima et al. 2001).  
BMP-2 was shown to induce the expression of the anti-neurogenic helix-loop-helix 
(HLH) transcription factors, Hes5, Id1 and Id3 by a smad-dependent mechanism 
(Nakashima et al. 2001).  These findings have also been extended to BMP-4 and BMP-
7, suggesting that BMP alteration of the fate of neuroepithelial precursors is via a 
common mechanism involving the induction of negative HLH transcription factors 
(Yanagisawa et al. 2001).  However, the effects of BMPs on astrocyte induction may 
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also be regionally specific, as BMPs did not have this effect on neural precursors 
isolated from the spinal cord (Mekki-Dauriac et al. 2002), suggesting that neural 
precursors in divergent regions of the CNS respond differently to BMP treatment.  
Recently it has emerged that the effects of BMPs on the differentiation of CNS stem 
cells is also dependent on local cell density (Rajan et al. 2003).  Neural stem cells 
isolated from the E14.5 rat cortex, predominantely differentiated into smooth muscle 
upon BMP-4 stimulation when the cell density is low, whereas glial differentiation 
predominated at higher local densities in response to BMP-4 (Rajan et al. 2003).  Smad 
activation was shown to be necessary for smooth muscle differentiation, while STAT 
activation was necessary for glial differentiation (Rajan et al. 2003).  In agreement with 
in vitro findings, transgenic BMP-4 over-expression during telencephalic development 
has been shown to increase the number of astrocytes, while reducing the number of 
oligodendrocytes generated (Gomes et al. 2003).  BMPs have also been shown to be 
neurotrophic factors for developing sensory neurons from the dorsal root ganglion 
(Farkas et al. 1999), serotonergic neurons (Galter et al. 1999), midbrain dopaminergic 
neurons (Jordan et al. 1997; and see below) and striatal neurons (Gratacos et al. 2001, 
2002).  BMPs also regulate the postnatal differentiation of cerebellar cells, increasing 
neurite length and arborisation of developing granular cells (Angley et al. 2003). 
 
3.6.4 The bone morphogenetic protein receptors and the nervous system 
BMPRs have been reported not to be expressed at E9 in the developing mouse brain, but 
to be detectable by Western blot at E12.  Their expression was shown to peak between 
E13 and P7, before decreasing with increasing gestational age (Zhang et al. 1998).  
Between E12 and E15 during mouse brain development, all three BMPRs are expressed 
in the ventricular zone (VZ) (Zhang et al. 1998), suggesting that BMP signalling may 
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play a role in neurogenesis at this stage of brain development, in agreement with 
previous findings (Kalyani et al. 1998, Li et al. 1998, Mabie et al. 1999, Mehler et al. 
2000).  By E16, BMPR-Ia is expressed in multiple structures of the mouse brain, 
including the striatal neuroepithelium, whereas expression of BMPR-Ib is limited to the 
frontal region of the neuroepithelium (Zhang et al. 1998).  With increasing age, BMPR-
Ia expression was found to increase in multiple brain structures whereas intensive 
BMPR-Ib expression was detected only in the anterior nuclei (Zhang et al. 1998).  In the 
adult mouse brain, BMPR-Ia shows a more widespread expression pattern than BMPR-
II and BMPR-Ib, with BMPR-Ib expression being limited to the anterior olfactory 
nucleus (Zhang et al. 1998).  Mice overexpressing constitutively active (ca) BMPR-Ia at 
E11.5 and E14 showed expansion of the dorsal region of the neural tube along the entire 
rostral-caudal axis (Panchision et al. 2001).  In contrast, mice overexpressing ca BMPR-
Ib showed increased caspase-3 activation in the ventricular neuroepithelium between 
E9.5 and E12.5, showing that the principal early response to BMPR-Ib activation during 
brain development is apoptosis (Panchision et al. 2001), in agreement with previous in 
vitro studies (Furuta et al. 1997, Mehler et al. 2000).  In later embryos (E13.5), the 
principal response to BMPR-Ib activation was differentiation to a neuronal phenotype 
(Panchision et al. 2001), also agreeing with previous in vitro studies (Kalyani et al. 
1998, Li et al. 1998, Mabie et al. 1999, Mehler et al. 2000).  Panchision et al. also 
showed that BMPR-Ia is expressed ubiquitously among neural precursors at all 
gestational ages, whereas BMPR-Ib is only expressed after E8.75 in the mouse, and is 
restricted to dorsal neural precursors (Panchision et al. 2001).  In agreement with a role 
of BMPR-Ib in dorsalisation of neural precursors, Panchision et al. found that 
proliferating ventral neural precursors exposed to BMP-2 induced the expression of 
BMPR-Ib and Msx-1 (a dorsal identity gene) and that this effect was inhibited by Shh, 
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suggesting that BMPR-Ib activation induces a dorsalising phenotype in proliferating 
ventral neural precursors (Panchision et al. 2001; discussed in more detail in Chapter 9). 
3.6.5 The growth/differentiation factors and the nervous system 
The GDFs represent a subfamily of the TGF- superfamily.  Although the precise 
functions of many GDFs in the nervous system are unknown, recent data suggests that 
they play a role in the development of discrete neuronal populations.   
GDF-1 is unusual among the TGF- superfamily members, in that it is 
specifically expressed in the nervous system (Lee 1991).  Transcripts for GDF-1 have 
been shown to be expressed in the developing mouse brain, and to increase during 
development, reaching maximal levels in the adult (Lee 1991).  Within the adult mouse 
CNS, transcripts for GDF-1 have been shown to be expressed in the diverse regions, 
including the spinal cord, the cerebellum and the brain stem (Lee 1991).  GDF-1 has 
also been shown to be strongly expressed in the hippocampus, cortex and thalamic 
nuclei during postnatal development in the mouse and rat brain (Soderstrom and 
Ebendal 1999), suggesting that it may play diverse roles during brain development, 
including a possible role in memory.  GDF-1 transcripts have also been detected in the 
developing mouse VM (Wall et al. 2000), however an analysis GDF-1 null mice 
revealed no defect in VM dopaminergic neuron development in the VM of these mice 
(Mr. Kyle Sousa, personal communication).  Activation of a smad2 dependant pathway 
by GDF-1 has been shown to control left-right patterning in the developing mouse 
embryo (Wall et al. 2000).   
GDF-7 (BMP-12) was initially identified using degenerate primers for conserved 
carboxy-terminal domains of TGF- superfamily members in mice (Storm et al. 1994).  
GDF-7 has been shown to be preferentially expressed in the primary motor area of the 
monkey neocortex (Watakabe et al. 2001).  The role of GDF-7 in the motor cortex is 
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unknown.  However, as the related factor, GDF-5, has been shown to be a dopaminergic 
neurotrophin (Krieglstein et al. 1995), it has been proposed that GDF-7 may be 
responsible for maintaining the dopaminergic innervation of the monkey neocortex 
(Watakabe et al. 2001) but no data exists to substantiate this claim.  In cultures of E13 
mouse dorsal telencephalon, GDF-7 and GDF-6 (BMP-13) have been shown to cause 
mitotic arrest of proliferating neuroepithelial precursors and to increase the numbers of 
neurons in these cultures (Li et al. 1998), suggesting that during development of the 
neocortex, GDF-7 may be involved in neurogenesis.  A more defined role for GDF-7 
was shown when it was demonstrated that this protein was expressed in the dorsal 
neuroepithelium at the mesencephalon/metencephalon boundary, the region that gives 
rise to granule neuron progenitors that migrate to the cerebellum (Alder et al. 1999).  It 
was shown that GDF-7 could induce ventral cells of this region, that do not normally 
express markers of granule neuron progenitors, to switch on the expression of these 
genes and generate mature granule neurons when transplanted to the external granule 
layer of the postnatal mouse cerebellum (Alder et al. 1999).  These findings have 
suggested that GDF-7 is involved in initiating the program of granule cell specification.  
It has also been shown that GDF-7 is essential for the development of a discrete class of 
commissural interneurons in the mouse spinal cord (Lee et al. 1998).  Outside the 
nervous system, GDF7 has also been shown to be expressed in the uterus, kidney and 
spleen (Watakabe et al. 2001).   
GDF-8 (myostatin) is mainly expressed in skeletal muscle, where it is thought to 
negatively regulate muscle growth (McPherron et al. 1997). Although GDF-8 expression 
is mainly restricted to skeletal elements in adult animals, it has been shown to be 
expressed in the developing zebra fish telencephalon (Radaelli et al. 2003).   
Strengthening the argument that GDFs play a role in cerebellar development, 
GDF-10 has been shown to be almost exclusively expressed in the adult mouse 
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cerebellum (Zhao et al. 1999).  GDF-10 was found to localise exclusively to the 
Purkinje cell layer of the cerebellum and was expressed in small cells surrounding the 
Purkinje cells (Zhao et al. 1999).  However, GDF-10 knockout mice did not show any 
defect in cerebellar development and appeared to be grossly normal (Zhao et al. 1999).  
As such, the function of GDF-10 in the development of the cerebellum and 
embryogenesis as a whole may be redundant with that of other growth factors and 
remains to be determined.  A subsequent report has shown that GDF-10 is also 
expressed in the postnatal mouse and rat cerebral cortex and hippocampus and that it 
eventually becomes restricted to the granule cell layer in the dentate gyrus from P21 
onwards (Soderstrom and Ebendal 1999), suggesting that it may play a role in memory.  
Outside the CNS, GDF-10 is expressed in developing craniofacial structures and in the 
vertebral column (Zhao et al. 1999), and like GDF-7 (Watakabe et al. 2001), is also 
expressed in uterus, kidney and spleen (Zhao et al. 1999), suggesting that these two 
GDFs may share overlapping functions in some tissues.   
Northern analysis has shown GDF-11 to be expressed only in dental pulp and in 
the brain in adult mice (Nakashima et al. 1999).  During mouse embryogenesis on E16, 
GDF-11 was shown to be expressed in diverse regions of the developing brain including 
the thalamus, hippocampus, striatum and the Purkinje cell layer of the cerebellum 
(Nakashima et al. 1999).  It is tempting to speculate that GDF11 in the striatum may 
function as a target-derived trophic factor for VM dopaminergic neurons, whose axons 
invade the striatum at E16 in the rat (Unsicker et al. 1996; see Figure 3.6).  In the adult 
mouse brain, GDF-11 is expressed in the thalamus, the Purkinje layer of the cerebellum, 
the hippocampus and scattered cells in the midbrain and hindbrain (Nakashima et al. 
1999).  The expression of GDF-10 (Zhao et al. 1999) and GDF-11 (Nakashima et al. 
1999) in the Purkinje cell layer of the cerebellum suggests that they may share 
overlapping functions and this may be a possible explanation for why GDF-10 knockout 
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mice have normal cerebellar development and function (Zhao et al. 1999).  It has been 
shown that GDF-11 knockout mice all die within twenty four hs after birth and have a 
range of renal and palate anomalies (McPherron et al. 1999), although the exact cause of 
death remains unknown.  GDF-11 knockout mice also displayed skeletal abnormalities, 
the reason being that GDF-11 is essential for specifying positional identity along the 
anterior/posterior axis (McPherron et al. 1999).  GDF-11 is also implicated in regulating 
positional identity of spinal motor neurons (Liu et al. 2001) and in inducing reversible 
cell cycle arrest in neuronal progenitors in the olafactory bulb, thus negatively 
regulating the generation of new neurons (Wu et al. 2003).   
GDF-15 (also known as macrophage inhibiting cytokine-1 (MIC-1)) (Bootcov et 
al. 1997; Böttner et al. 1999a, 1999b) has been shown to be expressed in the developing 
rat brain during the peri-natal period in diverse regions including the pons, medulla 
oblongata, striatum, cortex and hippocampus and to be expressed in purified cultures of 
astrocytes (Strelau et al. 2000).  The most prominent site of GDF-15 synthesis in the 
peri-natal rat brain is the choroid plexus (Strelau et al. 2000).  GDF-15 has also been 
shown to be a trophic and neuroprotective factor for E14 rat VM dopaminergic neurons 
in vitro and in vivo (Strelau et al. 2000).  Subsequently GDF-15 has been shown to be 
upregulated in neurons and macrophages/microglia in response to a cortical cryolesion 
(Schober et al. 2001), suggesting that it may act as an anti-inflammatory molecule 
following CNS lesions.  GDF-15 has also been shown to prevent low potassium-induced 
death of cerebellar granule neurons in culture (Subramaniam et al. 2003).   
GDF-16 has also been shown to be expressed in the hindbrain and epibranchial 
placodes during Xenopus development (Vokes and Krieg 2000), however its function in 
these areas remain unknown. 
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3.6.6 Growth differentiation factor-5 
The gene for GDF-5 is located on chromosome 2 in the mouse (Storm et al. 1994) and 
chromosome 20 in the human (Thomas et al. 1996).  Mutations in this gene have been 
shown to be responsible for Brachypodism (bp) in mice (Storm et al. 1994) and a 
recessive chondrodysplasia in humans (Thomas et al. 1996), both of which are 
characterised by skeletal abnormalities restricted to the limbs and limb joints, suggesting 
a role for GDF-5 in limb development. In vitro and in vivo studies have shown that 
GDF-5 plays roles in mesenchyme aggregation and chondrogenesis (Hötten et al. 1996; 
Francis-West et al. 1999; Nakamura et al. 1999), tendon and ligament formation 
(Wolfman et al. 1997; Aspenberg and Forslund 1999), tooth formation (Morotome et al. 
1998), morphogenesis of joints (Storm and Kingsley 1996) and angiogenesis 
(Yamashita et al. 1997, for review, see Buxton et al. 2001).  GDF-5 signals through 
binding to two serine / threonine kinase receptors, the type I receptor BMPR-IB and 
either of the type II receptors, BMPR-II or ActR-II (Nishitoh et al. 1996).  However 
recently it has emerged that Ror2, a orphan tyrosine kinase receptor, can act as a 
receptor for GDF-5 (Dr. P. Tylanowski, personal communication; see below).  A role 
for GDF-5 in the brain was suggested by the initial detection of its mRNA in the 
embryonic mouse brain (Storm et al. 1994).  Further experiments showed its presence in 
the cortex, brainstem, cerebellum and midbrain of newborn (P0) rat, albeit at low levels 
(Krieglstein et al. 1995b). Recent studies have reported neurotrophic and 
neuroprotective actions of GDF-5.  This protein has been shown to increase the survival 
of E14 VM dopaminergic neurons in vitro to about the same extent as TGF-3 and 
GDNF, well established dopaminergic neurotrophins (Krieglstein et al. 1995b). 
Furthermore, GDF-5 can attenuate dopaminergic neuronal death in E14 VM cultures 
induced by the neurotoxin MPP
+
 (Krieglstein et al. 1995b) or by free radical donors 
(Lingor et al. 1999). GDF-5 was found to induce a dramatic increase in numbers 
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astrocytes in these cultures (Krieglstein et al. 1995b), suggesting that its action may be 
indirect, possibly by stimulating the production of glial-derived growth factor(s) that 
may be involved in the neurotrophic response.  Another study showed that GDF-5 
increased the number of serotonergic neurons detected in cultures of E14 rat raphe 
nucleus by upregulating the expression of serotonergic markers (Galter et al. 1999), 
suggesting that it may exert distinct actions on different cell populations.  GDF-5 has 
also been shown to be a neurotrophic factor for sensory neurons from the dorsal root 
ganglia in vitro (Farkas et al. 1997).   
GDF-5 has also been shown to be a potent neurotrophic factor for dopaminergic 
neurons in vivo.  Intrastriatal administration of recombinant human GDF-5 significantly 
attenuated damage induced by 6-OHDA-induced lesions of the adult rat nigrostriatal 
pathway, a model of Parkinson's disease (Sullivan et al. 1997, 1999; Hurley et al. 2004).  
Other studies showed that GDF-5 is at least as potent as GDNF in enhancing the 
survival and functional activity of foetal VM grafts in 6-OHDA-lesioned rats (Sullivan 
et al. 1998).  More recently GDF-5 has been shown to be expressed in the developing rat 
brain with transcripts detected by in situ hybridisation in the Cajal-Retizus cells in the 
hippocampus (Kim et al. 2003).  This suggests that GDF-5 may also play a role during 
hippocampal development although a precise role for GDF-5 during brain development 
remains to be determined. 
 
3.7 The development of ventral midbrain dopaminergic neurons 
In the rat VM dopaminergic neurons proliferate between E11 and E15 undergoing their 
final mitotic divisions on E14-15 (Hanaway et al. 1971; Lauder and Bloom 1974; 
Altman and Bayer 1981; Solberg et al. 1993; Bayer et al. 1995).  In mice, the genesis of 
VM dopaminergic neurons follows a similar time course, with the neurons undergoing 
their final mitosis between E13 and E14 (Marti et al. 2002).  In the rat, axons of 
Figure 3.7:  
Representative photomicrographs showing cryosections through the developing 
rat nigrostriatal pathway at (A) E14, (B) E16 and (C) E18, immunostained fro 
TH. Scale bar = 100μm 
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nigrostriatal dopaminergic neurons start to invade the striatum at E16 and continue to 
grow pre- and post-natally (Unsicker et al. 1996, see Figure 3.6).  This process of 
neurite outgrowth from the VM to the striatum has been shown to be controlled by 
spatially and temporally regulated chemoattractive (from the MFB and later the 
striatum) and chemorepulsive (from the brainstem and cortex) cues from the 
surrounding brain regions (Gates et al. 2004).  However, the exact molecular nature of 
these cues remains to be determined.   The development of VM dopaminergic neurons is 
regulated by a number of transcriptional regulators and secreted molecules that regulate 
the induction of a dopaminergic fate and subsequent maturation to a mature phenotype.   
VM dopaminergic neurons are generated in the midbrain/hindbrain boundary 
under the influence of two major signalling centres, the isthmus and the floor plate (Ye 
et al. 1998).  Among the secreted molecules known to regulate the development of VM 
dopaminergic neurons, two of the most important are Shh and FGF-2-8 (Ye et al. 1998).  
Shh, which is secreted from the floor plate, determines the position of VM dopaminergic 
neurons along the dorso-ventral axis, whereas FGF-2-8, which is secreted from the 
isthmus determines the position of these neurons along the antero-posterior axis (Ye et 
al. 1998).  Gli proteins are zinc finger transcription factors that mediate the effects of 
Shh (Platt et al. 1997, Palma et al. 2004).  The crucial role played by Shh in the 
development of VM dopaminergic has been demonstrated by mouse genetics studies.  
Overexpression of Gli-1 in the mouse leads to the development of ectopic dopaminergic 
neurons (Hynes et al. 1997), and in Gli-2 deficient mice, VM dopaminergic neurons fail 
to develop (Matise et al. 1998).   
Members of the Wnt family of secreted glycoproteins are also expressed in the 
developing VM during the period of dopaminergic neurogenesis (Castelo-Branco et al. 
2003).  Wnt-1 has been shown to increase the proliferation of Nurr1-positive precursors, 
while Wnt5a increases the proportion of Nurr1-positive precursors that acquire a mature 
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dopaminergic phenotype and upregulates the expression of Pitx-3/Ptx-3 (see below) and 
c-ret (Castelo-Branco et al. 2003).  Mice lacking Wnt-1 fail to develop a midbrain and 
anterior hindbrain (Danielian and McMahon 1996), the regions where engrailed (En)-1 
and En-2 are expressed (Simon et al. 2001; see below) and it has been shown that Wnt1 
signalling is necessary to maintain En expression (Danielanian and McMahon 1996).  
This finding is complemented by a study showing that mice lacking low-density 
lipoprotein receptor-related protein (LRP6), which forms a component of the Wnt 
signalling complex, also display midbrain abnormalities similar to those of mice lacking 
Wnt-1 (Pinson et al. 2000).   
Another family of secreted molecules that are necessary to induce a VM 
dopaminergic cell fate are TGF-s.   Various TGF- isoforms have been shown to 
expressed in the floor plate and notochord (Unsicker et al. 1996).  Since Shh is also 
expressed in the floor plate (Ye et al. 1998), this suggests a role for TGF-s in the 
specification of ventral identity within the developing neural tube.  Recently, TGF-2 
and TGF-3 as well as the TGF- type II receptor, have all been shown to be expressed 
in the developing rat VM at E12.5 (Farkas et al. 2003).  TGF-3 has been shown to 
increase the numbers of cells expressing En-1, suggesting that TGF-3 may play a role 
in the maintenance of a VM dopaminergic phenotype (Farkas et al. 2003).  The 
induction of VM dopaminergic neurons by Shh was blocked by neutralising antibodies 
to TGF- and vice versa, suggesting that these two factors require each other as co-
factors to induce a VM dopaminergic cell fate (Farkas et al. 2003).  As it has previously 
been shown that Gli3 can interact with smad proteins that mediate TGF- signals (Liu et 
al. 1998), it is possible that cross talk between TGF- and Shh signalling pathways may 
be involved in the acquisition of a VM dopaminergic cell fate.  During the development 
of the neural tube in zebrafish, cyclops (a gene that encodes a protein related to the 
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TGF- superfamily member, Nodal, has been shown to be necessary for Shh expression 
in the ventral aspect of the neural tube (Muller et al. 2000).  This was dependant on 
smad2 (Muller et al. 2000), one of the smad proteins involved in mediating TGF- 
signalling (Roberts 1999).  The expression of BMP-2, -4 and –6 (Jordan et al. 1997) and 
GDF-5 (O'Keeffe et al. 2004a) in the developing rat VM suggests that these factors play 
a role in the development and/or subsequent maintenance of VM dopaminergic neurons.  
BMP-4 has been shown to induce En-1 expression in cultures from E12 rat VM; 
however, none of these cells expressed TH (Farkas et al. 2003), suggesting that 
additional co-factors are required to induce TH expression.  BMP-4 and –7 expression in 
the wall of the dorsal aorta has been shown to be essential for the induction of TH in 
neural crest derived cells (Reissmann et al. 1996).  However, the effect of BMPs on TH 
induction may be cell type-specific and temporally regulated, since other data has shown 
that BMPs are involved in the induction of cells with a dorsal identity in the hindbrain 
(Panchision et al. 2001; for review see Mehler et al. 1997).   
Once the induction of a VM dopaminergic fate has been induced by extrinsic 
factors as described above, several regulatory genes are required for initiating and 
maintaining the expression of these dopaminergic neurons.  Of the transcriptional 
regulators involved, Nurr-1 has been shown to be necessary for the development of 
dopaminergic neurons (Zetterstrom et al. 1997; Castillo et al. 1998).  It has also been 
shown to directly activate the TH promoter (Sakurada et al. 1999).  Over-expression of 
Nurr1 in ES cells has also been shown to upregulate a number of genes which are 
expressed by mature VM dopaminergic neurons, and these cells have been used to 
efficiently generate dopaminergic neurons (Kim et al 2002).  Recent data has shown that 
Nurr1 induces a dopaminergic cell fate independent of a role in ventralization and 
genesis of neuroepithelial cells of the neural plate (Sonntag et al. 2004) and that other 
factors are necessary to induce a fully mature dopaminergic phenotype (Wagner et al. 
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1999).  Mutations in the Nurr1 gene have been identified in familial PD, suggesting that 
Nurr1 is crucial to both the induction and maintenance of a mature dopaminergic 
phenotype (Le et al. 2003).  Pitx-3/Ptx-3 is another homeodomain transcription factor 
that is exclusively expressed in VM dopaminergic neurons (Smidt et al. 1997) however 
the role of Pitx-3/Ptx-3 in the development of these neurons remains to be determined.  
Lmx-1b is a LIM homeodomain transcription factor that is initially expressed in the 
midbrain/hindbrain boundary and dorsal neural tube and later expressed in developing 
and adult VM dopaminergic neurons (Asbreuk et al. 2002).  Lmx-1b has been show to 
induce the expression of Wnt-1 from the midbrain/hindbrain boundary (Adams et al. 
2000) and Wnt 1 has been shown to increase the proliferation of Nurr1-positive 
precursors (Castelo-Branco et al. 2003), suggesting that the Nurr1-positive precursor 
pool is expanded (at least in part) through Lmx-1b mediated induction of Wnt1, prior to 
terminal differentiation.  Lmx-1b knockout mice show normal development of Nurr1-
positive, TH-positive VM dopaminergic neurons, but these cells lose the expression of 
Pitx3/Ptx3 (Smidt et al. 2000), suggesting that Lmx-1b acts upstream of Pitx-3/Ptx-3 
and that the expression of these factors is independent of Nurr1 and TH expression in 
dopaminergic neurons.  This conclusion is supported by the demonstration that Nurr1 
knockout mice still express En and Pitx-3/Ptx-3 in the developing VM (Wallen et al. 
1999).  The engrailed homeodomain transcription factors, En-1 and En-2, are expressed 
in developing and adult VM dopaminergic neurons (Simon et al. 2001).  In single and 
double knockouts of En1 and/or En-2 in mice, VM dopaminergic neurons are initially 
specified, but these quickly disappear, thus En-1 or En-2 is required for the maintenance 
of these cells (Simon et al. 2001).  Recently the En-1and En-2 genes have been shown to 
be necessary to prevent apoptosis in midbrain dopaminergic neurons in mice, as 
dopaminergic neurons lacking these factors activated caspase-3 and underwent 
apoptosis (Alberi et al. 2004).  En-1 and En-2 have also been shown to regulate the 
 52 
expression of -synuclein in mouse VM dopaminergic neurons (Simon et al. 2001).  
Since mutations in -synuclein gene have been detected in PD (Polymeropoulos et al. 
1997), it is possible that alterations in En regulation of -synuclein production by En 
may be involved in PD, although this remains to be demonstrated.  A recent study has 
also found that HNF3, synaptotagmin 1 and Ebf3 genes are expressed during the 
development of mouse VM dopaminergic neurons (Thuret et al. 2004).  HNF3 is a 
winged helix transcription factor (Duncan et al. 1998).  It is expressed in the ventral 
midline from E9 onwards in the mouse in an overlapping expression pattern with Nurr1 
and is expressed by VM dopaminergic cells before they become postmitotic (Thuret et 
al. 2004). In the adult mouse, HNF3 expression is restricted to dopaminergic neurons 
in the SN and VTA (Thuret et al. 2004), suggesting some regulatory function in adult 
VM dopaminergic neurons.  Synaptotagmin I is a synaptic vesicle protein involved in 
the regulation of calcium-initiated exocytosis (Geppert et al. 1994).  It is expressed in 
adult rat SN dopaminergic neurons (Glavan et al. 2000) and in human SN (Galvin et al. 
2001).  During the development of mouse VM dopaminergic neurons, synaptotagmin I 
expression begins at E14 and continues into adulthood (Thuret et al. 2004).   The 
expression of synaptotagmin I by E14 VM dopaminergic neurons suggests that they are 
at least able to secrete dopamine in a calcium-dependant manner, and as dopamine has 
been shown to enhance dopaminergic differentiation from neural stem cells (Riaz et al. 
2002), it is possible that synaptotagmin plays an indirect role in the acquisition of a fully 
mature VM dopaminergic neuronal phenotype.  Ebf3 is a transcription factor containing 
a HLH dimerization domain and a zinc finger DNA binding domain (Garel et al. 1997).  
At E11 in the developing mouse VM, all TH-positive neurons have a Ebf3-positive 
nucleus (Thuret et al. 2004), however Ebf3 is only expressed from E11-E13 in these 
neurons (Thuret et al. 2004), suggesting that Ebf3 may be involved in induction of a VM 
dopaminergic phenotype and not in the maintenance of this phenotype.  The exact roles 
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of these genes during the development of VM dopaminergic neurons remains to be 
determined. 
 
3.8 The transforming growth factor- superfamily and midbrain dopaminergic 
neurons  
Following the demonstration that BMPs are expressed in the developing rat ventral 
mesencephalon at E13 and E15 (Jordan et al. 1997), these proteins have been shown to 
be neurotrophic factors for midbrain dopaminergic neurons (Jordan et al. 1997, Reiriz et 
al. 1999, Brederlau et al. 2002).  Treatment of E14 rat VM cultures for 8 days in vitro 
(DIV) in serum-free medium with BMPs (with treatment beginning on 2DIV) resulted in 
increases in TH numbers.  Differences in potency were seen between various BMP 
family members, with BMP-6 and BMP-12 being more effective than BMP-2, -4 and 
BMP-7 (Jordan et al. 1997).  BMP treatment also stimulated proliferation of astrocytes 
in these cultures (Jordan et al. 1997).  Inhibiting the BMP-induced increase in astrocytes 
was shown to abolish the surviving promoting effects of BMP-2 suggesting that BMPs 
may exert their neurotrophic indirectly through glia.  A further study showed that 
addition of BMP-2 at the time of plating of E14 rat VM cultures led to an increase in 
dopaminergic cell numbers by 7 DIV (Reiriz et al. 1999).  These findings show that 
early addition of BMPs to cultures of E14 VM results in improved survival.  In the 
earlier study, no increase in astrocytes were observed after BMP treatment (Reiriz et al. 
1999), unlike previous reports, which found that BMP treatment increased the numbers 
of astrocytes in these cultures (Jordan et al. 1997).  Blocking of astrocyte proliferation 
and differentiation did not block the neurotrophic effect of BMP-2 in the Reiriz study, 
suggesting that BMP-2 exerts a direct effect on TH neurons.  This is contrast to previous 
reports, which showed that prevention of the BMP-induced increase in the numbers of 
astrocytes abolished the increase in dopaminergic cell numbers (Galter et al. 1997).  At 
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this time, it remains controversial about how the neurotrophic effects of BMPs are 
mediated (directly on neurons or indirectly via glia).  However it has been shown that 
dopaminergic neurons in the adult rat substantia nigra express BMPR-II, suggesting that 
BMPs can exert a direct effect on dopaminergic neurons (discussed later).  However, as 
astrocyte progenitors (O2A cells) also express a full complement of BMP receptors 
(Mabie et al. 1997), perhaps BMPs exert effects on neurons and astrocytes.  Whether 
these effects are related remains to be determined.   
BMP-2 has also been shown to enhance the morphological development of E14 
VM dopaminergic neurons, leading to an approximately 1.4-fold increase in the number 
of primary neuritis and a five-fold increase in the total number of branch nodes per 
dopaminergic neurons, but no change in the somal area of these neurons (Reiriz et al. 
1999).  BMP-2 also improved the survival of E14 VM dopaminergic neurons in 
intrastriatal grafts in a 6-OHDA rat model of PD (Espejo et al. 1999).  A further study 
examined the effects of BMP-3, -5, -6, -7 and GDF-5, -6 on E14 VM cultures 
(Brederlau et al. 2002).  These factors were administered to the cultures after 6DIV and 
cultures were left to grow for a further 24 hs.  Apart from BMP3, all of the factors 
examined induced an increase in the numbers of astrocytes and a depletion of 
oligodendrocytes in these cultures; however only BMP-5, BMP-6 and BMP-7 increased 
the numbers of dopaminergic neurons (Brederlau et al. 2002).  These results are unlike 
those of a previous report, which showed that GDF-5 increased the numbers of 
dopaminergic neurons in E14 VM cultures (Krieglstein et al. 1995b).  However in the 
earlier study, GDF-5 was added at an earlier time point (2DIV).  TGF-1-3, ActA and 
GDNF have also been shown to be neurotrophic factors for midbrain dopaminergic 
neurons and, unlike the BMPs, did not increase the numbers of astrocytes in E14 rat VM 
cultures (Lin et al. 1993; Poulsen et al. 1994; Krieglstein et al. 1995a).  Other members 
of the GDNF subfamily have also been shown to be neurotrophic factors for E14 VM 
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dopaminergic neurons both in vitro and in vivo, with persephin (Milbrandt et al. 1998; 
Åkerud et al. 2002), neurturin (Horger et al. 1998) and artemin (Baloh et al. 1998) all 
having similar potencies to GDNF.  GDNF has also been shown to influence the 
morphological development of E14 VM dopaminergic neurons (Widmer et al. 2000).  
GDNF treatment for 7 DIV resulted in a two-fold increase in total neurite length and a 
1.5-fold increase in number of branch points per dopaminergic neuron (Widmer et al. 
2000).  Subsequently, treatment of E14VM cultures with GDNF and persphin for 5 DIV 
have been shown to result in a two-fold increase in neurite length per dopaminergic 
neuron (Åkerud et al. 2002). 
 
3.9 Objectives of the present study 
Although GDF-5 has been shown to be a dopaminergic neurotrophin no information 
regarding its expression during brain development or a detailed examination of its 
effects on dopaminergic neurons has been carried out.  This study aims to address the 
following points; 
 To characterise the expression of GDF-5 during rat brain development. 
 To examine if GDF-5 is associated with the developing and adult nigrostriatal 
system. 
 To examine the effects of GDF-5 on dopaminergic neurons in vitro. 
 To examine if GDF-5 is involved in the induction of a dopaminergic phenotype. 
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4.0 MATERIALS AND METHODS 
 
4.1 Tissue preparation for Western blotting 
Protein extracts from the brains of rat embryos aged E11 to E20 were prepared as 
follows.  Embryos were obtained by laparotomy from pregnant Sprague-Dawley rats, 
that had been lethally anaesthetised using sodium barbiturate (150 mg/kg, i.p.).  The 
embryonic sacs were placed in a cold petri dish of Hanks’ balanced salts solution 
(HBSS).  Following removal from the yolk sac, the embryos were killed by decapitation.  
The brains of the embryos were dissected out using a dissecting microscope (Zeiss, 
Germany), and placed in ice-cold HBSS.  The combined weight of all the brains was 
determined and then they were placed in a volume of homogenate buffer (see Appendix 
A) ten times the volume of their weight.  Homogenisation was carried out using a hand 
held dounce homogeniser (AGB, Ireland).  On completion of homogenisation, the 
samples were incubated on ice for 1 h and then spun for 12 min at 12,000 x g at 4ºC in a 
microcentrifuge (eppendorf), to remove insoluble debris.  The supernatant was removed 
and stored at -20ºC until protein determination was carried out.  P1 pups were killed by 
placing them on ice followed by decapitation and dissection of the brain.  Rats ranging 
in age from P6 to adult were lethally anaesthetised using sodium barbiturate (150 mg/kg, 
i.p.).  The brains and various tissues of adult rats were removed and homogenisation was 
carried out as described above for the preparation of the protein extract. 
 
4.2 Preparation of culture extracts for Western blotting 
Cultured cells were processed for Western blotting as follows.  After the required period 
of time in culture, the medium was removed from the culture dishes and the cells were 
washed in cold HBSS.   Following removal of the washing solution, an appropriate 
volume of homogenate buffer was added, as determined by the initial plating density 
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(50l of homogenate buffer per 1 x 106 cells). The samples were transferred to a 2ml 
Eppendorf tube, incubated on ice for 1 h and then spun for 12 min at 12,000 x g at 4ºC 
in a microcentrifuge (Eppendorf), to remove insoluble debris.  The supernatant was 
removed and stored at -20ºC until protein determination was carried out. 
 
4.3 Determination of protein concentration in medium/cell/tissue extracts 
The protein content in the samples was analysed according to the method of Bradford 
(1976) using 96-well flat bottom tissue culture plates (Nunc).  Bovine serum albumin 
(BSA; Sigma, USA) standards ranging from 5-50g/ml were diluted 1:2 with Bradford 
reagent (Bio-Rad) and the absorbance at 600 (A600) was measured using a 
spectrophotometer.  These readings were used to generate a linear standard curve.  An 
aliquot of each protein sample of unknown concentration was diluted 1:100 with sterile 
distilled water.  This solution was diluted 1:2 with Bradford reagent (Bio-Rad) and the 
absorbance at 600 (A600) was determined.  The protein concentration was determined by 
comparing the absorbance of each solution to the standard curve.  Four protein 
determinations were carried out for each sample and the mean calculated. 
 
4.4 Western blotting 
Protein extracts were analysed by sodium dodecyl sulfate (SDS)-polyacrylamide gels, 
following the protocol of Laemmli (1970) with modifications.  Extracts were analysed 
for the presence of GDF-5 by immunoblotting using a monoclonal GDF-5 antibody 
(P3/66).  30μg of protein from the extracts was diluted 1:2 in sample buffer (see 
appendix). The samples were boiled for 5 min prior to being loaded onto the gel.   A 
10% or 12% SDS-polyacrylamide  separating minigel with a 5% stacking gel was used 
(Bio-Rad, Mini-PROTEAN
®
 3 Cell, for gel recipes see Appendix A).  50-100 ng 
recombinant human (rh)GDF-5 protein (Biopharm GmbH, Germany; in 10mM sodium 
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citrate buffer (see Appendix B) was used as a positive control.  Biotinylated molecular 
weight markers (Amersham), diluted 1:10 according to the manufacturers instructions 
(see Appendix A), were loaded onto the gels to confirm molecular weights.  The gel was 
assembled and run for 45-50 mins at 200V according to the manufacturers instructions 
(Bio-Rad, Mini-PROTEAN
®
 3 Cell, instruction manual) using the recommended 
running buffer (see appendix).  Proteins were blotted to polyvinyl-idene difluoride 
(PVDF) membrane (Amersham).  Electrophoretic transfer was carried out at a constant 
current of 100 volts for one h in transfer buffer (see Appendix A), according to the 
manufacturers instructions (Bio-Rad, Mini-PROTEAN
®
 3 Cell, instruction manual).  
After immunoblotting, efficiency of protein transfer was evaluated by staining the gels 
for residual protein bands with Coomassie Blue (see Appendix A).  After transfer was 
completed, in some cases the PVDF membrane was stained with Ponceau S (see 
appendix) to confirm protein transfer.  Following this, the membrane was blocked for 1 
h in 5% w/v milk in 10mM phosphate buffered saline (PBS) (see Appendix A) with 1% 
tween-20 (PBST) (see AppendixA) at room temperature with gentle agitation on an 
orbital shaker.  The blocking solution was removed and the membrane rinsed twice in 
PBST before being incubated at 4ºC overnight with the primary antibody (for a list of all 
antibodies and working dilutions, see Appendix A) in 1% BSA in PBST.  The 
membranes were then washed (6 x 5 mins) in PBST and incubated at room temperature 
in anti-mouse peroxidase (for monoclonal antibodies; Amersham, 1:40,000), anti-rabbit 
peroxidase (for rabbit polyclonal antibodies; Amersham, 1:200,000) and anti-goat 
peroxidase (for goat polyclonal antibodies; Santa Cruz, 1:40,000) in 1% BSA in PBST 
for 1 h at room temperature with gentle agitation on an orbital shaker.  Following 
washing as above, visualisation of the antibody complexes was carried out using ECL-
Plus (Amersham) according to the manufacturers instructions.  ECL-plus reagent was 
applied to the blot for 5 min, then drained from the membrane.  The membrane was 
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sandwiched between two sheets of acetate and was placed in an autoradiography 
cassette and exposed to Hyperfilm
TM
 (Amersham).  The film was developed and fixed 
manually (Kodak GBX developing and fixing solution, Sigma).   After visualisation of 
the antibody complexes had been completed, the blot was stripped of all primary 
antibodies (western blot recycling kit, Chemicon, UK) and incubated in goat anti--actin 
(1:10,000, Santa-Cruz Biotech. USA) in 1% BSA in PBST for 1 h at room temperature.  
The blot was then washed as described above and incubated in anti-goat peroxidase 
(1:40,000, Santa-Cruz Biotech. USA) in 1% BSA in PBST for 1 h at room temperature.  
After washing as described above visualisation of the antibody complexes was carried 
out as above. 
 
4.5 Cell culture 
All in vitro work was carried out in a sterile laminar flow cabinet using strictly aseptic 
techniques.   
 
4.5.1 Culture of GDF-5 producing CHO cells 
The GDF-5 Chinese hamster ovary (CHO) cell line (MC-2), stably transfected with the 
human GDF-5 gene, was a kind gift from Biopharm GmbH, Heidelberg, Germany. This 
cell line was invented and subsequently patented [European patent: EP 0 866 125 A1] 
by Hoechst Marion Roussel, Ltd., Tokyo 107-8465, Japan.  The MC-2 cell line was 
maintained in GDF-5-CHO cell line serum medium (see Appendix B).  Cells were 
grown in sterile 25cm
2 
flasks (Nunc
®
) at 37
0 
C, 5% CO2.  Two thirds of the medium was 
discarded every 48 h and replaced with fresh medium (as above).  Once the cells were 
confluent, the entire supernatant was discarded and the confluent cellular monolayer was 
either passaged or thereafter cultured in serum-free conditions in order to initiate 
expression of GDF-5 proteins.  
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4.5.2 Passaging of CHO cells 
The medium was removed from the flask was then washed gently with 3ml of warm 
10mM PBS. Then 4ml of warm 0.25% trypsin solution was added and incubated for 5 
mins at 37
0 
C.  0.5mg/ml of soyabean trypsin inhibitor was added and the flask was 
gently tapped to dislodge the cells from the base of the flask.  5ml of serum-enriched 
medium was added and cell suspension was centrifuged at 1000rpm for 5 min. The 
supernatant was discarded and the cell pellet was resuspended in 1 ml of serum-enriched 
medium.  Estimates of total cell number were calculated using a haemocytometer 
(AGB) and 3 x 10
5
 cells were seeded in a new, sterile 25cm
2
 flask containing 10ml of 
warm serum-enriched medium.  
 
4.5.3 Culture in serum-free medium for GDF-5 protein expression 
When cells reached approximately 70% confluency, the serum-containing medium was 
removed and the cells washed gently with 3ml of warm 10mM PBS followed by 
washing with warm MEM (Sigma).  Then the confluent cellular monolayer was 
cultured in GDF-5-CHO cell line serum-free medium (see Appendix B).  Two-thirds of 
this ‘conditioned’ medium was thereafter replaced every day, with fresh medium. 
Supernatant samples were labelled and stored at –200 C.  The protein content in the 
medium samples was analysed according to the method of Bradford (Bradford, 1976) as 
described above and Western blotting using the P3/66 GDF-5 antibody was carried out 
as described above. 
 
4.5.4 Preparation of cultures of E14 VM 
E14 embryos were obtained by laparotomy from date-mated pregnant Sprague-Dawley 
rats (UCC Biological Services Unit) as described above.  The brains were isolated from 
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the heads and the VM dissected as previously described (Dunnett and Björklund, 1992).  
The dissected pieces of VM tissue were incubated in 2mls of 0.1% trypsin solution for 
15 mins at 37ºC.  0.5mg/ml of soyabean trypsin inhibitor was added and the tissue 
pieces were triturated using sterile flame-polished Pasteur pipettes for 10-15 strokes, 
with care being taken not to introduce air bubbles into the mixture.  The cell suspension 
was then centrifuged for 5 mins at 1500 rpm.  After discarding the supernatant, the 
tissue pellet was resuspended in 1ml of E14 plating medium (see Appendix B) using a 
P1000 pipette.  10l of this cell suspension was diluted 1:100 in 1ml of fresh plating 
medium and an estimate of total cell number was calculated using a haemocytometer 
(AGB).  The total number of cells in the suspension was calculated using the following 
formula; 
 
Cells/l = (Number of cells counted in 10 fields/10)  x  dilution  factor  x  10 
 
Cells were plated onto poly-D-lysine (0.1mg/ml Sigma; see Appendix B) coated 13mm 
diameter coverslips (AGB) in 96 well plates (Nunc) and/or 3cm diameter four well 
culture dishes (Nunc) at 1 x10
5
 cells/cm
2
 and incubated at 37ºC with 5% CO2.  One half 
of the culture medium was changed every 2 days.  For treatment of these cultures with 
GDF-5, GDF-5 was added directly to the cultures at a final concentration of either 1 or 
10 ng/ml. 
Fresh GDF-5 was added every 2 days when the medium was changed, at a final 
concentration of either 1 or 10 ng/ml.  Cultures were grown for 2, 4 or 6 DIV, depending 
on the experiment being performed, before being fixed and processed for 
immunocytochemistry (see below). 
 
4.5.5 Preparation of cultures of E12 VM  
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E12 cultures were prepared as described above, with the following exceptions.  Due to 
the small amount of tissue, the dissociated cell suspension, after centrifugation at 1,500 
rpm, was resuspended in 200l of serum free E12 medium (see Appendix B).  
Estimation of total cell number was performed as described above.  Cells were plated 
onto poly-D-lysine-coated (see Appendix B) 3cm diameter 4-well culture dishes (Nunc).  
2 x 10
4
 cells in 10l were pipetted onto each well and the cells allowed to settle for 30 
mins.  2ml of serum free E12 medium was added and the cultures incubated at 37ºC 
with 5% CO2.   
For TH induction experiment, growth factors were added directly to the cultures 
at a final concentration of 10 ng/ml.  After 1 DIV, cultures were fixed and processed for 
immunocytochemistry (see below). 
 
4.5.6 Brd-U labelling of cultures of E12 rat VM 
To label proliferating cells in cultures of E12 VM, 10M Brd-U (Sigma) was added 
directly to the culture medium for the final 5 h of the 24 h culture period.  Cells were 
fixed and processed for immunocytochemistry (see below). 
 
4.5.7 Preparation of neural progenitor cells from E12, E13 and E14 VM 
All cell suspensions were prepared as described above.  After centrifugation at 1,500 
rpm, the cell pellet was resuspended in 200l of expansion medium for neural 
progenitor cell culture (see Appendix B).  Estimation of total cell number was 
performed as described above.  Cells were seeded into 10cm
2
 flasks (Nunc) at a density 
of 1 x 10
6
 cells per flask in 5 ml of expansion medium.  Fresh EGF and FGF-2 was 
added every day with half the medium being replaced on the fourth day of culture.  For 
all experiments, cultures were grown for 6 DIV before being passaged for differentiation 
experiments. 
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4.5.8 Passaging of neural progenitor cells 
 
After 6 DIV expansion, the cells rapidly proliferated into neurospheres.  To passage the 
cells, the flasks were stood on their ends and the cells were removed using a 10ml 
pipette and transferred to a 20ml sterile tube.  Attached cells were detached by scraping 
with a cell scraper and washing out the flask with expansion medium.  After 
centrifugation at 1,500 rpm, the cell pellet was resuspended in 1ml of 0.1% trypsin 
solution for 15 mins at 37ºC.  0.5mg/ml of soyabean trypsin inhibitor was added and the 
mixture was triturated to a single cell suspension using sterile flame-polished Pasteur 
pipettes for 10-15 strokes, with care being taken not to introduce air bubbles into the 
mixture.  The cell suspension was then centrifuged for 5 mins at 1500 rpm.  After 
discarding the supernatant, the cell pellet was resuspended in 1ml of differentiation 
medium for neural progenitor cell culture (see Appendix B) and estimation of total cell 
number was performed as described above.  Cells were plated onto poly-D-lysine-coated 
(see Appendix B) 3cm diameter 4-well culture dishes (Nunc).  1 x 10
5
 cells in 20l were 
pipetted onto each well and the cells allowed to settle for 30 mins.  2ml of 
differentiation medium (see Appendix B) was added and the cultures incubated at 37ºC 
with 5% CO2.  Cultures were grown for 6 DIV before being fixed and processed for 
immunocytochemistry. 
  
4.6 Immunocytochemistry 
4.6.1 Cultures 
A similar immunocytochemical protocol was used for all cultures.  The medium was 
removed and the cultures were washed in HBSS and fixed in 4% paraformaldehyde 
(Sigma) at room temperature for 20 mins.  The paraformaldehyde was removed and the 
cultures were washed (3 x 10 mins) in 10mM PBS containing 0.02% Triton X-100 
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(PBS-Tx).  For TUJ-1 staining, cultures were fixed in ice-cold methanol (Sigma) instead 
of paraformaldehyde, for 10 mins at room temperature.  The methanol was removed and 
the cultures were washed (3 x 10 mins) in PBS-Tx.  Following fixation, all cultures were 
incubated in blocking solution (5% normal horse serum, 0.2% Triton X-100, in 10mM 
PBS, pH 7.4; see Appendix B) for either 1 h at room temperature or overnight at 4ºC.  
Following this step, the blocking solution was removed and the cultures incubated 
overnight in the desired primary antibody (see Appendix B) at 4ºC.  The primary 
antibody was removed, the cultures were washed (3 x 10 mins) in PBS-Tx and 
incubated at room temperature in anti-mouse FITC or anti-mouse TRITC (for 
monoclonal antibodies; Sigma, 1:50), anti-rabbit FITC or anti-rabbit TRITC (for rabbit 
polyclonal antibodies; Sigma, 1:50) or anti-goat FITC or anti-goat TRITC (for goat 
polyclonal antibodies; Sigma, 1:50) in blocking solution (see Appendix B) for 1 h at 
room temperature. Cultures were washed (3 x 10 mins) in PBS-Tx, counterstained with 
DAPI (10µg/ml; see Appendix B) for 4 mins and washed (3 x 10 mins) in PBS-Tx.  
Coverslips were mounted onto slides onto slides using mounting medium (Sigma; 
water:glycerol 1:1). 
For double staining, cultures were processed as described above and incubated 
overnight in the desired primary antibody (see Appendix B) at 4ºC.  Cultures were 
washed as above and incubated in the appropriate secondary antibody as above.  
Following washes, the cultures were re-incubated overnight in the second primary 
antibody in blocking solution (see Appendix B) at 4ºC.  Following washing, the 
appropriate secondary antibody was applied and cultures were washed and processed as 
described above. 
 
4.6.2 Embryonic brains 
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Sprague Dawley rat embryos, aged between E14 and E16 were obtained as 
described above.  Embryonic pups were immersed fixed in 4% 
paraformaldehyde at 4C for 24 hours followed by cryoprotection at 4C for 24 
hours in a 30% sucrose solution.  15m cryosections were cut onto gelatin 
coated glass slides, or electrostatically charged superfrost glass slides (Nunc). 
These were washed three times in PBS immersed in blocking solution 
(Appendix B) for 1 h at room temperature. Sections were incubated in anti-
rabbit-TH (Chemicon; 1:200) diluted in blocking solution at 4C for 24 hours. 
Sections were then washed for (3 x 2 mins in 10mM PBS). Primary antibody 
binding was detected by appropriate anti-rabbit FITC (1:50: Sigma).  Sections 
were again washed in PBS, and coverslipped using vectashield (vector). 
 
4.7 Measurement of cellular morphology 
For measurement of cellular morphology 50 neurons per treatment group (control, 
1ng/ml and 10ng/ml GDF-5) from 3 independent experiments, were analysed using 
established stereological methods (Mayhew 1991).  The two formulas used to calculate 
neurite length and cell somal area were as follows; 
   Neurite length = n x T x 

/2 
   Somal area      = n x B 
Where n = the number of times the neurites intersect the grid lines, T = the distance 
between the gridlines (taking the magnification into account), and B = the area 
associated with each point taking the magnification into account.  An assessment of 
branching was done by counting the numbers of “nodes” per cell.  Primary nodes were 
considered branches from the cell body, secondary nodes were considered branches of 
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primary neurites and so on for teritary and quaternary nodes.  Data is presented as the 
average per dopaminergic neuron. 
 
4.8 RNA isolation and RT-PCR 
The VM from E12, E13 and E14 Sprague-Dawley rat embryos was dissected as 
described below.  These tissue pieces were stored at 4ºC in RNA later solution (Sigma) 
until the RNA extraction was performed.  For cultured cells, the medium was removed, 
the cultures washed in 10mM PBS and the cells were stored in RNA later solution as 
above.  Total RNA was extracted using the RNeasy kit (Qiagen) according to the 
manufacturer’s instructions.  DNase (Promega) treatment of the extracted RNA was 
performed according to the manufactures instructions.  1µg of total RNA was reversed-
transcribed using the RT ImProm II reverse transcription system (Promega).  PCR 
reactions were carried out in a 25µl volume containing 50mM KCl, 1.5mM MgCl2 
(2mM for BMPR-Ia, 1mM for Ror2 and Msx1), 2µl cDNA, 10mM Tris pH 8.3, 200µM 
dNTPs, 800nM of each primer and 1U Taq.  The following primers were used for 
BMPR-II (Chen et al. 2003) and BMPR-Ia (Panchision et al. 2000).  All other primers 
were designed using Primer SelectTM program.  
Target mRNA Sense Primer (5’ to 3’ direction)          Anti-sense primer (5’ to 3’ direction) 
BMPR-II       GCTTCGCAGAATCAAGAACG         GTGGACTGAGTGGTGTTGTG   
BMPR-Ib      ACACGCCCATCCCTCATCAGA                ACGCCACTTTCCCATCCACACT 
BMPR-Ia      ACAGAAATTTATGGCACGCAA          CATACGCAAAGAACAGCATCTC 
 
Ror2        ATCGCCCGCTCCAACCCTCTCATC          ATCCCCATCTTGCTGCCGTCTCG 
 
Msx1        GGAGGCCGAGTTGGAGAAGTTGAA       AGAAGGGGTCGGAAGAGGGAGGAG 
 
Nurr1        CTGTCTCCCGCCTTTCACTCTTCT            ATTTCGGCGGCGCTTATCCA 
 
TH        TGTCACGTCCCCAAGGTTCAT                  GGGCAGGCCGGGTCTCTAAGT 
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Thirty-four cycles of PCR were performed with the following temperatures;  
Denaturation 94C for 30s, annealing at 57C (BMPR-II and BMPR-Ib), 55.1C 
(BMPR-Ia), 62.9C (Ror2), 62.1C (Msx1),  60.9C  (Nurr1) or 59.4C (TH) for 30s 
and elongation at 72C for 45s.  A final elongation step was performed at 72C for 5 
mins.  20µl of PCR product was run at 100V for 45 mins on a 1% agarose-TBE gel. 
 
4.9 Real time RT- PCR 
GenBank rat cDNA sequences were used in PRIMER EXPRESS 1.0 (Applied Biosystems) 
for primer design. The following oligonucleotides were used (Quantum RNA classical 
18S internal standard kit, Ambion, Austin, TX): 
cDNA that had been FACS sorted into TH+ and TH- fractions from the VM of the 
E13.5 TH-GFP mouse (a kind gift from Ms. Nina Rawal, Karolinska Institute) was used 
in for realtime PCR analysis to examine BMP receptor expression.   Real-time RT-PCR 
was performed in triplicate with
 
1  l of cDNA (1:10 dilution) and RT in a total volume 
of 25 μl. Each PCR consisted of 1Χ PCR buffer (Life Technologies) containing 3 mM 
MgCl2 (Life Technologies), 0.2 mM deoxynucleoside triphosphates (Promega), 0.3  M 
each of the forward and reverse primers, 1 unit of Platinum Taq DNA polymerase (Life 
Technologies), and 1unit of SYBR green (Molecular Probes). The PCR was performed 
with the ABI Prism
 
5700 detection system (Applied Biosystems) and started with 94C 
for 2 min, followed by 40 cycles, which each consisted of 94C for 30 s, 60C for 30 s , 
72C for 45 s, and 80C for 15 s.  A melting curve was obtained for each PCR product 
after each run to confirm that the SYBR green signal corresponded to a unique and 
specific amplicon.  
Standard curves were generated in every 96-well plate for every real-time PCR run by 
using serial three-fold dilutions of a reverse transcribed RNA extract from an E11.5 
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whole mouse embryo.  The resulting standard-curve plots were then used to convert the 
Cts (number of PCR cycles needed for a given template to be amplified to an established 
fluorescence threshold) into arbitrary quantities of initial template of a given sample. 
The expression levels were obtained by subtracting the RT- value for each sample from 
the corresponding RT+ value and then dividing that number by the value of the 
housekeeping gene encoding 18S rRNA, obtained for every sample in parallel assays. 
Each assay for a particular gene was repeated twice or three times in triplicate. Assays 
of 18S rRNA were run for each sample at the beginning and once or twice in the middle 
of assays to verify the integrity of the samples. The specificity of PCR primers was 
determined by BLAST run of the primer sequences. All PCR products were run in a 2% 
agarose gel to verify the size of the amplicon. The specificity of the PCR product was 
determined by sequencing the amplicon in random samples. 
Statistical analysis of the results was performed by one-way ANOVA. A Fisher's 
protected least significant difference test was used post hoc to identify specific points at 
which the different developmental stages differed from the earliest stage only when 
significantly different interactions occurred. Significant difference for all tests was 
assumed at the level of P < 0.05 (*, P < 0.05; **, P < 0.001; ***, P < 0.0001). 
 
 
 
 
 
 
 
 
 69 
 
 
 
 
5.0 EXPRESSION OF THE DOPAMINERGIC NEUROTROPHIN GROWTH 
DIFFERENTIATION FACTOR-5 IN THE DEVELOPING AND ADULT 
RAT BRAIN 
 
5.1 Aims 
 
 To characterise a monoclonal antibody to GDF-5 (P3/66) 
 To examine the production of GDF-5 in a stably-transfected CHO cell line 
 To examine the primary structure of the GDF-5 precursor protein and how it 
predicts processing of GDF-5. 
 To examine the temporal expression of GDF-5 during embryonic and postnatal 
rat brain development. 
 To examine GDF-5 expression in adult rat tissues, including different regions of 
the brain.   
 To determine if GDF-5 is expressed in the developing rat nigrostriatal system. 
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5.2 Introduction 
The TGF- superfamily is a group of multifunctional cytokines that play roles in many 
aspects of cell growth, differentiation and development.  It is made up of a number of 
structurally related molecules, including TGF-s, Acts, inhibins, BMPs, GDFs and more 
distant members like GDNF (for reviews, see Sporn and Roberts 1990; Kingsley 1994; 
Herpin et al. 2004). The BMP family is further divided into the Dpp (BMP-2, -4, dpp-c, 
GDF-5) and 60A (60A, BMP-5, -6, -7, -8) subgroups, as well as members such as 
BMP-3, GDF-6 and Vg1, which do not belong to either of these subgroups (Krieglstein 
et al. 2002). The GDFs are thought to play diverse roles in many tissues (Caricasole et 
al. 1998; Settle et al. 2001; Vitt and Hsueh 2001; Witthuhn and Bernlohr 2001).  In 
recent years, it has emerged that quite a number of these molecules, including GDF-1 
(Lee 1991; Soderstrom et al. 1996; Wall et al. 2000), GDF-5 (Krieglstein et al. 1995b), 
GDF-7 (Watakabe et al. 2001), GDF-10 (Soderstrom and Ebendal 1999), GDF-11 
(Nakashima et al. 1999), GDF-15 (Bottner et al. 1999a, 1999b; Strelau et al. 2000) and 
GDF-16 (Vokes and Krieg 2000), are expressed in the CNS.  The functions of these 
growth factors in the CNS remain largely unknown, although recent studies have shown 
that GDF-5 and GDF-15 have neurotrophic actions (Farkas et al. 1997; Sullivan et al. 
1997, 1999; Galter et al. 1999; Strelau et al. 2000; Subramaniam et al. 2003).  GDF-7 
may play a role in the development of the cerebellum (Alder et al. 1999) and GDF-11 
has been shown to negatively regulate neurogenesis during olfactory bulb development 
(Wu et al. 2003). 
The gene for GDF-5 is located on chromosome 2 in the mouse (Storm et al. 
1994) and chromosome 20 in the human (Thomas et al. 1996).  Mutations in this gene 
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have been shown to be responsible for bp in mice (Storm et al. 1994) and a recessive 
chondrodysplasia in humans (Thomas et al. 1996), both of which are characterised by 
skeletal abnormalities restricted to the limbs and limb joints, suggesting a role for 
GDF-5 in limb development. In vitro and in vivo studies have shown that GDF-5 plays 
roles in mesenchyme aggregation and chondrogenesis (Hötten et al. 1994; Francis-West 
et al. 1999; Nakamura et al. 1999), tendon and ligament formation (Wolfman et al. 
1997; Aspenberg and Forslund 1999), tooth formation (Morotome et al. 1998), 
morphogenesis of joints (Storm and Kingsley 1996) and angiogenesis (Yamashita et al. 
1997; for review, see Buxton et al. 2001).  GDF-5 signals through binding to two serine 
/ threonine kinase receptors, the type I receptor BMPR-IB and the type II receptor 
BMPR-II (Nishitoh et al. 1996). 
A role for GDF-5 in the brain was suggested by the initial detection of GDF-5 
mRNA in the embryonic mouse brain (Storm et al. 1994). Further experiments showed 
its presence in the cortex, brainstem, cerebellum and midbrain of newborn (P0) rat, 
albeit at low levels (Krieglstein et al. 1995b). Recent studies have reported neurotrophic 
and neuroprotective actions of GDF-5.  This protein has been shown to increase the 
survival of embryonic day E14 VM dopaminergic neurons in vitro to about the same 
extent as TGF-3 and GDNF, well established dopaminergic neurotrophins (Krieglstein 
et al. 1995a). Furthermore, GDF-5 can attenuate dopaminergic neuronal death induced 
by MPP
+
 (Krieglstein et al. 1995b) or by free radical donors (Lingor et al. 1999). GDF-5 
was found to induce a dramatic increase in the numbers of glial fibrillary acid protein 
(GFAP)-immunopositive cells in these cultures (Krieglstein et al. 1995b), suggesting 
that its neurotrophic action may be indirect, possibly by stimulating the production of 
glial-derived growth factor(s) which may be involved in the neurotrophic response.  
Another study showed that GDF-5 increased the number of serotonergic neurons 
detected in cultures of E14 rat raphe nucleus by upregulating the expression of 
 72 
serotonergic markers (Galter et al. 1999), suggesting that it may exert distinct actions on 
different cell populations. GDF-5 has also been shown to be a potent neurotrophic factor 
for dopaminergic neurons in vivo. Intracerebral administration of recombinant human 
GDF-5 significantly attenuated damage induced by 6-OHDA-induced lesions of the 
adult rat nigrostriatal pathway (Sullivan et al. 1997, 1999; Hurley et al. 2004).  Further 
studies showed that GDF-5 is at least as potent as GDNF in enhancing the survival and 
functional activity of foetal VM grafts in 6-OHDA-lesioned rats (Sullivan et al. 1998). 
In this study, we examined the expression of GDF-5 protein in various organs of 
the adult rat, in particular the brain. Although neurotrophic actions of GDF-5 have been 
described, there is little information regarding the functions of GDF-5 in the brain. The 
presence of GDF-5 mRNA in the neonatal rat brain, including the midbrain, has been 
shown (Krieglstein et al. 1995b), however, very little is known about the expression of 
this protein in the developing or mature brain.  The present study used Western blotting 
to characterise the expression of GDF-5 protein in extracts of developing and adult rat 
brain. Because of the reported neurotrophic actions of this protein on nigrostriatal 
dopaminergic neurons, the expression of GDF-5 in this region of the brain, both during 
its development and in the adult, was also investigated. Finally, GDF-5 expression in 
cultures of dopaminergic neurons from E14 rat VM was examined.  
 
 
 
 
 
 
 
 
 73 
 
 
 
5.3 Results 
 
5.3.1 Two different isoforms of GDF-5 precursor protein suggests active secretion 
Western blotting using cell extracts and conditioned medium from the GDF-5-secreting 
CHO cells showed that GDF-5 exists intracellularly as a precursor protein, and not the 
mature protein of 15kDa (Figure 5.1A).  Mature 15kDa protein was only detected in the 
conditioned medium (Figure 5.1B, lanes 3-7).  This suggests that cleavage of the GDF-5 
precursor protein to the mature form of GDF-5 may be a membrane-associated event.  
Primary structure analysis (www.expasy.org) of the GDF-5 precursor protein, revealed 
that amino acids 1-27 at the N-terminal were likely to be a signal peptide.  When the 
molecular weight of the entire precursor protein was compared with that of the precursor 
protein minus the signal peptide, a 3kDa difference was observed between the two 
forms.  The use of varying gel concentrations in western blotting experiments, allowed 
two distinct bands in the region of 55kDa to be discerned (Figure 5.4).  When the 
molecular weights of these bands were calculated, they differed by 3 kDa, in agreement 
with the predicted molecular weights of the two isoforms of the precursor protein.   
 
5.3.2 Active secretion of GDF-5 in a stably-transfected CHO cell line 
The monoclonal antibody P3/66 was raised against the peptide fragment 
PLATRQGKRPSKNLKARC of the human GDF-5 protein.  Alignment of this peptide 
fragment to the human GDF-5 protein sequence showed that it corresponds to amino 
acids 383-400, located near the C-terminal of the protein (Figure 5.2A).  Western 
blotting using recombinant human GDF-5 protein (which migrates as a 25kDa dimer 
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under non-reducing conditions), showed that the antibody had a greater affinity for the 
reduced form of GDF-5, which migrates as a monomer of approximately 15kDa (Figure 
5.2B).  Thus all further western blots were carried out under reducing conditions.  To 
further characterise this antibody, CHO cells stably transfected with the human gene 
GDF-5 gene (a kind gift from Dr. M. Hanke, Bioharm GmbH), were used.  Western 
blotting using lysates from these cells showed that no 15kDa band was detected 
intracellular while a number of high molecular weight bands were detected (Figure 
5.1A).  Western blotting using conditioned medium from these cells showed that the 
cells secreted GDF-5 for at least 15 DIV (Figure 5.1B).  As predicted, P3/66 antibody 
detected a band of 15kDa in conditioned medium from these cells (Figure 5.1B, lanes 3-
8), while no band was detected in conditioned medium from mock transfected cells 
(Figure 5.1B, lanes 1-2).  P3/66 antibody also detected a number of high molecular 
weight bands in the conditioned medium (see figure 5.1B). 
 
5.3.3 Analysis of high molecular weight bands 
The lowest of the high molecular weight isoforms detected intracellularly and in the 
conditioned medium from the GDF-5-expressing CHO cells was calculated to have a 
molecular weight of 54.6 kDa.  Analysis of the molecular weight of the band found in 
brain samples found it to have a very similar molecular weight, i.e 55kDa.   Prediction 
of the Mw of the human and mouse GDF-5 precursor proteins (www.expasy.org) 
showed that they have Mw of 55.4 kDa and 54.9 kDa respectively.  This suggested that 
the band of approximately 55kDa which appeared in both conditioned medium from the 
CHO cells and in brain samples, corresponded to the monomeric form of the GDF-5 
precursor protein.  To confirm this, an immunoabsorption assay was carried out to test 
the specificity of binding of the monoclonal antibody P3/66 (Figure 5.3A, B). The 
antibody was incubated overnight in an excess of monomeric rhGDF-5 before being 
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used in a Western blot on extracts from adult rat midbrain and striatum. This resulted in 
the immunoreactive band for rhGDF-5 being extremely reduced in intensity (Figure 
5.3B), indicating specific binding of the P3/66 antibody to GDF-5 protein. The 
immunoreactive bands for the midbrain and striatum tissue extracts were also greatly 
reduced in intensity, indicating that the band at ~55kD in the samples corresponded to 
the GDF-5 (precursor) protein (Figure 5.3A, B). 
 
5.3.4 GDF-5 is expressed in the developing and adult rat brain 
Western blots on samples prepared from various aged embryonic rat brains, showed 
expression of a distinct band of ~55kDa.  Expression of the ~55kDa band was not 
present at E11, but appeared at E12 and increased in intensity up to E14, before 
decreasing gradually with increasing age, until only a very weak band could be detected 
at P1 (Figure 5.5A, B). Recombinant human GDF-5 was detected as a clear band at 
~15kDa in each blot, corresponding to the processed monomeric (reduced) form of the 
protein (Figure 5.5A, B).  
Postnatally, the expression of ~55kDa immunoreactive band increased in intensity with 
increasing age, reaching maximal levels in the adult brain. Whereas only a very faint 
band was present in whole brain extracts from P1 rat brain, bands of increasing intensity 
were detected in extracts from P6, P14 and P22 brain (Figure 5.5A, B). The band 
observed at P22 was of comparable intensity to that seen in extracts from adult rat 
striatum and whole brain (Figure 5.5A, B).  
The changes in intensity of the GDF-5-immunoreactive bands in each blot were verified 
by normalising their intensity to that of the corresponding -actin-immunoreactive band 
for each age. 
 
5.3.5 Expression of GDF-5 is tissue-specific 
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Of the organs examined, GDF-5 was expressed in adult rat heart and brain, but not in 
lung, liver, kidney or spleen (Figure 5.6A, B).  Expression in heart tissue was very 
intense. Within the adult rat brain, GDF-5 protein was detected in the cortex, striatum, 
midbrain and cerebellum (Figure 5.7A, B).  
 
5.3.6 GDF-5 is expressed in the developing rat VM in vivo  
Immunoreactive bands at molecular weight ~55kDa were also found in protein extracts 
from the developing rat VM. This expression was present at E12 and increased in 
intensity up to E14, at which time it was maximal (Figure 5.8A). Between E15 and P2, 
there was a gradual decrease in GDF-5 expression levels (Figure 5.8A). The time-course 
of expression of GDF-5 in the VM closely paralleled that of the expression of TH, a 
marker for dopaminergic neurons. TH expression became apparent at E13, peaked at 
E15 and was present at high levels at the later ages which were examined, that is E18, 
E19 and P2 (Figure 5.8B).  
 
5.3.7 GDF-5 is expressed in the developing rat VM in vitro  
GDF-5 protein was detected by immunocytochemisty in untreated E14 VM cultures at 2 
DIV.  Expression of this protein was widespread in many cells, which possessed the 
typical morphology of neurons.  GDF-5 was found to be expressed throughout the cell 
bodies and processes (Figure 5.9A, B). 
 
5.3.8 GDF-5 is expressed in the developing rat striatum in vivo 
Immunoreactive bands at the molecular weight ~55kDa were found in protein extracts 
from the developing rat striatum.   Strong expression of GDF-5 was observed in all ages 
examined (E14-E20), however expression decreased slightly with increasing age (Figure 
5.10).              
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5.4 Discussion 
 
5.4.1 Technical considerations regarding Western blotting for GDF-5  
Members of the TGF-ß superfamily are synthesised as large precursor proteins that 
contain an N-terminal signal sequence and a prodomain of varying size. The precursor 
proteins are cleaved at a RXXR site to release a mature C-terminal segment of 110-140 
amino acids.  The active signalling molecules are made up of hetero- or homodimers of 
this C-terminal region (Kingsley 1994, Venkataraman et al. 1995). Mature GDF-5 is a 
dimer composed of two 12.5kDa monomers, which are linked by a disulphide bond 
(Hötten et al. 1994). In this study, rhGDF-5 consistently migrated at an apparent 
molecular weight of ~15kDa under reducing conditions, as has been reported previously 
(Hötten et al. 1996). 
In the present study, a monoclonal antibody to GDF-5 detected a band of 
approximately 55kDa on Western blots of extracts from developing and adult rat brain 
and conditioned medium from GDF-5 expressing CHO cells, which matches the 
predicted molecular weight of the mouse precursor protein (Storm et al. 1994).  An 
immunoabsorption assay confirmed the specificity of the monoclonal antibody P3/66 to 
GDF-5.   
Mature GDF-5 was not detected in extracts from either developing or adult rat 
brain in this study.  Since the antibody used is capable of recognising the mature form of 
GDF-5 (shown by Western blotting using the recombinant protein), it is probable that 
the levels of mature GDF-5 in the tissue lysates may be below the detection limit of this 
technique.  Another member of the TGF- superfamily, GDF-15, has recently been 
reported to be present in the mature form in brain tissue at levels which are too low to be 
detected by Western blotting (Strelau et al. 2000). This study detected an 
immunoreactive band at ~30 kDa, which corresponds to the GDF-15 precursor. These 
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results are supported by a previous study which showed that very low levels of mature 
GDF-15 exist intracellularly, while the precursor form is in abundance (Bootcov et al. 
1997).  Similarly, mature GDF-1 protein could not be detected using Western blotting 
on extracts of mouse embryonic tissue, while the precursor form was detected in 
abundance (Wall et al. 2000).  Similar findings have also been found for BMP-4 
transfected COS-1 cells (Constam and Robertson 1999).  Our findings also show that 
intracellularly GDF-5 exists predominantly in the precursor form.  The lack of mature 
GDF-5 intracellularly suggests that cleavage of the mature protein from the precursor 
protein may be a membrane-associated event, possibly mediated by subtilisin-like 
proprotein convertases, as has been shown for Nodal and BMP-4 (Constam and 
Robertson 1999).  However this theory requires further investigation.   
As discussed above, the immunoreactive band of ~55kDa which was found in 
brain tissue in the present study is likely to correspond to the GDF-5 precursor protein.  
However, given that no mature GDF-5 was detected in brain extracts, it is possible that 
no GDF-5 mature protein is made/secreted by cells in these tissues.  An analysis of the 
mouse and human GDF-5 precursor proteins suggest the presence of a stretch of 27 
amino acids at the N-terminal, which may function as a signal peptide.  Cleavage of this 
signal peptide would result in two isoforms of the precursor proteins that would differ in 
molecular weight by 3.2 kDa.  Our finding of two immunoreactive bands in the adult rat 
brain extracts, that differ in molecular weight by 3 kDa, suggests that cleavage of this 
signal peptide may occur in vivo.  This suggests active cleavage of the GDF-5 precursor 
protein by intracellular proteases.  It has been previously shown that the amino acid 
composition of the region of the pro-domain surrounding the R-X-X-R cleavage site 
determines the cleavage efficiency and that the pro-domain can influence the stability of 
the mature protein (Constam and Robertson 1999).  Transfection studies have shown 
that, although the Nodal precursor is efficiently cleaved, no mature protein could be 
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detected in conditioned medium from these transfected cells, suggesting that mature 
Nodal is highly unstable.  When the precursor domain of BMP-4 was fused to the 
mature part of nodal, mature Nodal protein could be detected in the conditioned medium 
from transfected cells (Constam and Robertson 1999).  This suggests that the pro-
domain can exert a stabilising influence on the mature protein.  Our finding that mature 
GDF-5 was detectable in conditioned medium from transfected cells, and the presence 
of high molecular weight isoforms in both cell lysates and conditioned medium from 
transfected cells, suggests that the GDF-5 precursor domain may be involved in 
stabilising the mature GDF-5 protein. 
 
5.4.2 GDF-5 expression in the adult rat heart 
This study has found high levels of GDF-5 expression in the adult rat heart. A cardiac 
function for the BMPs has previously been suggested, since high levels of expression of 
BMP receptors have been found in the developing mouse heart (Böttner et al. 1999a) 
and various BMPs have been shown to play a critical role in cardiomyocyte 
differentiation (Monzen et al. 2002).  Furthermore, ectopic expression of dominant 
negative BMPR-IA or BMPR-II receptors in xenopus embryos was found to reduce or 
prevent heart formation (Shi et al. 2000), supporting a critical role for the BMPs in 
cardiac development.  Some members of the BMP family, such as BMP-10, are 
expressed specifically in the heart in the adult mouse (Neuhaus et al. 1999).  Others, 
such as GDF-15, show a much wider expression pattern and are distributed in many 
adult tissues, including the heart (Böttner et al. 1999b).  The present study has found that 
the detectable expression of GDF-5 in the adult rat is limited to the brain and heart.  To 
our knowledge, this is the first demonstration of GDF-5 protein expression in the adult 
rat heart, suggesting a role for GDF-5 in cardiac function. 
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5.4.3 GDF-5 expression in the adult rat brain 
The neuroprotective effects of intracerebral injection of rhGDF-5 prior to and following 
a 6-OHDA lesion of the adult rat nigrostriatal dopaminergic pathway in vivo have been 
reported (Sullivan et al. 1997, 1999; Hurley et al. 2004).  The present study has found 
that GDF-5 is widely expressed in many regions of the adult rat brain, including the 
cortex, striatum, midbrain and cerebellum.  The finding that GDF-5 is expressed in the 
adult rat striatum and midbrain, along with its documented neurotrophic effects on 
nigrostriatal dopaminergic neurons, suggests that it may play a role in the maintenance 
of the nigrostriatal system in the mature brain. One of the GDF-5 receptors, BMPR-II, 
has been shown to be expressed by dopaminergic neurons in the SN and VTA in the 
adult rat (Charytoniuk et al. 2000), supporting the idea that GDF-5 can exert a direct 
effect on dopaminergic neurons. 
To our knowledge, the present study is the first report of GDF-5 protein 
expression in the adult rat cerebellum.  The widespread expression of the BMP receptors 
(Soderstrom et al. 1996) and the expression of GDFs such as GDF-10 (Zhao et al. 1999) 
in the developing and adult mouse cerebellum suggest that the GDFs play a role in 
cerebellar function.  The present study shows here that GDF-5 is expressed in the adult 
rat cortex, a region in which other GDFs, such as GDF-15 (Strelau et al. 2000; Schober 
et al. 2001) and GDF-7 (Watakabe et al. 2001), are expressed.  Due to their widespread 
expression, the functions of GDF-5 and the other BMPs are probably numerous.  
Although the neurotrophic actions of these proteins on certain neuronal populations 
have been documented (Krieglstein et al. 1995a, 1995b; Farkas et al. 1997, 1999; Jordan 
et al. 1997; Sullivan et al. 1997, 1999; Galter et al. 1999; Strelau et al. 2000; Reiriz et al. 
2002; Hurley et al. 2004) and the expression of BMPR-II (Charytoniuk et al. 2000) and 
GDF-15 (Schober et al. 2001) has been shown to be up-regulated following CNS injury, 
the precise roles of these proteins in the mature CNS remain to be established. 
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5.4.4 GDF-5 expression in the developing rat brain 
The present study demonstrates a temporally-regulated expression of GDF-5 protein in 
the developing rat brain, suggesting a function for this protein during brain maturation. 
GDF-5 binds to the receptors BMPR-IB and BMPR-II (Nishitoh et al. 1996), both of 
which have been shown to be widely expressed from E12 onwards in the mouse brain 
(Dewulf et al. 1995; Zhang et al. 1998).  The present study found that GDF-5 expression 
in the rat brain begins on E12, peaks at E14 and persists throughout the embryonic 
developmental period. This finding, combined with the presence of its receptors during 
this period, implies that GDF-5 plays a role in brain development.  Other members of 
the BMP family have been shown to play many roles during neural development, in 
various brain regions (for review see Mehler et al. 1997). In particular, BMPs have been 
found to promote a commitment to astroglial cell lineage (Gross et al. 1996; Mabie et al. 
1997); this is supported by the appropriate temporal expression of the BMPs and their 
receptors in the developing brain (Soderstrom et al. 1996; Zhang et al. 1998).  
Furthermore, BMP-2 can alter the developmental pathway of embryonic mouse brain 
cells from neurogenesis to gliogenesis in vitro (Nakashima et al. 2001; Yanagisawa et 
al. 2001). A recent study found that transgenic over-expression of BMP-4 increased 
astroglial and decreased oligodendrocyte lineage commitment in multiple brain regions 
(Gomes et al. 2003). However, the effects of BMPs may be both spatially and 
temporally dependent. For example, BMPs can induce neuronal differentiation of 
ventricular zone progenitor cells (Li et al. 1998, Mabie et al. 1999), while they promote 
astroglial cell lineage in subventricular zone progenitors (Gross et al. 1996). The BMPs 
have also been suggested to be involved in cerebellar development, since various BMPs 
have been shown to induce the expression of granule neuron markers in vitro (Alder et 
al. 1999) and caBMP receptors can cause cerebellar abnormalities in the chick embryo 
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(Ming et al. 2002).  The role(s) that GDF-5 plays during normal brain development 
remain to be established.  One possibility is that the GDF and BMP family members 
play opposing or synergistic roles in the determination of cell fate in the CNS.   
 
5.4.5 GDF-5 expression in the developing rat ventral mesencephalon 
After finding GDF-5 expression in the adult rat nigrostriatal system, its expression in the 
region of the brain from which this system develops, the VM, was investigated.  
Transplantation of embryonic VM tissue has been used as an experimental therapy for 
Parkinson’s disease (for recent reviews, see Hagell and Brundin 2001, Barker 2002, 
Borlongan and Sanberg 2002). However, one of the limiting factors of this approach is 
the poor survival of the dopaminergic neurons after transplantation.  Supplementation of 
the transplants with various neurotrophic factors has had some success in improving 
neuronal survival (for review, see Brundin et al. 2000). Transplantation of rat VM tissue 
to 6-OHDA lesioned adult rats is used to model the clinical situation, in order to 
optimise transplantation procedures and to experimentally test factors that may improve 
graft survival. In the rat VM, dopaminergic neurons proliferate between E11 and E15, 
undergoing their final mitotic divisions on E14-15 (Hanaway et al. 1971; Lauder and 
Bloom 1974; Altman and Bayer 1981; Solberg et al. 1993; Bayer et al. 1995).  Thus, 
tissue is generally harvested from the rat VM at E14 for experimental modelling of 
transplantation for Parkinson's disease. The identification of neurotrophic factors that 
are expressed in the developing VM at the time that this tissue would be harvested for 
transplantation should yield important information about potential factors which could 
be used to support this tissue after transplantation. 
The expression of various BMPs (Jordan et al. 1997) in the developing rodent 
mesencephalon suggest that the BMPs play a role in the development and survival of 
these nigrostriatal dopaminergic neurons.  The neurotrophic abilities of various BMPs 
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and GDFs on dopaminergic neurons from the E14 VM have been documented 
(Krieglstein et al. 1995a, 1995b; Jordan et al. 1997; Sullivan et al. 1998; Strelau et al. 
2000; Brederlau et al. 2002).  The present study shows for the first time that GDF-5 is 
expressed in the developing VM from E12 onwards and that levels of this protein reach 
a peak on E14, the day on which dopaminergic neurons undergo their terminal 
differentiation. Neurons of the rat VM are produced between days E11 and E15, with 
maximal production being reported on days E14 and E15 (Hanaway et al. 1971) or on 
E13 (Lauder and Bloom, 1974). A further study found that production of these neurons 
was evenly distributed throughout days E13, 14 and 15 (Altman and Bayer 1981). 
Dopamine can be first detected in the tegmentum of rat embryos of crown-rump length 9 
mm, which corresponds to day E13 (Olson and Seiger 1972). Thus the time-course of 
GDF-5 expression found in the present study parallels that of VM dopaminergic neuron 
production, suggesting that it plays a role in dopaminergic neuron development. 
Furthermore, the time-course of GDF-5 expression in this brain region was found to be 
consistent with that of TH, a marker for dopaminergic neurons. These data, along with 
previous reports that administration of exogenous rhGDF-5 has survival-promoting 
effects on dopaminergic neurons in cultures of rat E14 VM (Krieglstein et al. 1995b; 
Lingor et al. 1999), further supports the use of GDF-5 as an adjunct to E14 VM 
transplants for Parkinson's disease.  It is also interesting to note that the expression of 
Nurr1, an orphan nuclear receptor crucial for the development of midbrain dopaminergic 
neurons (Zetterstrom et al. 1997; Castillo et al. 1998), during development of the rat 
VM, peaks between E13 and E15 (Volpicelli et al. 2004), paralleling that of GDF-5.  It 
is possible that GDF-5 may play a role in Nurr1 expression and subsequently TH 
expression (see Chapter 9). 
 
 
 84 
5.4.6 GDF-5 expression in the developing rat striatum  
GDF-5 was strongly expressed in the embryonic rat striatum at each of the embryonic 
ages examined.  Given the strong expression of GDF-5 at E14, it is likely that protein 
expression begins at an earlier stage in development than this, however earlier ages were 
not examined in this study.  The demonstration that various BMPs and their receptors, 
including those for GDF-5, have been detected in the striatum at various stages during 
development (Dewulf et al. 1995; Soderstrom et al. 1996; Mehler et al. 1997; Zhang et 
al. 1998; Charytoniuk et al. 2000), suggests that various BMPs/GDFs may play a role in 
the striatal development.  The role(s) of GDF-5 in the striatal development may be 
diverse.  In the rat, axons of nigral dopaminergic neurons start to invade the striatum at 
E16 and continue to do this pre- and post-natally (Unsicker et al. 1996).  This process of 
neurite outgrowth from the VM to the striatum has been shown to be controlled by 
spatially and temporally regulated chemoattractive (from the MFB and later the 
striatum) and chemoreplusive (from the brainstem and cortex) cues, from the 
surrounding brain regions (Gates et al. 2004).  It is possible that GDF-5 may act as a 
chemoattractant for developing nigrostriatal axons.   
The present study also found GDF-5 expression in the developing and adult rat 
striatum.  The striatum contains GABAergic neurons, a subset of which co-express the 
calcium binding protein calbindin, that degenerate in Huntingtons disease (Kiyama et al. 
1990).   As BMP-2 has been shown to promote calbindin phenotype and promote 
dendritic growth in cultured rat striatal neurons (Gratacòs et al. 2001), it is possible 
GDF-5 may also exert an effect on this neuronal population, and may be useful to study 
in relation to its use a neurotrophic factor for treatment of Huntingtons disease.   
 
 
 
Figure 5.1: 
 
Representative immunoblots of (A) cell extracts and (B) conditioned medium 
from a GDF-5 secreting CHO cell line, stained with P3/66 antibody.  (A) shows 
that intracellularly the P3/66 antibody detects a number of high molecular weight 
bands but not the mature 15kDa processed form of GDF5.  (B) shows 
conditioned medium from GDF-5 secreting CHO cells, lane1 = control 
transfected CHO cells at 1 DIV, lane 2= control cells at 3 DIV, lanes 3-8 = GDF-
5 secreting cells at 1, 3, 5, 7, 14, 21 DIV respectively.  Lane 9 = 50ng rhGDF-5 
run as a positive control.  Only the mature form of GDF-5 (15kDa) was detected 
in conditioned medium from the GDF-5 secreting CHO cells. 
 
Figure 5.2: 
 
(A) Clustal W sequence alignment showing the residues in the C-terminal 
end of the human GDF-5 protein that the antibody P3/66 recognises.  
Alignments were done using a web-based version of Clustal W available 
at www.embl.org. 
(B) Representative western blot showing characterisation of the P3/66 
antibody.  50ng/ml rhGDF-5 was run in each lane, in either reducing 
sample buffer containing 100mM of DTT (+ DTT) or in sample buffer 
not containing DTT (-DTT).  When run under reducing conditions which 
breaks the di-sulphide bonds involved in dimer formation, rhGDF-5 
migrates as a monomer of approximately 15kDa.  Although the antibody 
shows greater affinity for the reduced form of rhGDF-5, the 25kDa non-
reduced form of GDF-5 can be detected under non-reducing conditions. 
 
Figure 5.3: 
 
Representative western blots of an immunoabsorption assay confirming the 
specificity of P3/66 antibody for GDF-5.  (A) represents a control blot where the 
primary antibody was applied as normal.  (B) shows a blot probed with P3/66 
antibody that had been preincubated with excess monomeric rhGDF-5 prior to 
application on the blot.  Lane 1 = adult rat striatum, lane 2 = adult rat SN, lane 3 
= 50ng rh GDF-5. 
 
 
Figure 5.4: 
 
Representative western blot showing two different processed forms of the GDF-5 
precursor protein in adult rat brain samples.  Values shown on the left indicate 
molecular weight in kDa.  Lane 1 = E20 VM, lane 2 = adult rat striatum, lane 3 = 
adult rat SN.  The two different processed forms are indicated by black arrows. 
 
 
Figure 5.5:   
 
(A) Representative immunoblot of GDF-5 expression in whole brain extracts 
from rats aged E11 to E20, P1, 6, 14, 22 and in the adult rat striatum (STR), 
whole brain (WB) and kidney (KID) using the P3/66 antibody.  The bands at 
55kDa correspond to the predicted molecular weight of the GDF-5 precursor 
protein.  Molecular weight markers are shown in the left hand lane.  RhGDF-5 
was run in the right hand lane.  The blot was stripped of GDF-5 antibody and 
reprobed with antibody to -actin (B). 
 
 
 
Figure 5.6: 
 
(A) Representative immunoblot of GDF-5 expression in extracts from adult 
rat tissues using the P3/66 antibody to GDF-5.  Lane 1 = brain, lane 2 = heart, 
lane 3 = lung, lane 4 = liver, lane 5 = kidney, lane 6 = spleen.  Molecular weight 
markers are shown in the left hand lane.  rhGDF-5 was run in the right hand lane 
(data not shown).  The blot was stripped of GDF-5 antibody and reprobed with 
antibody to -actin (B). 
 
 
 
Figure 5.7: 
 
(A)  Representative immunoblot of GDF-5 expression in extracts from adult 
rat brain using the P3/66 antibody.  Lane 1 = cortex, lane 2 = striatum, lane 3 = 
midbrain, lane 4 = cerebellum.  The blot was stripped of GDF-5 antibody and 
reprobed with antibody to -actin (B). 
 
Figure 5.8: 
 
GDF-5 expression in the developing rat VM in vivo.  (A) Representative 
immunoblot of GDF-5 (55 kDa) expression in VM from rats aged E12, 13, 14, 
15, 18, 19 and P2. Blots were stripped of GDF-5 antibody and probed with 
antiserum to TH (B; bands at 45 kDa), then stripped and probed with antibody to 
-actin (C). 
 
 
Figure 5.9: 
 
Immunocytochemical analysis of GDF-5 expression in cultures of E14 rat VM 
after 2 DIV, using P3/66 antibody, which was visualised using anti-mouse IgG 
linked to FITC (A).  Cultures were counter-stained with DAPI (B). (Bar = 50 
m.) 
 
Figure 5.10: 
 
 
GDF-5 expression in the developing rat striatum in vivo.  Representative 
immunoblot of GDF-5 (55 kDa) expression in the striatum from rats aged E14-
E20. 
 
 
 85 
6.0 EFFECTS OF GDF-5 ON THE NUMBERS AND MORPHOLOGY OF 
EMBRYONIC RAT MIDBRAIN DOPAMINERGIC NEURONS IN VITRO 
 
6.1 Aims  
 
 To examine the effects of GDF-5 treatment on numbers of dopaminergic neurons 
and astrocytes in cultures of E14 rat VM. 
 To examine the expression of BMP receptors in E14 rat VM and potential 
changes in their expression with time in culture. 
 To determine if BMPR-Ib is necessary for GDF-5 to have effects on 
dopaminergic neurons in vitro. 
 To examine the effects of GDF-5 on the morphology of dopaminergic neurons in 
cultures of E14 rat VM. 
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6.2 Introduction 
The TGF- superfamily is a large family of structurally related growth factors.  It can be 
divided into two main groups, based on phylogenetic relationships; the TGF-/Act 
group and the BMP/GDF group (for recent review, see de Caestecker, 2004 and Chapter 
3).  The BMPs represent one of the largest families of the TGF- superfamily and have 
been shown to have effects on a variety of neuronal populations (for reviews, see 
Mehler et al., 1997; Ebendal et al, 1998). Various BMPs, as well as their receptors 
(BMPRs) and antagonists, have been shown to be expressed in the adult rat brain, 
including the SN and the striatum, suggesting that BMPs may modulate the function of 
these regions in adulthood (Tomizawa et al., 1995; Soderstrom et al., 1996; Mehler et 
al., 1997; Zhang et al., 1998; Soderstrom & Ebendal, 1999; Charytoniuk et al., 2000; 
Strelau et al., 2000; Chen et al., 2003).  BMP-2, -4 and -6 are expressed in the 
developing rat VM at E13 and E15 (Jordan et al., 1997). Recently, it has been reported 
that BMP-5, -6 and -7 increase the numbers of dopaminergic neurons in cultures of E14 
rat VM (Brederlau et al., 2002).  These studies suggest that BMP family members may 
be involved in dopaminergic neurogenesis and / or provide neurotrophic support in the 
developing VM.  
The GDFs belong to the same subfamily of the TGF- superfamily as the BMPs and 
have been shown to be involved in a variety of developmental processes, ranging from 
chondrogenesis in the developing limb to the regulation of ovarian follicle development 
(for recent reviews, see Edwards & Francis-West, 2001; Balemans & Van Hul, 2002; 
Knight & Glister, 2003).  The role of GDF-5 in limb development has been well 
established (for review see Buxton et al., 2001) and mutations in the GDF-5 gene result 
in skeletal abnormalities in mice (Storm et al., 1994) and humans (Thomas et al., 1996).  
Recently it has emerged that a number of the GDFs are expressed in the nervous system 
(Lee, 1991; Bottner et al., 1999; Nakashima et al., 1999; Soderstrom & Ebendal, 1999; 
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Zhao et al., 1999; Vokes & Kreig, 2000; Schober et al., 2001; Watabake et al., 2001). 
We (O’Keeffe et al, 2004a; see Chapter 5) and others (Krieglstein et al., 1995b) have 
shown that GDF-5 is expressed in the developing rat brain.  Furthermore, we have found 
that GDF-5 is expressed in the developing rat VM during the period of dopaminergic 
neurogenesis, which peaks on E14 (O’Keeffe et al. 2004a; see Chapter 5). It has been 
shown that GDF-5 can protect E14 rat VM dopaminergic neurons from neurotoxic 
agents (Krieglstein et al., 1995a; Lingor et al., 1999). Furthermore, GDF-5 has 
neuroprotective effects on the adult nigrostriatal dopaminergic pathway in the 6-OHDA 
rat model of PD (Sullivan et al., 1997, 1999; Hurley et al., 2004) and improves the 
survival of grafts of E14 rat dopaminergic neurons in this rat model of PD (Sullivan et 
al., 1998).  Together, these studies suggest that GDF-5 may act as a dopaminergic 
neurotrophin, both during the development of the VM and in the adult brain. Although 
GDF-5 has been previously shown to increase the survival of dopaminergic neurons in 
vitro (Krieglstein et al., 1995b), its effects on the morphological development of these 
neurons has not been reported.  
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6.3      Results 
 
6.3.1 GDF-5 increases the numbers of dopaminergic neurons and astrocytes in E14 rat 
VM cultures 
Treatment of E14 rat VM cultures for 6 DIV with GDF-5 exerted effects on 
dopaminergic neurons and astrocytes, since Western blotting experiments showed that 
GDF-5 treatment increased the levels of expression of TH and GFAP protein in these 
cultures.  However GDF-5 did not alter the expression of the neuronal marker -III 
tubulin (Figure 6.1A-D). 
GDF-5 treatment resulted in an increase in the numbers of TH-immunopositive neurons 
surviving for 6 DIV (Figure 6.2A, B, C). Application of GDF-5 at doses of 1ng/ml and 
10ng/ml resulted in significant increases (3.1- and 2.6-fold, respectively) in the number 
of dopaminergic neurons, when compared to control values (Figure 6.4A; P<0.001). No 
significant difference was observed between the numbers of dopaminergic neurons in 
cultures treated with 1ng/ml and 10ng/ml GDF-5.  
GDF-5 treatment for 6 DIV also induced a marked increase in the numbers of GFAP-
immunopositive cells in the cultures (Figure 6.3A, B, C). Treatment with GDF-5 at 
doses of 1ng/ml and 10ng/ml resulted in significant increases (2.3- and 5.6-fold, 
respectively) in the number of astrocytes, when compared to control values (Figure 
6.4B; P<0.001). In contrast to GDF-5’s effect on the numbers of dopaminergic neurons, 
its effect on astrocytes was dose-dependent, with a significant difference observed 
between the numbers of GFAP-immunopositive cells in cultures which had been treated 
with 1ng/ml and 10ng/ml GDF-5 (Figure 6.4B; P<0.001). 
There was no significant difference in either the total number of cells (as determined by 
DAPI staining) or the number of TUJ-1-immunopositive cells between any of the treated 
or untreated cultures (see Chapter 7, Figure 7.4). 
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6.3.2 Loss of BMPR-Ib expression in vitro abolishes the ability of GDF-5 to increase 
the numbers of dopaminergic neurons 
RT-PCR analysis demonstrated the expression of all three BMP receptors, BMPR-Ia, -Ib 
and -II, in extracts of E14 rat VM (Figure 6.5A). However, when cells from the E14 VM 
were cultured, the expression of BMPR-Ib was dramatically down-regulated, even after 
1 DIV (Figure 6.5C). Low levels of BMPR-Ib mRNA were present at 1, 2 and 4 DIV 
(Figure 6.5C), but expression was completely lost by 6 DIV (Figure 6.5B, C). In 
contrast, the expression of BMPR-Ia and –II remained in the cultures after 6 DIV 
(Figure 6.5B).  Immunocytochemistry was used to confirm the RT-PCR.  Cells which 
were immunopositive for BMPR-II and BMPR-Ia were detected in the cultures after 6 
DIV (Figure 6.6A and B, respectively), but no positive immunostaining for BMPR-Ib 
was observed in any cultures at this time-point (Figure 6.6C).  Negative controls where 
the primary antibody was omitted displayed no staining for each antibody tested (Figure 
6.6D).  Cultures treated with 10ng/ml GDF-5 for 24 h at the time of plating displayed a 
significant increase in the numbers of dopaminergic neurons when compared to 
untreated cultures (Figure 6.7A; P<0.05). However, when 10ng/ml GDF-5 was added at 
6 DIV for 24 h, no increase in the numbers of dopaminergic neurons was observed 
(Figure 6.7B). 
 
6.3.3 GDF-5 improves the morphology of dopaminergic neurons in E14 rat VM 
cultures 
Morphological analysis of the cultured dopaminergic neurons revealed that treatment 
with GDF-5 (at doses of either 1ng/ml or 10ng/ml) resulted in increased differentiation 
of these cells in vitro.  Dopaminergic neurons had a more complex morphology 
following GDF-5 treatment when compared to controls (Figure 6.8A, B). 
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A significant increase in total neurite length per dopaminergic neuron was observed in 
GDF-5-treated cultures, when compared to control cultures (Figure 6.9A; P<0.001). 
Both doses of GDF-5 significantly increased neurite length at all levels of the neuritic 
field (P<0.001), with the greatest increases (at least four-fold) measured in the length of 
secondary and tertiary neurites and smaller increases observed in the length of primary 
and quaternary neurites (Figure 6.10A). The average somal area per dopaminergic 
neuron was also significantly increased following GDF-5 treatment (Figure 6.9B; 
P<0.001). The number of branch points per dopaminergic neuron (as measured by the 
mean number of nodes per dopaminergic neuron) was significantly increased by GDF-5 
treatment (Figure 6.9C; P<0.001). Analysis of the degree of branching at different levels 
of the neuritic field established that the greatest increases were at the level of secondary 
and tertiary branches, compared to those at primary and quaternary branches (Figure 
6.10B). There was no significant difference between the effects of the two doses of 
GDF-5 on any of these morphological parameters.   
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6.4 Discussion 
 
6.4.1 Effects of GDF-5 on the cellular composition of E14 rat VM cultures 
This study examined the effect of GDF-5 on cultures of E14 rat VM.  When applied at 
the time of plating, GDF-5 increased the numbers of dopaminergic neurons present in 
the cultures after 6 DIV, in agreement with previous studies (Krieglstein et al., 1995b).  
GDF-5 was added to the culture medium at this early stage because it had been 
previously observed that during the development of the rat VM, GDF-5 protein levels 
peak on E14 (O’Keeffe et al. 2004a; see Chapter 5).  It is known that dopaminergic 
neurons in the rat VM undergo their final mitosis at E14 or E15 (Altman & Bayer, 1981; 
Bayer et al., 1995), thus factor(s) involved in the induction of a dopaminergic fate or in 
regulating the survival of these neurons would be expected to peak in the VM at about 
E14.  
Previous reports have shown that addition of the neurotrophic factors GDNF, 
TGF-1/2/3 or ActA, to E14 rat VM cultures at 24 hs after plating, induced 1.5-, ~2.3- 
and 1.6-fold increases, respectively, in the numbers of dopaminergic neurons after 8 
DIV when compared to controls (Krieglstein et al., 1995a).  It has also been shown that 
treatment of E14VM cultures with 10ng/ml BMP-2 for 7DIV, resulted in a 2.37 fold 
increase in the numbers of dopaminergic neurons compared to controls (Reiriz et al. 
1998).  In the present study, GDF-5 treatment from the time of plating resulted in a ~3-
fold increase in dopaminergic neuronal survival after 6 DIV.  Thus, GDF-5 has powerful 
neurotrophic effects on mesencephalic dopaminergic neurons in culture and is one of the 
most potent dopaminergic neurotrophins documented to date. 
It has recently been reported that GDF-5 treatment does not increase the numbers 
of dopaminergic neurons in cultures of E14 rat VM (Brederlau et al., 2002). The 
apparent discrepancy between this study and the present one may be explained by the 
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fact that, in our study, GDF-5 was added from the time of plating of the cultures (i.e. 
DIV 0), whereas Brederlau and co-workers did not apply GDF-5 to their cultures until 
DIV 7.  Given that GDF-5 protein levels in the developing rat VM peak on E14 and are 
subsequently down-regulated, reaching lowest levels around birth (O’Keeffe et al., 
2004a; see Chapter 5), it is possible that E14 dopaminergic neurons may become less 
responsive to GDF-5 as they mature.  This may be due to changing receptor expression 
patterns with maturation in vitro  (see below). 
In agreement with previous reports (Krielgstein et al., 1995b; Brederlau et al., 
2002), it was found here that GDF-5 treatment resulted in an increase in the numbers of 
GFAP-positive cells in these cultures. This raises the possibility that GDF-5 may 
mediate its effect on neuronal survival in the cultures indirectly, by increasing the 
numbers of astrocytes and thus increasing the levels of astrocyte-derived neurotrophic 
factors. It has been shown that the presence or absence of astrocytes affects the 
morphological development of E14 rat VM dopaminergic neurons in vitro (Wood et al., 
2003).   Thus, GDF-5 may indirectly increase the numbers of dopaminergic neurons and 
improve their morphological development by increasing the numbers of astrocytes 
present in the culture. The effect of GDF-5 to increase the number of astrocytes in these 
cultures was dose-dependent, unlike its effect on the number of dopaminergic neurons. 
Thus, the increase in the number of astrocytes with increasing dose of GDF-5 was not 
paralleled by an increase in the numbers of dopaminergic neurons.  This suggests that 
the effect of GDF-5 on these neurons is not solely due to an astrocyte-mediated action. 
Indeed, another study in our laboratory has found that the effects of GDF-5 on the 
survival of dopaminergic neurons in vitro are not significantly reduced by depletion of 
astrocytes in E14 rat VM cultures (Wood et al., in preparation).   This is in agreement 
with a previous study showing that although BMP-2 increases the numbers of astroglial 
cells in E14 rat VM cultures, its neurotrophic effect on dopaminergic neurons is not 
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mediated by astroglial cells (Reiriz et al. 1998).  A direct action on dopaminergic 
neurons is substantiated by the fact that GDF-5 application to E14 rat VM cultures at 1 
DIV results in nuclear accumulation of phosphorylated smad proteins in these cells (see 
Chapter 7).  The possibility of a direct action of GDF-5 on dopaminergic neurons is also 
supported by the fact that mRNA for both BMPR-Ib and BMPRII, the receptors which 
are necessary for GDF-5 signalling (Nishitoh et al. 1996), have been found in the adult 
rat SN and striatum (Chen et al., 2003). Furthermore, the expression of BMPR-II mRNA 
has been localised to dopaminergic neurons in the adult rat SN (Charytoniuk et al., 
2000).  
 
6.4.2 Expression of BMP receptors in the rat VM 
In agreement with previous studies on chick embryos (Ming et al., 2002), we have found 
BMPR-II, -Ia and BMPR-Ib are expressed in the rat VM at E14. The expression of 
various BMPs (Jordan et al., 1997), GDF-1 (Wall et al. 2000) and GDF-5 (O’Keeffe et 
al., 2004a; see Chapter 5) in the VM at this stage suggests that cells in this tissue at this 
stage of development are responsive to BMP and GDF signalling. It has been reported 
that the expression of BMPs generally peaks around the perinatal period (for review, see 
Mehler et al., 1997). However, we have found that GDF-5 expression peaks much 
earlier during rat brain development (at E14 in both whole brain and VM), reaching its 
lowest level around the perinatal period before being up-regulated in the post-natal 
period to reach high levels in the adult brain, including the SN and striatum (O’Keeffe et 
al., 2004a; see Chapter 5). The expression of BMPR-II, -Ia and BMPR-Ib in the adult rat 
striatum and SN (Chen et al. 2003), suggests that BMPs/GDF-5 play roles in these 
regions in the adult rat brain.   
It has been suggested that the maturation state of dopaminergic neurons in E14 
VM cultures at 7 DIV are representative of these mature dopaminergic neurons at the 
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time of birth (Brederlau et al., 2002). Brederlau and co-workers have shown that 
neurons at this stage of development are affected by BMP signalling, as evidenced by 
the increase in TH-immunopositive neurons and nuclear translocation of smad proteins, 
but that they are largely unresponsive to GDF-5 (Brederlau et al., 2002). Our findings 
complement these results, since we show that the expression of BMPR-Ib is down-
regulated in these cultures after 6 DIV, suggesting that they become unresponsive to 
GDF-5 at this stage in culture. In agreement, we found that addition of GDF-5 for 24 h 
at 0 DIV (when BMPR-Ib is present) induced a significant increase in the numbers of 
dopaminergic neurons in these cultures, whereas addition of GDF-5 for 24 h after 6 DIV 
(when BMPR-Ib is no longer expressed) did not. This suggests that the actions of GDF-
5 and various other BMPs on the development and survival of rat VM dopaminergic 
neurons may be exerted at different stages during embryonic development, with GDF-5 
acting at an earlier stage than the BMPs. Given its earlier expression, GDF-5 may be 
involved in the induction of a dopaminergic phenotype in progenitor cells in this area of 
the brain, an action which has been bestowed on other members of the TGF- 
superfamily (Farkas et al., 2003, see Chapter 6). 
 
6.4.3 Effects of GDF-5 on the morphology of dopaminergic neurons 
Having shown that GDF-5 increases the numbers of dopaminergic neurons in vitro, it 
was assessed whether this factor might also affect the morphological development of 
these neurons in vitro.  Previous studies have shown that BMPs can affect the 
morphological development of striatal neurons (Gratacòs et al., 2001).  Another member 
of the TGF- superfamily, GDNF, has been shown to be a potent neurotrophic factor for 
dopaminergic neurons in VM cultures (Lin et al., 1993; Krieglstein et al., 1995a).  It has 
been reported that treatment with 10ng/ml GDNF for 7 DIV resulted in an increase in 
neurite length and branching of dopaminergic neurons in E14 rat VM cultures (Widmer 
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et al., 2000).  In that study, GDNF resulted in a 1.5-fold increase in the total neurite 
length per dopaminergic neuron (Widmer et al., 2000).  Also, treatment of E14 VM 
dopaminergic neurons for 5DIV with 10ng/ml persphin has been shown to result in a 2-
fold increase in total neurite length per dopaminergic neurons (Åkerud et al. 2002).  The 
present findings are similar, showing that GDF-5 treatment for 6 DIV resulted in a 2.5-
fold increase in the total neurite length per dopaminergic neuron. Cell somal area was 
reported to be increased by 1.3-fold by GDNF treatment in the Widmer study, while in 
the present study a 1.4-fold increase in this parameter due to GDF-5 treatment was 
observed.  Widmer and co-workers also found that treatment with GDNF resulted in a 
1.4-fold increase in the number of primary nodes per dopaminergic neuron (Widmer et 
al., 2000).  In agreement, GDF-5 treatment resulted in a 1.4-fold increase in the numbers 
of primary nodes per dopaminergic neuron. BMP-2 has also been shown to affect the 
morphological development of E14 rat VM dopaminergic neurons (Reiriz et al. 1998).  
In agreement with the present findings, treatment of rat E14 VM cultures with 10ng/ml 
BMP-2 for 7 DIV resulted in a 1.4-fold increase in the number of primary nodes per 
dopaminergic neuron, although no effect on somal area was seen  (Reiriz et al. 1998).  
Furthermore, our detailed morphological analysis showed that GDF-5 treatment resulted 
in an increase in neurite branching and neurite length at all levels of the neuritic field. 
The greatest effects were seen on the secondary and tertiary neurites, where GDF-5 
induced a ~5-fold increase in length (in comparison to ~1.6-fold increase in length of 
primary neurites).    
These results show that GDF-5, like other members of the TGF- superfamily, 
has potent effects on the morphological development of VM dopaminergic neurons in 
vitro.  The observed increases in dopaminergic neuronal survival and in the size of their 
neuritic fields have important implications for research on intrastriatal neuronal 
transplantation for PD, where efforts are concentrated on promoting the survival of 
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dopaminergic neurons and their functional integration into the host striatum after 
transplantation.  It has been reported that GDNF treatment can increase fiber outgrowth 
from embryonic rat dopaminergic VM tissue after transplantation into the striatum of 6-
OHDA lesioned rats (Rosenblad et al., 1996; Wang et al., 1996).  It has also been shown 
that GDF-5 is at least as effective as GDNF in improving the survival of grafts of E14 
VM in a rat model of PD (Sullivan et al., 1998). Furthermore previous studies have 
found that during the development of the rat VM, GDF-5 expression peaks at E14 
(O’Keeffe et al., 2004a; see Chapter 3), while that of GDNF peaks at a later date 
(O’Keeffe and Sullivan, unpublished observations).   These findings suggest that GDF-5 
may be a candidate neurotrophic factor for use in attempts to improve the survival, 
neurite outgrowth and functional integration of transplanted embryonic dopaminergic 
neurons for the treatment of PD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1:   
 
Representative Western blots on protein extracts from cultures of E14 rat VM 
grown for 6 DIV, immunostained for  (A) TUJ, (B) GFAP, (C) TH and (D) -
actin.  Densitometric analysis after normalisation to -actin levels for the 
corresponding sample showed that GDF-5 treatment induced no change in TUJ 
levels but increased levels of GFAP and TH. 
 
 
Figure 6.2:   
 
Photomicrographs showing representative cultures of E14 rat VM grown for 6 
DIV, immunocytochemically stained for TH.   (A) shows a control culture, (B) 
shows a culture that received 1ng/ml GDF-5 every 2 DIV, (C) shows a culture 
that received 10ng/ml GDF-5 every 2 DIV.   
Scale bar = 100m 
 
 
Figure 6.3:   
 
Photomicrographs showing representative cultures of E14 rat VM grown for 6 
DIV, immunocytochemically stained for GFAP.  (A) shows a control culture, (B) 
shows a culture that received 1ng/ml GDF-5 every 2 DIV, (C) shows a culture 
that received 10ng/ml GDF-5 every 2 DIV.   
Scale bar = 100m 
 
 
Figure 6.4: 
 
Increase in numbers of (A) TH-immunopositive and (B) GFAP-immunopositive 
cells in cultures treated with 1ng/ml or 10ng/ml GDF-5 every 2DIV for 6 DIV, 
expressed as a percentage of those in untreated cultures.  Data represent mean  
SEM taken from three independent experiments.   
** P<0.001  compared to untreated (control) cultures 
$ P<0.001  
 
 
Figure 6.5: 
 
RT-PCR analysis of the expression of BMP receptors, BMPR-II, BMPR-Ib, 
BMPR-Ia, in (A) freshly dissected E14 rat VM tissue and (B) cultures of E14 rat 
VM grown for 6 DIV.  (C) RT-PCR analysis showing the loss of expression of 
BMPR-Ib in E14 rat VM tissue over 6 days in culture.  
 
 
 
Figure 6.6: 
 
Immunocytochemical analysis of the BMP receptors, (A) BMPR-II, (B) BMPR-
Ia and (C) BMPR-Ib in E14 rat VM cultures after 6 DIV.  (D) shows a negative 
control, i.e. a cultures that received no primary antibody.   
Scale bar = 50m. 
 
 
Figure 6.7: 
 
Numbers of dopaminergic neurons per field in E14 rat VM cultures at (A) 1 DIV 
and (B) 6 DIV following treatment with 10ng/ml GDF-5 for 24 hours.  Data 
represent mean  SEM taken from two independent experiments.   
** P<0.05 compared to untreated (control) cultures. 
  
Figure 6.8: 
 
Representative dopaminergic neurons in E14 rat VM culture, 
immunocytochemically stained for TH after 6 DIV, grown under (A) control 
conditions, or (B) in medium containing 10ng/ml GDF5.   
Scale bar = 20m.   
 
 
Figure 6.9:   
 
Effects of GDF-5 treatment on (A) total neurite length per dopaminergic neuron, 
(B) somal area per dopaminergic neuron and (C) number of branches per 
dopaminergic neuron in E14 rat VM culture after 6 DIV.  Data represent mean  
SEM taken from 50 neurons from 3 independent experiments. 
** P<0.001 compared to untreated (control) cultures. 
 
 
Figure 6.10:   
 
Effects of GDF-5 treatment on (A) neurite length and (B) numbers of branches at 
each level of the neurite field in dopaminergic neurons in E14 rat VM culture 
after 6 DIV.  Data represent mean  SEM taken from 50 neurons from 3 
independent experiments. 
** P<0.001 compared to untreated (control) cultures. 
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7.0 ANALYSIS OF THE MECHANISM OF GDF-5 INDUCED INCREASES 
IN TH-POSITIVE CELL NUMBERS AND THE EFFECT OF GDF-5 AND 
WNT-5a CO-TREATMENT ON TH-POSITIVE CELL  NUMBERS IN 
E14 RAT VM CULTURES 
 
7.1 Aims  
 
 To examine the expression of BMP receptors in the VM of TH-GFP mice. 
 To analyse phospho-smad activation by GDF-5 in E14 VM cultures. 
 To analyse the mechanism of increase in dopaminergic numbers induced by 
GDF-5. 
 To examine the expression of Ror2 in E14 rat VM. 
 To examine the effect on numbers of TH-positive cells when adding GDF-5 and 
Wnt-5a to cultures of E14 rat VM. 
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7.2 Introduction 
 
Treatment with GDF-5 has been shown to increase the numbers and improve the 
morphological development of E14 rat VM dopaminergic neurons (O’Keeffe et al. 
2004b; chapter 6).  However it is not known whether GDF-5 improves the survival of 
dopaminergic neurons, or induces a dopaminergic phenotype in uncommitted 
precursors.  Furthermore, little is known about GDF-5’s mechanism of action on 
neuronal cells.  For example whether it induces phospho-smad activation.  Many studies 
have examined the effects of adding BMPs to cultures of E14 rat VM (Krieglstein et al. 
1995a, 1995b; Jordan et al. 1997; Lingor et al. 1999; Brederlau et al. 2002).  However, it 
is not been shown that embryonic dopaminergic neurons from the VM express BMP 
receptors, although adult dopaminergic neurons have been shown to express transcripts 
for BMPR-II (Charytoniuk et al. 2000).  All BMPs and GDFs are thought to signal 
through the serine/threonine kinase receptors (for review see de Caestecker 2004).  
However recently it has emerged that a tyrosine kinase receptor called Ror2 can act as a 
receptor for GDF-5 (Dr. P. Tylanowski, personal communication) and Wnt-5a (Oishi et 
al. 2003).  Ror2 (along with Ror1) was cloned from a human neuroblastoma cell line 
(Masiakowski and Carroll 1992). 
As Wnt-5a has previously been shown to increase the numbers of dopaminergic 
neurons in E14 rat VM cultures (Castelo-Branco et al. 2003), it is possible that GDF-5 
and Wnt-5a may have additive or synergistic effects in this system. 
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7.3 Results 
 
7.3.1 BMP receptors are expressed in VM of TH-GFP mouse 
In the TH-GFP mouse, GFP expression is under the control of the TH promoter.  As 
such, cells in the VM that express TH also express GFP.  Using FACS sorting, cells can 
be separated into TH-positive and TH-negative fractions.  Real-time PCR analysis using 
cDNA from the VM of E13.5 TH-GFP mice that was FACS sorted into from TH+ and 
TH- fractions (a kind gift from Ms. Nina Rawal, Karolinska Institute), showed that 
BMPR-II and BMPR-Ia were expressed in TH-positive and TH-negative fractions 
(Figure 7.1A, B respectively).  Surprisingly no expression of BMPR-Ib was detected in 
either TH+ or TH- fractions. 
No expression of BMPR-Ib was detected in either the TH-positive or TH-negative 
fractions in the E13.5 VM.  However RT-PCR analysis on RNA extracted from the E14 
rat VM showed that that all three BMP receptors are expressed in the rat VM (Chapter 
6; Figure 6.5A).  A pilot study (data not shown) revealed that BMPR-Ib is expressed in 
the eight-week old human VM. 
 
7.3.2 GDF-5 stimulates smad activation and nuclear translocation in neurons 
 Addition of GDF-5 (50ng/ml) for two hs to E14 rat VM cultures which had been 
growing for 24 hs in serum-free medium, induced nuclear accumulation of 
phosphoryalted smad-1, -5, -8 (Figure 7.2B).  No smad-1, -5, -8 phosphorylation was 
observed in untreated cultures (Figure 7.2A). 
 
7.3.3 GDF-5 increases the numbers of TH-positive  but not TUJ-1-positive, Nurr-1-
positive or total cell number in E14 rat VM cultures 
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Treatment of cultures of E14 rat VM grown for 3 DIV in serum-free conditions with 
10ng/ml GDF-5 induced an approximately two-fold increase in the numbers of TH-
positive cells when compared to control cultures (Figure 7.3A, B, C; P<0.01).  No 
difference was observed between neuronal numbers in control cultures and GDF-5 
treated cultures (Figure 7.4A, B, C).   No difference was also observed between the total 
numbers of cells in control cultures and GDF-5 treated cultures (Figure 7.5A, B, C).  
When the data was expressed as percentages of total cells, GDF-5 increased the 
percentage of neurons (Figure 7.6A; P<0.01) and the percentage of cells that expressed 
TH (Figure 7.6B; P<0.01).  No difference was observed between the numbers of Nurr-1 
positive cells in control cultures and GDF-5 treated cultures (Figure 7.7A, B, C), 
whereas the percentage of Nurr-1 positive cells that expressed TH in GDF-5 treated 
cultures was significantly increased (Figure 7.7D; P<0.05).  No difference was observed 
between the numbers of pyknotic nuclei in control cultures and GDF-5 treated cultures 
(Figure 7.8). 
 
7.3.4 GDF-5 and Wnt-5a do not have additive effects to increase the numbers of 
dopaminergic neurons in cultures of E14 rat VM 
RT-PCR analysis showed that Ror2 was strongly expressed in RNA extracted from the 
E14 rat VM (Figure 7.9A).  The presence of this novel receptor for both GDF-5 and 
Wnt-5a may allow these factors to increase the numbers of TH-positive neurons in 
cultures of E14 rat VM to a greater extent than either factor alone.  To examine this 
further, cultures of E14 rat VM were treated with Wnt-5a, GDF-5 or a combination of 
both.  As observed previously, GDF-5 treatment of E14 rat VM cultures for 3 DIV 
resulted in an approximately three-fold increase in the percentage of neurons expressing 
TH (Figure 7.9B; P<0.01) and approximately a two-fold increase in the percentage of 
total cells that expressed TH (Figure 7.9C; P<0.01).  Wnt-5a treatment induced similar 
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increases in the percentage of neurons that expressed TH (Figure 7.9B; P<0.01) and in 
the percentage of total cells that expressed TH (Figure 7.9C; P<0.01).  No significant 
synergistic or additive effects were seen in either parameter following GDF-5 and Wnt-
5a co-treatment (Figure 7.9B, C).  A control for Wnt-5a involved adding to the cultures 
the buffer used in the extraction of Wnt-5a.  No significant increase in the percentage of 
neurons expressing TH (Figure 7.10B) or in the percentage of total numbers of cells 
expressing TH was found on addition of the extraction buffer (Figure 7.9C). 
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7.4 Discussion 
 
7.4.1 Species differences exist between mouse and rat in terms of BMP receptor 
expression 
Previously it has been shown that GDF-5 signals most efficiently through BMPR-II and 
BMPR-Ib, but not through BMPR-Ia in the rat osteo-progenitor like cell line ROB-C26 
(Nisitoh et al. 1996).  The present finding that BMPR-Ib is not expressed in the E13 
mouse VM is in agreement with previous reports showing that BMPR-Ib is not 
expressed in the developing mouse VM (Dewulf et al. 1995; Zhang et al. 1998), and that 
at E15 the expression of BMPR-Ib in the mouse brain was restricted to the frontal region 
of the VZ and the olafactory neuroepithelium (Zhang et al. 1998).  The present finding 
that BMPR-II and BMPR-Ia are expressed on TH-positive neurons in the mouse VM 
suggests that these neurons are subject to BMP signalling at this stage of their 
development.  However a previous study has shown that BMPR-II, BMPR-Ia and 
BMPR-Ib are all expressed in the rat VM of equivalent development age (O’Keeffe et 
al. 2004b; see Chapter 6), suggesting that fundamental species differences exist between 
mouse and rat in terms of the expression of BMP receptors. 
 These findings raise the important issue about which experimental system most 
closely represents the human VM at an equivalent stage of development.  As GDF-5 
improves the survival of E14 rat VM dopaminergic neurons after grafting in a rat 6-
OHDA model of PD (Sullivan et al. 1998) it has become a candidate neurotrophin for 
the use in the treatment of PD.  This is supported by the observation that BMPR-Ib is 
expressed in the rat VM at E14 (O’Keeffe et al. 2004b; see Chapter 6).  However 
BMPR-Ib is not expressed whereas in the mouse E13 VM (present study; Zhang et al. 
1998), which suggests that GDF-5 may not be a neurotrophic factor for mouse VM 
dopaminergic neurons.  If the human VM does not express BMPR-Ib it is unlikely that 
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GDF-5 could be applied to the treatment of PD in humans.  However, a pilot study 
carried out as a follow-up to the present set of experiments showed that BMPR-II, 
BMPR-Ia and BMPR-Ib are all expressed in the eight-week old human VM (O’Keeffe 
et al. unpublished observations).  These findings show that care should be taken when 
interpreting the findings of studies examining the effects of BMPs on mouse VM 
dopaminergic neurons.  Furthermore they suggest that the E14 rat VM more closely 
mirrors the human VM of similar developmental status and should be used in 
experimental settings to examine the potential neurotrophic effect of BMPs and GDFs 
on dopaminergic neurons.  It also suggests that GDF-5 may be useful in the clinical 
setting for the treatment as the appropriate receptors exist for it to have a neurotrophic 
effect. 
 
7.4.2 GDF-5 phosphorylates smad protein in cultures of E14 rat VM 
Binding of BMPs and GDFs to their appropriate type II receptor results in 
phosphorylation of type I receptors.  Through a series of phosphorylations and protein 
interactions, these activate smad effector proteins which move into the nucleus and 
affect transcription (for review see ten Dijke, P. et al. 2000).  Previously it has been 
shown that BMP-5, -6 and BMP-7, but not GDF-5, activated and induced the nuclear 
translocation of phosphorylated smad proteins when applied to cultures of E14 rat VM 
after 7DIV (Brederlau et al. 2002).  However, the present findings have shown that with 
increasing time in culture, BMPR-Ib expression is lost, whereas BMPR-II and BMPR-Ia 
remain strongly expressed until at least 7DIV (O’Keeffe et al. 2004b; Chapter 6).  In the 
present set of experiments, these findings have been expanded to show that when GDF-5 
was applied to cultures of E14 rat VM at a time when BMPR-Ib remains to be expressed 
(1DIV), smad activation and nuclear translocation occured in a subset of TUJ-1-positive 
cells.  GDF-5 also has been reported to activate p38 MAPK and Erk signal transduction 
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pathways in a mouse chondrogenic cell line, ADTC5 (Nakamura et al. 1999).  A recent 
study has also shown that BMP-5 activates smad-phosphorylation and p38 MAPK 
signal transduction during chick limb development (Zuzarte-Luís et al. 2004).  
Interestingly, it was found that certain genes were induced by BMP-5 in a p38 MAPK-
dependant manner, while other genes were induced in a p-38 MAPK independent 
manner (Zuzarte-Luís et al. 2004).  Although the present set of experiments have shown 
that GDF-5 stimulates smad activation in neuronal cells, it cannot be ruled out that the 
effects of GDF-5 on the numbers of TH-positive cells and on the morphological 
development of these cells in vitro (O’Keeffe et al. 2004b; Chapter 6) are due at least in 
part to a smad-independent pathway. 
 
7.4.3 GDF-5 increases the proportion of neurons that acquire a TH phenotype 
Although previous experiments had established that GDF-5 increases the numbers of 
TH-positive neurons in cultures of E14 rat VM (Krieglstein et al. 1995b; O’Keeffe et al. 
2004b; see Chapter 6) it was not know whether it also affected other neurons in these 
cultures.  A single dose of 10ng/ml GDF-5 added to cultures of E14 rat VM at the time 
of plating resulted in a two-fold increase in the numbers of TH-positive cells after 3 DIV 
but no differences were observed in the numbers of TUJ-1-positive cells or in the total 
numbers of cells in these cultures. As the proportion of TH-positive neurons of the total 
TUJ-1-positive neurons was increased, this data shows that GDF-5 selectively affects 
VM dopamine neurons and promotes the acquisition of a dopaminergic phenotype.   
The effects of GDF-5 reported here are similar to those previously reported for 
Wnt-5a (Castelo-Branco et al. 2003).  Wnt-5a is a member of the Wnt family of secreted 
glycoproteins that is expressed in the developing VM (Parr et al. 1993; Castelo-Branco 
et al. 2003).  Wnt-5a did not affect the numbers of neurons in cultures of E14 rat VM 
after 3 DIV, but resulted in an approximately two-fold increase in the numbers of TH-
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positive neurons and in the proportion of TH-positive neurons of the total TUJ-1-
positive neurons (Castelo-Branco et al. 2003).  Wnt-5a also increased the proportion of 
nurr1-positive cells that were TH-positive.  The present findings suggest that GDF-5 
acts in a similar manner to Wnt-5a in cultures of E14 rat VM. 
 
7.4.4 GDF-5 and Wnt-5a act on a similar dopaminergic precursor cells 
In agreement with previous findings showing that Ror2 is expressed in the mouse VM at 
E9.5 (Takeuchi et al. 2000), the present study found the expression of Ror2 in the rat 
VM at E14.  As Ror2 can act as a receptor for both GDF-5 (Dr. P. Tylanowski personal 
communication) and Wnt-5a (Oishi et al. 2003), it is not surprising that is expressed in 
the E14 rat VM when both GDF-5 (O’Keeffe et al. 2004a; Chapter 5) and Wnt-5a 
(Castelo-Branco et al. 2003) are expressed at high levels.  The expression of Ror2 has 
been shown to peak at around E16 in the mouse brain and to decrease with increasing 
age reaching its lowest level in the adult (Paganoni and Ferreira 2003).  A previous 
report has shown that Ror2 is expressed in the growth cones of immature cultures of 
E16 mouse hippocampal neurons (Paganoni and Ferreira 2003), possibly indicating a 
role in neurite outgrowth.  Since it is also expressed on immature dopaminergic neurons, 
it is tempting to speculate that the effects of GDF-5 on the morphological development 
of dopaminergic neurons (O’Keeffe et al. 2004b; Chapter 6) may be (at least in part) 
mediated by Ror2.  Ror2 has also been shown to be expressed in cortical astrocytes 
(Paganoni et al. 2004).  Thus it is possible that the increase in astrocyte number induced 
by GDF-5 in cultures of E14 rat VM may be mediated by Ror2.  However, it remains to 
be determined whether Ror2 is expressed in astrocytes in these cultures.  The 
establishment of the precise role(s) (if any), that Ror2 plays in GDF-5 signalling will 
require further studies. 
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 As previously mentioned, Wnt-5a is expressed in the rat VM at E13.5.  Wnt-5a 
treatment increases the numbers of dopaminergic neurons in cultures of E14 rat VM by 
increasing the proportion of Nurr1-positive precursors that acquired a dopaminergic 
phenotype (Castelo-Branco et al. 2003).  The present study found that GDF-5 acts in a 
similar manner; increasing numbers of dopaminergic neurons in cultures of E14 rat VM 
by increasing the proportion of nurr1-positive precursors that acquire a dopaminergic 
phenotype.  These findings suggest that GDF-5 and Wnt-5a could potentially have 
synergistic effects on dopaminergic neurons in cultures of E14 rat VM.  Transcriptional 
regulation of certain Wnt target genes occurs through nuclear translocation of a 
transcriptional complex containing -catenin and a member of the Tcf family (for 
review see Polakis 2000), while BMP signalling requires nuclear translocation of 
activated smad proteins as previously discussed (for review see de Caestecker et al. 
2004).  Synergy between TGF- and Wnt signalling has also been shown to regulate 
developmental events in a variety of tissues (Cadigan and Nusse 1997; Whitman 1998).  
A previous report has shown that BMP and Wnt signalling cooperate to regulate the 
expression of the transcription factor Emx2 in the dorsal mouse telencephalon (Theil et 
al. 2002).  The present set of experiments found that the effect of adding both GDF-5 
and Wnt-5a to cultures of E14 rat VM was the same as adding GDF-5 or Wnt-5a alone.  
This suggests that these factors act on the same population of precursor cells in these 
cultures and do not act in a synergistic fashion to increase dopaminergic neuron number 
in cultures of the E14 rat VM. 
 
 
 
 
 
Figure 7.1:   
 
Real-time PCR analysis of the expression of (A) BMPR-II and (B) BMPR-Ia in 
FACS-sorteed TH-positive and TH-fractions of the VM of the E13 TH-GFP 
mouse.  Data represent mean  SEM from 6 repetitions of the PCR per sample.   
* P<0.05  compared to TH- fraction. 
  
Figure 7.2:   
 
Photomicrographs showing representative cultures of E14 rat VM grown for 1 
DIV.  GDF-5 was added to the culture medium after 24 hours and cells were 
allowed to survive for a further 2 hours.  Cultures were fixed and  
immunocytochemically stained for TUJ (red) and phosphorylated smad-1, -5, -8 
(green).  No smad activation was seen in (A) control cultures, whereas in (B) 
GDF-5 treated cultures, nuclear accumalation of phosphorylated smad protein 
was seen in a subset of neurons. 
Scale bar = 25m 
 
 
Figure 7.3:   
 
Photomicrographs showing representative cultures of E14 rat VM grown for 3 
DIV, immunocytochemically stained for TH.   (A) shows a control culture, (B) 
shows a culture that received 10ng/ml GDF-5 at time of plating.  (C) Graphical 
representation of mean numbers of TH-positive cells per field in control cultures 
and cultures treated with 10ng/ml GDF-5.  Data represent mean  SEM taken 
from three independent experiments.   
**P<0.01 when compared to control cultures. 
  
Figure 7.4:   
 
Photomicrographs showing representative cultures of E14 rat VM grown for 3 
DIV, immunocytochemically stained for TUJ.   (A) shows a control culture, (B) 
shows a culture that received 10ng/ml GDF-5 at time of plating.  (C) Graphical 
representation of mean numbers of TUJ-positive cells per field in control cultures 
and cultures treated with 10ng/ml GDF-5.  Data represent mean  SEM taken 
from three independent experiments.   
N.S. no significant difference. 
 
 
 
Figure 7.5:   
 
Photomicrographs showing representative cultures of E14 rat VM grown for 3 
DIV, immunocytochemically stained for DAPI.   (A) shows a control culture, (B) 
shows a culture that received 10ng/ml GDF-5 at time of plating.  (C) Graphical 
representation of mean numbers of DAPI-positive cells per field in control 
cultures and cultures treated with 10ng/ml GDF-5.  Data represent mean  SEM 
taken from three independent experiments.   
N.S. no significant difference. 
 
 
Figure 7.6:   
 
Graphical representation of  (A) the percentage of neurons and (B) the 
percentage of total cells that were TH-positive in cultures of E14 rat VM grown 
for 3 DIV, immunocytochemically double-stained for (A) TH/TUJ or (B) 
TH/DAPI.  Data represent mean  SEM taken from three independent 
experiments.   
**P<0.01 compared to control cultures. 
 
 
Figure 7.7:   
 
Photomicrographs showing representative cultures of E14 rat VM grown for 3 
DIV, immunocytochemically stained for Nurr1 (black) and TH (brown).   (A) 
shows a control culture, (B) shows a culture that received 10ng/ml GDF-5 at time 
of plating.  (C) Graphical representation of mean numbers of nurr1-positive cells 
per field in control cultures and cultures treated with 10ng/ml GDF-5.  (D) 
Graphical representation showing the percentage of nurr1-positive cells that also 
expressed TH in control cultures and cultures treated with 10ng/ml GDF-5.  Data 
represent mean  SEM taken from three independent experiments.   
*P<0.05 when compared to control cultures. 
N.S. no significant difference. 
  
Figure 7.8:   
 
Graphical representation of mean numbers of apoptotic nuclei per field in control 
cultures and cultures treated with 10ng/ml GDF-5 as detected by DAPI staining.   
N.S. no significant difference 
 
 
 
Figure 7.9:   
 
(A) RT-PCR analysis of the expression of the Ror2 receptor in freshly dissected 
E14 rat VM tissue.   Graphical representation showing (B) the percentage of 
neurons and (C) the percentage of total cells that were TH-positive in cultures of 
E14 rat VM grown for 3 DIV, then immunocytochemically double-stained for 
(B) TH/TUJ or (C) TH/DAPI that were treated with GDF-5, Wnt-5a or a 
combination of both.  
Data represent mean  SEM taken from two independent experiments 
**P<0.01 compared to control cultures 
*P<0.05 compared to control cultures 
N.S. no significant difference 
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8.0 AGE-RELATED DIFFERENCES IN THE ABILITY OF EXPANDED 
VENTRAL MESENCEPHALIC PROGENITORS TO GENERATE 
DISTINCT CELL TYPES WHEN INDUCED TO DIFFERENTIATE 
 
8.1 Aims  
 
 To compare the volume and diameter of neurospheres derived from E12, E13 
and E14 rat VM 
 To examine whether the age of donor tissue influences ability to differentiate 
into distinct cell phenotypes 
 To examine dopaminergic neuronal differentiation from expanded NPC from 
E12, E13 and E14 rat VM. 
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8.2 Introduction 
NSCs exist in the developing and adult brain which give rise to progenitor cells capable 
of differentiating into the major cell types of the nervous system, neurons, astrocytes or 
oligodendrocytes (for review see Gage, 2000).  These neural stem cells can be isolated 
from the embryonic mouse (Reynolds et al. 1992), rat (Svendsen et al. 1995) and human 
(Carpenter et al. 1999) CNS.  NSCs can proliferate in culture in response to EGF and 
FGF-2, generating structures called “neurospheres”, which are free-floating spherical 
aggregates.  Cells in these neurospheres express the intermediate filament protein nestin, 
which is used as a marker of multipotential stem cells (Frederiksen et al. 1988).  Cells 
derived from these neurospheres can subsequently give rise to neurons, astrocytes and 
oligodendrocytes (for review see Gage 2000).  Thus these cells can be used to study 
lineage specification from NSCs and have the potential to generate cells for 
transplantation approaches to the treatment of neurodegenerative diseases (for reviews 
see Svendsen and Smith 1999; Caldwell 2001; Rossi and Cattaneo 2002). 
Transplantation of embryonic dopaminergic neurons to the damaged brain is a 
potential treatment for PD, however one of the main limiting factors to this approach is 
the poor survival of these neurons after transplantation (for review see Brundin et al 
2000).  Due to the large numbers of dopaminergic cells required for transplantation, 
alternative sources of these cells are being sought.  Expanded precursors from the 
developing mouse (Studer et al. 1998), rodent (Ostenfeld et al. 2002) and human 
(Carpenter et al. 1999; Ostenfeld et al. 2002) midbrain have been shown to have the 
potential to differentiate into TH-expressing dopaminergic neurons in vitro and 
following transplantation to the CNS (Studer et al. 1998).  As such, they may be of use 
to generate an alternative supply of dopaminergic neurons for transplantation 
approaches to Parkinson’s disease. 
Although many groups have expanded cells from the embryonic rodent VM, the 
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age of donor tissue used in these experiments varies.  E12 (Studer et al. 1998), E14 
(Ostenfeld et al. 2002) and E18 (Svendsen et al. 1995) VM have all been used to 
generate neurospheres.  In the rat VM, dopaminergic neurons proliferate between E11 
and E15, undergoing their final mitotic divisions on E14-15 (Altman and Bayer 1981; 
Bayer et al. 1995).  Thus dopaminergic neuronal precursor cells in an undifferentiated 
state would be expected to be present in the rat VM from E11 to E14, after which point 
they may become post-mitotic.  In the present set of experiments, the yields of various 
cell types generated from neurospheres derived from E12, E13 and E14 rat VM were 
compared, as was the ability of these neurospheres to give rise to dopaminergic neurons.  
The results show that the percentage of each cell type generated in these cultures varies 
with the age of the donor tissue.  The ability of the neurospheres to generate 
dopmainergic neurons was also found to be age dependent.  The size of neurospheres 
derived from each of the three ages was also examined. 
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8.3 Results 
 
8.3.1 Neurosphere characteristics during expansion phase 
Dissociated cells from E12, E13 and E14 VM, seeded into expansion medium, were 
seen to form small clusters after 1 DIV, with these clusters proliferating into 
recognizable neurospheres after 2 DIV.  The diameter of the neurospheres from each 
age, approximately doubled every 2 DIV (Figure 8.1-8.3; Appendix III).  By 6 DIV for 
E13 and as early as 4 DIV for E14, some of the neurospheres in these cultures stuck to 
the bottom of the flask, with “islands” of cells forming around them (Figure 8.3B, C).  
These attached spheres continued to increase in size.  Interestingly, very few of the E12 
neurospheres ever stuck to the bottom of the flask, the majority of them remained free-
floating (Figure 8.1A, 8.2A, 8.3A).  After 6 DIV of expansion, all the spheres were 
nestin positive, indicating their multipotentiality. 
 
8.3.2 Comparison of sphere diameter and volume during expansion phase 
During the expansion phase, neurospheres from E12 and E13 cultures were very similar 
in size, with no significant difference in the diameter of these neurospheres at 2, 4 or 6 
DIV (Figure 8.1D, 8.2D, 8.3D respectively).  However, the diameter of neurospheres 
from E14 cultures was significantly smaller than that of neurospheres from E12 and E13 
cultures at 2, 4, and 6 DIV (Figure 8.1D, 8.2D, 8.3D respectively; P<0.01).  The 
volumes of neurospheres from E12 and E13 cultures were not significantly different at 
2, 4 or 6 DIV (Figure 8.1E, 8.2E, 8.3E respectively). The volume of neurospheres from 
E14 cultures was significantly smaller than that of neurospheres from E12 and E13 
cultures at 2, 4, and 6 DIV (Figure 8.1E, 8.2E, 8.3E respectively; P<0.01).  
 
8.3.3 Differentiation of expanded VM neurospheres 
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After 6 DIV expansion, neurospheres were dissociated to single cells and plated onto 
poly-D-lysine coated wells and allowed to differentiate after for a further 6 DIV, in the 
presence of 1% FCS, without EGF and FGF-2.  At 24 h after plating, the cells derived 
from neurospheres of all ages had developed processes, but lacked the morphological 
characteristics of mature neuronal cell types.  After 6 DIV, cultures were fixed and 
stained for TUJ-1, MAP-2ab, GFAP, MBP and nestin.  Cells immunoreactive for all 
markers were found in cultures from neurospheres of all ages, but the percentage of the 
different cell type generated varied with the age of the culture (Figure 8.4 – 8.9).   
 
8.3.4 Neuronal differentiation 
E12 cultures contained the highest percentage of neurons (TUJ-1-positive cells; 19.3 ± 
0.6%, MAP-2ab-positive cells; 17.2 ± 0.6%; Figure 8.4A, Figure 8.5A respectively), 
with E13 (TUJ-1-positive cells; 12.8 ± 1.9%, MAP-2ab-positive cells; 11.9 ± 0.6%; 
Figure 8.4B, Figure 8.5B respectively) and E14 (TUJ-1-positive cells; 6.9 ± 1.2%, 
MAP-2ab; 3.5 ± 0.4%; Figure 8.4C, Figure 8.5C respectively) having significantly 
fewer neurons (Figure 8.4D, Figure 8.5D respectively; P< 0.01).  The percentage 
neurons generated in E14 cultures was significantly lower than that in E13 cultures 
(Figure 8.4D, Figure 8.5D respectively; P< 0.01). 
 
8.3.5 Astro/Oligodendroglial differentiation 
E12 cultures contained the lowest percentage of GFAP-positive cells (9.4  ± 0.6%; 
Figure 8.6A), with E13 (48.6 ± 3.8%; Figure 8.6B) and E14 (44.0 ± 2.0%; Figure 8.6C) 
cultures having significantly more GFAP-positive cells (Figure 8.6D; P<0.01).  There 
was no significant difference between the percentage of GFAP-positive cells in E13 and 
E14 cultures (Figure 8.6D).   
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E12 cultures contained the lowest percentage of MBP-positive cells (3.7 ± 2.0%; 
Figure 8.7A), with E13 (5.5 ± 0.6%; Figure 8.7B) and E14 (13.5 ± 1.4%; Figure 8.7C) 
cultures having significantly more MBP-positive cells (Figure 8.7D; P< 0.01).  There 
was a significant difference between the percentage of MBP-positive cells in E13 and 
E14 cultures (Figure 8.6D; P< 0.01).   
 
8.3.6 Persistence of nestin expression 
After 6 DIV differentiation, neurons, astrocytes and oligodendrocytes were present in all 
cultures.  However, many cells in these cultures still express the intermediate filament 
protein, nestin.  E12 cultures contained the highest percentage of nestin-positive cells 
(61.1 ± 2.8%; Figure 8.8A), with E13 (41.6 ± 3.1%; Figure 8.8B) and E14 (46.0 ± 2.0%; 
Figure 8.8C) cultures having significantly less nestin-positive cells (Figure 8.8D; P< 
0.01).  There was no significant difference between the percentage of nestin-positive 
cells in E13 and E14 cultures (Figure 8.8D).   
 
8.3.7 Dopaminergic differentiation of VM neurospheres 
Dopaminergic neurons were generated with much less frequency than all other cell types 
examined.  Only E12 neurospheres consistently generated dopaminergic neurons upon 
differentiation.  In E12 differentiated cultures, approximately 2% (1.7%  0.2%; Figure 
8.9A, D) of the total cells were TH-positive.  This means that of the neurons generated 
by E12 neurospheres (19.3 ± 0.6%), approximately 9% of these were dopaminergic.  
TH-positive neurons are rarely found in E13 differentiated cultures occurring at a 
frequency of one or two per coverslip (Figure 8.9B, D).  Dopaminergic neurons were 
not found in E14 differentiated cultures (Figure 8.9C, D).   
It has previously been suggested that dopaminergic neurons derived from 
neurospheres from E14 rat VM were not generated from a multipotential stem cell, but 
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were postmitotic neurons already present in the tissue at the time of dissection that 
survived in the neurosphere during the culture period (Ostenfeld et al. 2002).  To 
address this issue, the expression of nurr1, an orphan nuclear receptor crucial for the 
development of midbrain dopaminergic neurons (Zetterstrom et al. 1997, Castillo et al. 
1998), and of TH were examined using RT-PCR in neurospheres from E12, E13 and 
E14 rat VM after 6 DIV expansion as described above.  No expression of nurr1 (Figure 
8.10A) or TH (Figure 8.10B) was found in any of the neurospheres examined, 
suggesting that the dopaminergic neurons present after 6DIV differentiation of E12 
neurosphere cultures arose from cells in the neurospheres which did not yet express 
these markers of differentiated dopaminergic neurons after 6 DIV of expansion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 114 
8.4 Discussion 
 
8.4.1 Age-related differences in the growth rates of rodent neurospheres 
The effect of the age of the donor VM on the growth rates of the neurospheres in culture 
was apparent when sphere diameter and volume was measured at 2, 4 and 6 DIV during 
the expansion phase.  Previously it has been shown that after 7 DIV expansion in 
medium containing 2% B27 with 20ng/ml EGF and 20ng/ml FGF-2, E14 rat VM 
neurospheres had a mean diameter of 260 ± 10m (Ostenfeld et al. 2002).  This is in 
agreement with the present finding that after 6 DIV expansion in culture, E14 
neurospheres had a mean diameter of 189.9 ± 16.4m.  Neurospheres generated from 
E12 and E13, were significantly larger (in volume and diameter) than E14 neurospheres 
at all time points tested, with no significant differences observed between neurospheres 
generated from E12 and E13 VM.  One explanation for this may be due to the timing of 
VM development.  It has been proposed that by E14, many cells in the VM have 
undergone their last mitotic division and express TH (Altman and Bayer, 1981, Bayer et 
al. 1995).  Thus at E14, the VM would contain fewer multipotential cells than at E12 or 
E13, which might explain the smaller size of neurospheres generated from this region at 
E14.  Many cells isolated from the E12 VM and cultured in vitro for 24 hs have been 
shown to express nestin (Krieglstein et al. 2003; see Chapter 9), but less are nestin-
positive in cultures of E13 or E14 VM after 1 DIV (O'Keeffe et al. unpublished 
observations). 
 
8.4.2 Percentages of each cell type generated from VM neurospheres is dependent on 
the age of the donor VM 
Having established that the growth rates of neurospheres are dependent on the age of the 
donor VM, the cell types present when these neurospheres were allowed to differentiate 
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were analysed.  Removal of mitogens and exposure to serum has previously been shown 
to promote the differentiation of nestin-positive cells to mature phenotypes (Carpenter et 
al. 1999; Carvey et al. 2001; Storch et al. 2001).  Neurospheres were dissociated, plated 
onto poly-D-lysine-coated dishes and allowed them to differentiate for 6 DIV.  In 
agreement with previous studies, the dissociated cells gave rise to neurons, glia and 
oligodendrocytes (Svendsen et al. 1995, Ostenfeld et al. 2002).  The numbers of each 
cell type generated however, was dependent on the age of the donor VM.  Ostenfeld et 
al. (2002) found that expansion of E14 VM as neurospheres for 7 DIV followed by 
differentiation for 7DIV generated approximately 8% neurons as measured by TUJ-1-
immunoreactivity.  This agrees with the present finding that 6.9  1.2% of the total cells 
were neurons.  However in this study E14 neurospheres generated the lower numbers of 
neurons compared to E12 and E13 neurospheres, with neuronal differentiation 
increasing with decreasing age of donor (E12>E13>E14).  The enhanced neuronal 
differentiation from E12 neurospheres may be explained by the fact that neurogenesis 
begins in the VM from E11 onwards (Hanaway et al. 1971; Lauder and Bloom 1974; 
Altman and Bayer 1981; Solberg et al. 1993; Bayer et al. 1995) and decreases as the VM 
matures.  With increasing age, it is likely that the numbers of neuronal progenitors in the 
VM and thus in neurospheres generated from the VM decreases.  This may explain why 
neurospheres generated from later aged VM show a progressive decrease in their ability 
to give rise to neurons, as more cells in these neurospheres may be nestin-expressing 
glial restricted precursors (GRPs). 
In contrast to the lower generation of neurons from later aged VM, there is a 
progressive increase in the numbers of oligodendrocytes generated from neurospheres 
from later aged VM (E12<E13<E14).  Again, these results agree with previous reports 
which showed that E14 VM rodent neurospheres generate approximately 10-20% 
oligodendrocytes after 7 DIV expansion followed by 7 DIV differentiation (Ostenfeld et 
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al. 2002).  In the present study 13.5 ± 1.4% of the total cells generated from E14 
neurospheres were oligodendrocytes.   The lower generation of oligodendrocytes from 
neurospheres generated from VM of earlier ages may also be a reflection of the 
developmental status of the tissue at the time of harvesting for cell culture.  It is possible 
that with increasing age, more cells in the VM are GRPs, which may explain the 
increased oligodendroglial differentiation from neurospheres of later ages.  In E12 
cultures, GFAP-positive cells constituted approximately 10% of the total cells.  In E13 
cultures, the percentage GFAP-positive cells was four-fold higher.  There was no 
significant difference in the percentage of GFAP-positive cells between E13 and E14 
cultures.   This suggests that by E13, many more cells may be GRPs than at E12, 
explaining the increase in GFAP-positive cells generated from E13 and E14 
neurospheres.   
In contrast to the present study, Peaire et al. (2003) found that E12 VM expanded 
for 9 DIV in N2 containing medium supplemented with 10ng/ml FGF-2, and allowed to 
differentiate for three further days after mitogen withdrawal, gave rise to neurons 
(MAP2-positive), which represented 99% of the total cells and glia (GFAP-positive) 
which represented 1% of the total cells.  No nestin or MBP expression was found in 
these cultures three days after mitogen withdrawal (Peaire et al. 2003).  In the present 
study, only ~18% of the total cells in E12 differentiated cultures stained positively for 
MAP-2, with ~ 10% of the total cell population being GFAP-positive and 4% of the 
total cell population MBP-positive.  A high level of nestin expression (~ 60% of total 
cells) remained in the E12 cultures after six days of differentiation.  In agreement, Chow 
et al. (2000) generated free-floating neurospheres from E14 rat spinal cord, dissociated 
these to single cells after expansion and allowed these cells to differentiate for four or 
eight days in the presence of 10% FCS.  In their cultures, approximately 70% of the total 
cells expressed nestin (Chow et al. 2000). 
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One possible explanation for the discrepancies between the above-mentioned 
studies, may be the differences in culture techniques used.  Peaire et al. (2003) grew 
neurospheres as attached “microislands”, while here and in other studies (Chow et al. 
2000; Ostenfeld et al. 2002) neurospheres were grown as free-floating aggregates.  
Interestingly, Studer and co-workers also found a lower percentage of GFAP-positive 
cells (~3% when cells were differentiated in 10% serum, ~1% when cells were 
differentiated in serum free medium) in cultures generated from E12 rat expanded 
mesencephalic precursors grown as attached neurospheres for seven days in N2 medium 
supplemented with 10ng/ml FGF-2 (Studer et al. 1998), than was found in the present 
study (10%).  In agreement with Peaire et al. (2003), no oligodendrocytes (Gal C-
positive) were found in these cultures (Studer et al. 1998).  So it is possible that method 
of expansion of mesencephalic progenitors may influence the potential of these cells to 
differentiate into mature cell types and this warrants further investigation. 
The high level of nestin expression that remained in cultures of neurospheres of 
each of the three ages after seven days differentiation suggests that these cells retain 
multipotency and could be induced to differentiate into a required cell type.  This means 
that factors capable of inducing multipotent stem cells to differentiate into a specific 
lineage may be useful in generating a required cell type.  For example, retinoic acid has 
been shown to induce neuronal differentiation from rodent stem cells (Ruhnke et al. 
2003).  BMPs have been shown to enhance astrocyte differentiation from mouse 
telencephalic neural progenitor cells (Nakishima et al. 2001) while having a negative 
influence on oligodendrocyte differentiation (Yung et al. 2002).  In contrast to the 
effects of BMPs, Shh has been shown to promote commitment to an oligodendroglial 
lineage (Yung et al. 2002).  Detailed analysis of the intrinsic ability of neurospheres, 
generated from various CNS regions from different stages of development to 
differentiate into mature neural cell types will allow selection of the most suitable age of 
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donor tissue to use to generate a specific cell type.  For example the present experiments 
suggest that E14 VM would be the most suitable age of those examined here if 
oligodendrocyte differentiation was required.  Factors influencing this differentiation 
could then be examined for their ability to produce a population of oligodendrocytes for 
transplantation approaches to demyelinating disease (for review see Halfpenny et al. 
2002). 
 The present study found that 1.7% of the total cells were TH-positive in the E12 
cultures after six days of differentiation.  This finding is in agreement with previous 
reports showing that 1.2% of the total cells in cultures of neurospheres from the nine 
week old human VM, were TH-positive following differentiation (Horiguchi et al. 
2004).  However to rule out the possibility that dopaminergic neurons derived from 
neurospheres from the E12 rat VM were not generated from a multipotential stem cell, 
but were postmitotic neurons already present in the tissue at the time of dissection that 
survived in the neurosphere during the culture period, we analysed the expression of 
nurr1 and TH in the neurospheres prior to differentiation.  As no expression of Nurr1 
and TH was seen in any of the neurospheres from each of the ages examined, the 
dopaminergic neurons must have differentiated from a cell not yet expressing these 
markers.  This finding is supported by a report showing that no TH-positive neurons 
were present in neurospheres from the E14 rat VM after expansion under similar 
conditions as used in the present study (Storch et al. 2003).  Previous reports have also 
showed that TH-positive neurons derived from rat mesencephalic neurospheres, produce 
and release dopamine, express voltage-gated sodium and potassium currents and fire 
action potentials which are functional characteristics of mature midbrain dopaminergic 
neurons (Storch et al. 2003).  This data along with the present findings suggest that the 
production of dopaminergic neurons from expanded mesencephalic precursors is a 
viable method of producing dopamine neurons for transplantation approaches to PD, 
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however the age of donor tissue used is a crucial factor in determining the numbers of 
dopaminergic neurons that can be generated.  Factors that improve dopaminergic 
neuronal differentiation can then be used to enhance this differentiation process (for 
reviews see Caldwell 2001; Arenas 2002) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1:   
 
Photomicrographs showing representative cultures of neurospheres from (A) 
E12, (B) E13 and (C) E14 VM at 2 DIV.  Graphical representation of (D) 
neurosphere diameter and (E) neurosphere volume from each of the ages 
examined. Data represents mean  SEM taken from 3 independent experiments; 
4 coverslips per experiment. 
N.S.  no significant difference  
**  P<0.01 compared to E12 and E13 values. 
Scale bar = 100m 
 
 
 
 
Figure 8.2:   
 
Photomicrographs showing representative cultures of neurospheres from (A) 
E12, (B) E13 and (C) E14 VM at 4 DIV.  Graphical representation of (D) 
neurosphere diameter and (E) neurosphere volume from each of the ages 
examined. Data represents mean  SEM taken from 3 independent experiments; 
4 coverslips per experiment. 
N.S.  no significant difference  
**  P<0.01 compared to E12 and E13 values. 
Scale bar = 100m 
 
 
 
Figure 8.3:   
 
Photomicrographs showing representative cultures of neurospheres from (A) 
E12, (B) E13 and (C) E14 VM at 6 DIV.  Graphical representation of (D) 
neurosphere diameter and (E) neurosphere volume from each of the ages 
examined. Data represents mean  SEM taken from 3 independent experiments; 
4 coverslips per experiment. 
N.S.  no significant difference  
**  P<0.01 compared to E12 and E13 values. 
Scale bar = 100m 
 
Figure 8.4:   
 
Photomicrographs showing representative differentiated cultures plated from 
neurospheres from (A) E12, (B) E13 and (C) E14 VM expanded for 6 DIV.   
Cultures were immunocytochemically stained for TUJ.  (D) Graphical 
representation of the percentage of total cells staining positively for TUJ in each 
of the three culture types.  Data represents mean  SEM taken from 3 
independent experiments; 4 coverslips per experiment. 
**  P<0.01 compared to E12 values. 
$ P<0.01  
Scale bar = 100m 
 
 
 
 
 
Figure 8.5:   
 
Photomicrographs showing representative differentiated cultures plated from 
neurospheres from (A) E12, (B) E13 and (C) E14 VM expanded for 6 DIV.   
Cultures were immunocytochemically stained for MAP-2.   (D) Graphical 
representation of the percentage of total cells staining positively for MAP-2 in 
each of the three cultures.  Data represents mean  SEM taken from 2 
independent experiments; 4 coverslips per experiment. 
**  P<0.01 compared to E12 values. 
$ P>0.01  
Scale bar = 100m 
 
 
 
Figure 8.6:   
 
Photomicrographs showing representative differentiated cultures plated from 
neurospheres from (A) E12, (B) E13 and (C) E14 VM expanded for 6 DIV.   
Cultures were immunocytochemically stained for GFAP. (D) Graphical 
representation of the percentage of total cells staining positively for GFAP in 
each of the three cultures.  Data represents mean  SEM taken from 3 
independent experiments; 4 coverslips per experiment. 
**  P>0.01 compared to E12 values. 
N.S.  no significant difference  
Scale bar = 100m 
 
 
 
Figure 8.7:   
 
Photomicrographs showing representative differentiated cultures plated from 
neurospheres from (A) E12, (B) E13 and (C) E14 VM expanded for 6 DIV.   
Cultures were immunocytochemically stained for MBP.  (D) Graphical 
representation of the percentage of total cells staining positively for MBP in each 
of the three cultures.  Data represents mean  SEM taken from 3 independent 
experiments; 4 coverslips per experiment. 
**  P<0.01 compared to E12 values. 
$ P<0.01  
Scale bar = 100m 
 
 
 
Figure 8.8:   
 
Photomicrographs showing representative cultures of differentiated cultures 
plated from neurospheres from (A) E12, (B) E13 and (C) E14 VM expanded for 
6 DIV.   Cultures were immunocytochemically stained for nestin.  (D) Graphical 
representation of the percentage of total cells staining positively for nestin in 
each of the three cultures.  Data represents mean  SEM taken from 2 
independent experiments; 4 coverslips per experiment. 
**  P>0.01 compared to E12 values. 
N.S.  no significant difference  
Scale bar = 100m 
 
 
 
Figure 8.9:   
 
Photomicrographs showing representative cultures of differentiated cultures 
plated from neurospheres from (A) E12, (B) E13, (C) E14 VM expanded for 6 
DIV.   Cultures were immunocytochemically stained for TH.  (D) Graphical 
representation of the percentage of total cells staining positive for TH in each of 
the three cultures.  Data represents mean  SEM taken from 3 independent with 4 
coverslips per experiment. 
Scale bar = 100m 
 
 
 
Figure 8.10:   
 
RT-PCR for (A) nurr1 and (B) TH on cDNA from neurospheres prepared from 
E12, E13 and E14 rat VM after 6 DIV expansion.  cDNA prepared from freshly-
dissected E13 VM was used as a positive control.  (C) 18s RNA was run to 
confirm the presence of intact of cDNA used in each of the samples.  The 
demonstrated lack of nurr1 and TH expression in the E12 neurospheres shows 
that dopaminergic neurons derived from E12 neurospheres are as a result of 
differentiation from stem cells which did not yet express these markers after 6 
DIV expansion rather than committed precursors or post-mitotic dopaminergic 
neurons that were contained in the sphere before differentiation. 
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9.0 THE ROLE OF GDF-5 AND BMPR-IB IN INDUCING DOPAMINERGIC 
DIFFERENTIATION IN CULTURES OF THE E12 RAT VM 
 
9.1 Aims  
 
 To examine the expression of GDF-5’s receptors during dopaminergic 
neurogenesis in the VM. 
 To characterise cultures of E12 VM after 1 DIV. 
 To examine the effects of GDF-5 on cultures of E12 VM after 1 DIV. 
 To examine the effect of GDF-5 on gene expression of BMPR-II, BMPR-Ia and 
BMPR-Ib, Ror2, Nurr1 and TH in E12 expanded VM precursor cells. 
 To examine the role of BMPR-Ib signalling in TH induction by GDF-5. 
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9.2 Introduction 
 
The VM contains the developing dopaminergic neurons of the future SN, those that 
degenerate in PD.  Unravelling the factors that play a role in the development of these 
neurons is important if efficient generation of mature functional dopaminergic neurons 
from stem cells for use in transplantation approaches to PD is to become a reality.  In the 
rat VM, dopaminergic neurons proliferate between E11 and E15, undergoing their final 
mitotic divisions on E14-15 (Hanaway et al. 1971; Lauder and Bloom 1974; Altman and 
Bayer 1981; Solberg et al. 1993; Bayer et al. 1995).  In the rat, axons start to invade the 
striatum at E16 and continue to grow pre- and post-natally (Unsicker et al. 1996).  VM 
dopaminergic neurons are generated in the midbrain/hindbrain boundary under the 
influence of two major signalling centres, the isthmus and the floor plate (Ye et al. 
1998).  Among the secreted molecules known to regulate the development of VM 
dopaminergic neurons, two of the most important are Shh and FGF-2-8 (Ye et al. 1998).   
TGF-2, TGF-3 and the TGF- type II receptor have been shown to be expressed in 
the developing rat VM at E12.5 and are required for the induction of dopaminergic 
neurons by Shh (Farkas et al. 2003).  A number of transcription factors have also been 
shown to be crucial for the development of VM dopaminergic neurons.  These include 
Nurr-1 (Zetterstrom et al. 1997; Castillo et al. 1998), Pitx-3/Ptx-3 (Smidt et al. 1997), 
Lmx-1b (Asbreuk et al. 2002) and the En genes, En-1 and En-2 (Simon et al. 2001). 
Recently further genes which are involved in this process have been identified (Thuret et 
al. 2004).   
Although GDF-5 expression peaks on E14 during the development of the rat 
VM, it is also expressed at E12 (O’Keeffe et al. 2004a), which is the day the first 
dopaminergic neurons in the VM express TH (Hanaway et al. 1971; Lauder and Bloom 
1974; Altman and Bayer 1981; Solberg et al. 1993; Bayer et al. 1995).  GDF-5 has been 
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shown to increase the numbers of TH neurons in cultures of E14 rat VM (O’Keeffe et al. 
2004b; see Chapter 6) and to improve the morphological development of these neurons 
(O’Keeffe et al. 2004b; see Chapter 6).  However, there is no information on whether 
GDF-5 is involved in the induction of a dopaminergic fate in early (E12) rat VM.  The 
present set of experiments examined the ability of GDF-5 to induce dopaminergic 
differentiation from neural progenitor cells from the VM.  Also the involvement of 
BMPR-Ib in this induction was examined.   
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9.3 Results 
 
9.3.1 BMPR-II, BMPR-Ia and BMPR-Ib are expressed in the rat VM at E12, E13 and 
E14 
Previous experiments have shown that GDF-5 is expressed in the E14 rat VM (O’Keeffe 
et al. 2004a; see Chapter 5), improves the morphological development of E14 rat VM 
dopaminergic neurons in vitro (O’Keeffe et al. 2004b; see Chapter 6) and increases 
dopaminergic neuronal differentiation in E14 rat VM cultures (see Chapter 7).  
Furthermore GDF-5 has been shown to be expressed in the rat VM at E12 (O’Keeffe et 
al. 2004a; see Chapter 5).  However no function has been described for GDF-5 on early 
VM precursors at this stage of development (E12).  To confirm that the appropriate 
receptors for GDF-5 were present in the VM at E12, RT-PCR for BMPR-II, BMPR-Ia 
and BMPR-Ib was carried out on cDNA from the rat VM at E12, E13 and E14.  The 
pieces of VM were dissected from the area immediately adjacent to the ventral midline 
and rostral to the isthmus.  Every effort was made to remove all contaminating 
meningeal tissue.  The receptors for BMPR-II, BMPR-Ib and BMPR-Ia were detected 
from E12 through to E14 (Figure 9.1A, B, C respectively).  18s RNA was run as a 
positive control (Figure 9.1D) and reactions without the RT enzyme were carried out to 
ensure that no contaminating genomic DNA was present (Figure 9.1E).  
Immunocytochemistry for BMPR-II, BMPR-Ia and BMPR-Ib was performed on 
cultures of E12 rat VM after 1 DIV to confirm the RT-PCR results.  Widespread 
expression of all three receptors was seen in these cultures (Figure 9.2A-C).  Negative 
control cultures, which omitted the primary antibody from the staining procedure, 
consistently displayed no staining (Figure 9.2D).  This finding that the appropriate 
receptors are present in the rat VM at E12, along with the previous report showing that 
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GDF-5 is expressed in the rat VM at E12 (O’Keeffe et al 2004a; Chapter 3), suggests 
that GDF-5 plays a role at this stage of development of the rat VM. 
 
9.3.2 GDF-5 increases numbers of TH neurons in E12 VM cultures 
To analyse the role of GDF-5 in the rat VM at E12, cultures of E12 rat VM were grown 
for 1 DIV.  Initially the expression of neuronal, glial and precursor cells markers in the 
cultures was characterised.  After 1 DIV 56.1  4.3% of the total cells were TUJ-1-
positive (Figure 9.3A, E), 1.9  0.1% of the total cells were TH-positive (Figure 9.3A, 
E) and 26.8  1.3% of the total cells were BrdU-positive (Figure 9.3C, E).  A high 
proportion of the cells (approximately 40%) expressed nestin after 1 DIV (Figure 9.3B).  
No GFAP or MBP expression was found in these cultures (Figure 9.3D).   
Addition of 10ng/ml GDF-5 to these cultures at the time of plating induced a 
significant increase in the numbers of TH-positive cells after 1DIV when compared to 
controls (P<0.05; Figure 9.4A, B, C).  This increase in TH-positive cell number could 
have been due to a) induction of TH expression in uncommitted precursors, b) 
proliferation of TH-positive cells which were already in the culture and/or c) increased 
survival of TH-positive cells in these cultures.   
To address the possibility that GDF-5 treatment increased survival or prevented 
cell death in these cultures, the degree of cell death in these cultures was measured by 
counting pyknotic (apoptotic) nuclei using DAPI staining.   There was no significant 
difference in the number of apoptotic cells or in the total number of cells in control 
cultures compared to GDF-5 treated cultures (Figure 9.5A, B respectively), which 
suggested that GDF-5 did not influence the survival of cells in these cultures.    To 
examine whether GDF-5 may have stimulated the proliferation of TH-positive cells in 
these cultures thus increasing their number, cell proliferation was examined.  Repeated 
 125 
experiments found no cells which were doubled-labelled with proliferating cell nuclear 
antigen (PCNA) and TH, which showed that GDF-5 did not stimulate proliferation of 
TH-positive cells in these cultures (Figure 9.6A, B).  Furthermore there was no 
significant difference in the numbers of BrdU-positive cells in control cultures 
compared to GDF-5-treated cultures, confirming that GDF-5 did not have an effect on 
cell proliferation in these cultures (Figure 9.6C).  These experiments suggest that the 
increase in TH-positive cell numbers induced by GDF-5 treatment was as a result of 
induction of TH expression in progenitor cells. 
 
9.3.3 GDF-5, BMP2 and Shh induce Nurr1 and TH in VM NPCs 
To further examine the possibility that GDF-5 induces TH expression in progenitor 
cells, cultures of NPCs were established from the E12 rat VM.  The reason for using 
cultures of NPCs was two-fold.  Firstly, more cells are available in these cultures than 
primary cultures of E12 rat VM for subsequent RT-PCR analysis.  Secondly, it was 
important to determine whether GDF-5 can induce Nurr1 and TH expression in 
proliferating NPCs, since these cells (and not primary cultures of E12 VM) have been 
proposed as a potential source of cells for generating dopaminergic neurons for the 
treatment of PD. 
The experimental protocol involved culturing cells for 6DIV in 2% B27, 
20ng/ml EGF/FGF-2 followed by treatment with GDF-5 and the other factors for 24 hs 
(Figure 9.7).  During the 6DIV of expansion, single cells proliferated into large cultures 
that were attached to the bottom of each well (Figure 9.8A).  Although other groups 
have performed similar experiments using FGF-2 alone (Panchision et al. 2001), in the 
present set of experiments it was found that the cells did not proliferate effectively in 
either FGF-2 or EGF alone (Figure 9.8B, C).  Thus both EGF and FGF-2 were used in 
this set of experiments.    
 126 
After 6DIV expansion, cultures were treated with GDF-5, BMP-2, BMP-2 and 
Shh or BMP-2 and GDF-5 for 24 hs.  RT-PCR was used to analyse gene expression in 
these cultures.  Densitometic analysis of the RT-PCR data revealed that treatment with 
GDF-5, BMP2 or BMP2 and Shh increased the expression of BMPR-Ib, BMPR-Ia, 
nurr1 and TH (Figure 9.9 A, B, D, E respectively) when compared to control cultures.  
BMP-2 and GDF-5 co-treatment down-regulated the expression of BMPR-Ib, BMPR-Ia, 
Nurr1 and TH when compared to the controls (Figure 9.9A, B, D, E respectively).   
BMP-2 has previously been shown to upregulate the expression of Msx-1, a gene 
normally expressed in the most dorsal domain of the spinal cord and forebrain (Grove et 
al. 1998; Bang et al. 1999); this up-regulation was prevented by treatment with Shh 
(Panchision et al. 2001).  Thus the expression of Msx1 in the cultures in response to the 
aforementioned treatments was examined in the present study.  BMP-2 did not induce 
the expression of Msx1 (Figure 9.9F).  As a positive control, Msx1 was amplified from 
cDNA prepared from the adult rat brain, indicating that the amplification parameters for 
Msx1 were optimal.   
The tyrosine kinase receptor Ror2 (see Chapter 7) was recently found to be a 
receptor for GDF-5 (Dr. Prezmko Tylanowski, personal communication) and Wnt-5a 
(Oishi et al. 2003).  In the present study, no expression of Ror-2 was found in control 
cultures.  Treatment with GDF-5 or BMP-2 and Shh co-treatment induced the 
expression of Ror2 in these cultures, whereas BMP-2 alone did not (Figure 9.9C).  Co-
treatment with BMP-2 abolished the induction of Ror-2 induced by GDF-5 alone 
(Figure 9.9C).  
 
9.3.4 GDF-5 increases numbers of TH-positive cells in differentiated VM NPCs 
Although GDF-5 increased the expression of nurr1 and TH in proliferating VM NPCs, it 
was not known if increased numbers of dopaminergic neurons could be generated when 
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these cells were induced to differentiate.  This is important to demonstrate if GDF-5 is to 
be used to induce dopaminergic neuronal differentiation from expanded NPCs for 
transplantation approaches to PD.  As a pilot study to assess this, proliferating VM 
NPCs from the E12 rat VM were differentiated with or without GDF-5 for 6 DIV.  In 
GDF-5-treated cultures (Figure 9.10A) there appeared to be increased numbers of 
dopaminergic neurons compared to control cultures (Figure 9.10A), however further 
experiments are necessary to confirm and quantify this finding. 
 
9.3.5 Signalling through BMPR-Ib is required for increases in Nurr1 and TH 
expression by BMP-2 
In order to examine the role of BMPR-Ib (the type I receptor shared by both GDF-5 and 
BMP-2), in increasing the expression of nurr1 and TH by GDF-5 and BMP-2, blocking 
antibodies to BMPR-Ib were used to inhibit ligand binding to the receptor.  As GDF-5 
induced the expression of Ror2 (see above), BMP-2 was used instead of GDF-5 in this 
experiment.  RT-PCR was used to analyse the expression of nurr1 and TH in the treated 
cultures.  Densitometric analysis of the RT-PCR data showed that treatment of the 
cultures with BMP-2 increased the expression of nurr1 (Figure 9.11A, D) and TH 
(Figure 9.11B, E) when compared to control cultures.  Treatment with blocking 
antibodies to BMPR-Ib abolished this effect (Figure 9.11A-E), suggesting that 
signalling through BMPR-Ib is required for induction of nurr1 and TH by BMP-2 (and 
presumably GDF-5) in E12 rat VM progenitor cells.  
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9.4 Discussion 
 
9.4.1 BMP receptors are expressed during the period of dopaminergic neurogenesis in 
the rat VM. 
In the developing rat VM, BMP-2, -4 and –6 (Jordan et al. 1997) and GDF-5 (O'Keeffe 
et al. 2004a) are expressed at E13, E14 and E15.  In the mouse VM, GDF-1 has been 
shown to be expressed from E9.5 onwards (Wall et al. 2000).  This suggests that 
dopaminergic neurons are subject to BMP/GDF signalling during their development.  
The receptors for GDF-5 have been shown to be BMPR-II and BMPR-Ib (Nishitoh et al. 
1996).  More recently, Ror2 has been identified as a novel receptor for GDF-5 (Dr. 
Prezmko Tylanowski, personal communication).  However it has previously been 
reported by in situ hybridisation studies that BMPR-Ia is expressed in all proliferative 
regions of the developing mouse neural tube after gastrulation, whereas BMPR-Ib 
expression is restricted to the dorsal domain of the neural tube (DeWulf et al. 1995; 
Panchision et al. 2001).  In the present study, expression of all three BMP receptors was 
found in the developing rat VM.  The discrepancy between these studies could possibly 
be explained by the varying sensitivities of the techniques used.  For example, a 
previous study has shown widespread expression of GDF-15 in various regions of the 
rat brain at P1 that is detectable by RT-PCR and Western bloting, whereas in situ 
hybridisation detected transcripts for GDF-15 only in the choroids plexus (Strelau et al. 
2000).  As such the findings of the present study taken together with those of previous 
studies (DeWulf et al. 1995; Panchision et al. 2001), suggest that, while BMPR-Ib 
expression may be at its highest in the dorsal domain of the neural tube, it is also 
expressed in the ventral midbrain at lower levels.  This suggests that it plays a role(s) 
during VM development (see below).  The present set of experiments provide the first 
direct evidence that cells in the E12 rat VM express all three BMP receptors.  
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9.4.2 GDF-5 increases the numbers of TH-immunopositive cells in E12 rat VM 
cultures 
Cultures of E12 rat VM were used to examine the effect of GDF-5 on the numbers of 
TH-positive cells in tissue taken at an early stage of dopaminergic neuron development.  
A similar culture system has been used previously to examine the effects of TGF- on 
rat dopaminergic neurons at E12 (Farkas et al. 2003).  Initially the cultures were 
characterised in order to determine the types of cells present after 24 hs in vitro.  Slight 
differences were observed between culture composition in the present experiment and 
that of Farkas and co-workers.  In the present experiments, 56.1% of the cells in the 
culture expressed TUJ-1, compared to 34.6% in the Farkas study.  Farkas et al. also 
observed a higher percentage of TH-positive cells; 8.7% compared to 1.9% in the 
present set of experiments.  These discrepancies may be due to the accuracy of the 
dissection, which may have differed between the experiments, and would greatly 
influence the relative percentages of cells present in the cultures.  Many cells in the 
present set of experiments were nestin-positive and thus probably represented neural 
progenitor cells.  The high degree of cells that were BrdU-positive indicates that many 
cells in these cultures were still proliferating and had not undergone their final mitotic 
division, which is thought to occur at about E14 in dopaminergic neurons of the rat VM 
(Hanaway et al. 1971; Lauder and Bloom 1974; Altman and Bayer 1981; Solberg et al. 
1993; Bayer et al. 1995).   
Previously it has been shown that treatment of E12 rat VM cultures for 24 hs 
with 1ng/ml TGF- resulted in a two-fold increase in the numbers of TH-positive 
neurons (Farkas et al. 2003).  In the present set of experiments, GDF-5 resulted in an 
increase of 1.6-fold of these neurons.  In agreement with the Farkas study, this increase 
was not due to an increase in total cell number or proliferation of TH-positive cells as no 
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cells which were stained positively for both TH and PCNA could be found and GDF-5 
did not increase the numbers of cells that incorporated BrdU.  Taken together, the data 
presented here show that the GDF-5-mediated increase in the numbers of TH-positive 
neurons in cultures of E12 rat VM is caused by induction of a dopaminergic phenotype 
in progenitor cells. 
 
9.4.3 GDF-5 and BMP-2 induce nurr1 and TH in NPCs from E12 rat VM  
In an attempt to try and provide direct evidence that GDF-5 can induce a dopaminergic 
phenotype in progenitor cells, cells from the E12 rat VM were expanded using 20ng/ml 
EGF and 20ng/ml FGF-2 for 6 days, followed by treatment with the aforementioned 
factors for 24 hs in the presence of EGF and FGF-2.  A previous study examined the 
effect of BMP-2 treatment on E12 rat VM cells expanded in a similar manner 
(Panchision et al. 2001).  In that study, no BMPR-Ib expression was found in the 
cultures after 6 DIV.  BMP-2 induced the expression of BMPR-Ib and of the dorsal 
identity gene, Msx1, and this induction could be blocked by Shh (Panchision et al. 
2001).  In the present experiment, it was found that BMPR-Ib was expressed in these 
cultures after 6 DIV and that BMP-2 did not induce the expression of Msx1 but instead 
up-regulated nurr1 and TH.  These results suggest that, instead of acting as a dorsalising 
factor as previously suggested (Panchision et al. 2001), BMP-2 acts as a ventralising 
factor.  One possible reason for the discrepancy between these experiments may be due 
to the presence of EGF in the present study.  In the experiments of Panchision and co-
workers, FGF-2 alone was used as the mitogen, whereas in the present set of 
experiments, both EGF and FGF-2 were used as mitogens because either factor alone 
did not result in efficient expansion of the cells.   
EGF has been shown to activate a p42/44 Erk-mediated pathway, which 
phosphorylates specific serine residues in the linker region of smad-1, preventing BMP-
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induced nuclear accumulation of smad-1 (Kretzschamer et al. 1997).  So in the presence 
of EGF, signalling through a smad-dependant mechanism is thought to be in-activated.  
This fact may provide a possible explanation for the discrepancy seen between the 
Panchision study and the present study.  As Panchision and co-workers did not have 
EGF present in their cultures, it is possible that the BMP-2-mediated induction of a 
dorsal phenotype seen in their study was dependant on a smad-mediated signal.  In the 
present experiment the presence of EGF (which is thought to inactivate smad signalling) 
suggests that the induction of a ventral phenotype may be achieved by a smad-
independent mechanism.  One possibility is that GDF-5 could have an effect through 
activation of members of the MAPK kinase family.  In support of this hypothesis, a 
recent report found that GDF-8 activated a p38 MAPK signal transduction pathway 
through TGF--activated kinase 1 (TAK1) that induced changes in gene expression that 
were independent of smad signalling (Philip et al. 2004 in press).   Previous reports have 
also shown BMP-5-mediated induction of certain genes in the developing limb occurs 
through a smad-dependant mechanism, while the induction of other genes occur through 
a smad-independent mechanism (Zuzarte-Luís et al. 2004).  Furthermore BMPs and 
GDFs have been reported to activate signalling pathways other than the smad pathway.  
For example GDF-5, BMP-2 and GDF-15 can activate MAPK kinase signalling 
cascades, including P38 and Erk-MAPK kinase (Nakamura et al. 1999; Hassel et al. 
2003; Subramaniam et al. 2003, respectively).  The precise signalling events leading to 
the increase in nurr1 and TH expression found in the present study remain to be 
established, but it is clear that the functions of BMP-2 during mesencephalic 
development are not clearly understood (Panchision et al. 2001).  These experiments 
also suggest the possibility that EGF may act as a “switch”, by allowing the same ligand 
(BMP-2) to have different effects depending on the (possibly) graded expression of EGF 
in the developing neural tube. 
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 Panchision and co-workers reported that the actions of BMP-2 in cultures of the 
E12 rat VM could be blocked by Shh.  Shh is expressed in the floor plate and notochord, 
is secreted from the floor plate, and induces neurons in the midbrain to adopt a 
dopaminergic fate (Hynes et al. 1995a, 1995b).  Shh has been shown to require TGF- 
(which activates smad-signalling) for this effect (Farkas et al. 2003).  In the present set 
of experiments, treatment with Shh and BMP-2 in combination had the same effect as 
treatment with BMP-2 alone; that is upregulation of nurr1 and TH expression.   This 
suggests that Shh does not block the effects of BMP-2 to induce a dopaminergic 
(ventral) phenotype, in contrast to its blocking effect on BMP-2 induction of a dorsal 
phenotype in ventral cells.   
The expression of BMP-2 in the E13 rat VM (Jordan et al. 1997) and GDF-5 
(O’Keeffe et al. 2004a) from E12 on in rat VM is surprising given that in the present set 
of experiments BMP-2 and GDF-5 alone increase nurr1 and TH-expression but when 
added together to the culture they downregulate the expression of nurr1 and completely 
switch off the expression of TH.  This may be due to competition for binding to BMPR-
Ib.  To explain how such a finding could be reconciled with the in vivo scenario is 
difficult however it is possible that these factors may act as negative influencers of the 
others function.  In order to examine this the amounts of BMP-2 and GDF-5 relative to 
each other should be compared during rat VM development. 
Ror2 (along with Ror1) was cloned from a human neuroblastoma cell line 
(Masiakowski and Carroll, 1992).  Recently, Ror2 has been identified as a receptor for 
GDF-5 (Dr. Prezmko Tylanowski personal communication) and for Wnt-5a (Oishi et al. 
2003).  In the present set of experiments, GDF-5, but not BMP-2, induced the 
expression of Ror2, suggesting that GDF-5 may facilitate signalling by itself and by 
Wnt-5a in the developing VM, by providing an appropriate receptor.  Previously it has 
been shown that the expression of Wnt-5a peaks on E11.5 in the rat VM (Castelo-
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Branco et al. 2003) which correlates with the onset of GDF-5 expression in the VM 
found in the present study (O’Keeffe et al. 2004a; see Chapter 5).  Even though GDF-5 
and Wnt-5a have no additive effects in increasing TH-positive cell numbers in cultures 
of E14 rat VM (see Chapter 6), it is possible that GDF-5 provides a niche for Wnt-5a 
signalling to occur by inducing a receptor which Wnt-5a can act on.  As Ror2 was not 
induced by BMP-2 treatment but was induced by BMP-2/Shh co-treatment, this 
suggested that Shh alone can also induce the expression of Ror2.  However any role for 
Ror2 in dopaminergic differentiation or induction remains to be established.  The 
increased numbers of TH-positive neurons following differentiation of GDF-5-treated 
cultures suggests that GDF-5 may be useful in inducing dopaminergic differentiation 
from expanded mesencephalic precursor cells for transplantation approaches to PD. 
 
9.4.5 Requirement for BMPR-Ib in BMP-2-mediated nurr1 and TH induction 
In the present set of experiments, both BMP-2 and GDF-5 increased the expression of 
nurr1 and TH in cultures of NPCs from the E12 rat VM.  In order to achieve 
intracellular smad activation, phosphorylation of type-I receptors by type-II receptors 
following ligand binding is necessary (for review see ten Dijke. et al. 2000).  Of the 
type-I receptors, BMP-2 and GDF-5 can both act through BMPR-Ib (for review see 
Mehler et al. 1997).  As such it was likely that signalling through BMPR-Ib was 
involved in the induction of nurr1 and TH by BMP-2 and GDF-5.  As GDF-5 induced 
Ror2 expression whereas BMP-2 did not, BMP-2 was the ligand chosen to use in the 
experiments designed to examine this question, because the use of GDF-5 would have 
introduced another receptor, of unknown function, into the experiment.  Blocking 
antibodies to BMPR-Ib abolished the BMP-2 induced increase in nurr1 and TH 
expression, which suggested that signalling through BMPR-Ib is required for the 
increase in nurr1 and TH induced by BMP-2 (and presumably by GDF-5, although this 
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will need to be shown directly).  Previous reports have shown that BMPR-Ib signalling 
is involved in the generation of dorsal identity within the neural tube (Panchision et al. 
2001).  The present set of experiments provide the first evidence that BMPR-Ib can also 
be involved in the generation of ventral cell types in the rat midbrain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1: 
 
RT-PCR analysis of the expression of BMP receptors (A) BMPR-II, (B) BMPR-
Ib, (C) BMPR-Ia in freshly dissected E12, E13 and E14 rat VM tissue.  (D) 18s 
RNA was run to confirm the presence of intact of cDNA used in each of the 
samples.  (E) An RT minus group was also used for the 18s RNA to confirm that 
there was no contamination of the cDNA samples with genomic DNA. 
 
 
Figure 9.2: 
 
Immunocytochemical analysis of the BMP receptors, (A) BMPR-II, (B) BMPR-
Ia and (C) BMPR-Ib in E12 rat VM cultures after 1 DIV.  (D) shows a negative 
control, i.e. a cultures that received no primary antibody.   
Scale bar = 50m 
 
 
Figure 9.3: 
 
Photomicrographs showing representative cultures of E12 rat VM grown for 1 
DIV. Cultures were immunocytochemically stained for (A) TH (red), TUJ 
(green) and DAPI (blue), (B) nestin (green) and DAPI (blue), (C) BrdU (green) 
and DAPI (blue) and (D) GFAP (red), MBP (green) and DAPI (blue).  (E) 
Graphical representation of showing the percentage of total cells in E12 VM 
cultures after 1 DIV expressing TUJ, TH and BrdU.  Data represent mean  SEM 
taken from three independent experiments.   
Scale bar = 100m 
 
Figure 9.4: 
 
Photomicrographs showing representative cultures of E12 rat VM grown for 1 
DIV, immunocytochemically stained for TH (green) and DAPI (blue).  (A) 
shows a control culture, (B) shows a culture that received 10ng/ml GDF-5 at the 
time of plating.  (C) Graphical representation showing the average number of 
TH-positive neurons per field in control and GDF-5 treated cultures.  Data 
represent mean  SEM taken from three independent experiments.   
*P<0.05 compared to control cultures 
Scale bar = 100m 
 
 
 
Figure 9.5: 
 
Graphical representations showing (A) the average numbers of apoptotic cells 
per field and (B) the average number of total cells per field in control and GDF-5 
treated cultures after 1 DIV.  Data represent mean  SEM taken from three 
independent experiments.   
N.S.  no significant difference between control and GDF-5 treated cultures 
 
 
 
 
Figure 9.6: 
 
Photomicrographs showing representative cultures of E12 rat VM grown for 1 
DIV, immunocytochemically stained for PCNA (red), TH (green) and DAPI 
(blue).  (A) shows a control culture, (B) shows a culture that received 10ng/ml 
GDF-5 at the time of plating.  (C) Graphical representation showing the average 
number of BrdU-positive nuclei per field in control and GDF-5 treated cultures.  
Data represent mean  SEM taken from two independent experiments.   
N.S.  no significant difference between control and GDF-5 treated cultures 
Scale bar = 20m 
 
 
 
Figure 9.7: 
 
Diagram showing the experimental protocol used to examine gene expression in 
expanded neural progenitor cells from the E12 VM.  1x 104 cells were plated in 
complete medium (see appendix A) supplemented with 2% B27, 20ng/ml EGF 
and 20ng/ml FGF and expanded for 6 DIV.  After 6 DIV GDF-5, BMP-2 and 
combinations of both were added to the culture medium.  24hours later medium 
was removed and RNA extracted for analysis by RT-PCR. 
 
 
 
 
Figure 9.8: 
Phase contrast photomicrographs of E12 NPCs grown in medium containing (A) 
20ng/ml EGF and 20ng/ml FGF, (B) 20ng/ml EGF and (C) 20ng/ml FGF, for 6 
DIV.  
 
Figure 9.9: 
RT-PCR analysis of (A) BMPR-Ia, (B) BMPR-IB, (C) Ror2, (D) Nurr 1, (E) TH, 
(F) Msx1, (G) positive control for Msx-1 amplified from cDNA prepared from 
the adult rat brain and (H) 18s RNA gene expression in expanded neural 
progenitors from the E12 rat VM following the treatments shown. 
 
 
 
Figure 9.10: 
 
Photomicrographs showing representative cultures of expanded neural 
progenitors prepared form the E12 rat VM expanded for 6 DIV and allowed to 
differentiate for a further 6 DIV in (A) control medium and (B) in medium 
containing 50ng/ml GDF-5.  Cultures were immunocytochemically stained for 
TH (red), TUJ (green) and DAPI (blue). 
Scale bar = 100m 
 
 
 
Figure 9.11: 
 
RT-PCR analysis of (A) nurr1 (B) TH and (C) 18s RNA gene expression in 
expanded neural progenitors from the E12 rat VM following the treatments 
shown.  Graphical representations of (D) nurr1 levels and (E) TH levels in 
control cultures compared to those in BMP-2 and BMP-2/IgG-BMPR-Ib 
cultures.  Data was generated by densiometric analysis comparing nurr1 and TH 
levels normalised to those of 18s RNA. 
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10.0 FINAL DISCUSSION 
 
Experimental evidence has resulted in GDF-5 being proposed as a candidate 
neurotrophin for the treatment of PD.  Based on published studies, GDF-5 improves the 
survival of embryonic dopaminergic neurons grafted to the striatum in a rat model of PD 
(Sullivan et al. 1998).  Furthermore GDF-5 protects adult nigrostriatal dopaminergic 
neurons when directly administered to the striatum or SN in a rat model of PD (Sullivan 
et al. 1997, 1999; Hurley et al. 2004).  If GDF-5 is to be used in a clinical setting for the 
treatment of PD, many questions must be answered regarding it roles and expression 
pattern during brain development and in particular its roles in dopaminergic neuron 
development.   
Prior to the beginning of this thesis, it was not known if GDF-5 was expressed in 
the developing or adult nigrostriatal system.  These studies have shown that GDF-5 is 
associated with both the developing and adult nigrostriatal system (O’Keeffe et al. 
2004a), which suggests that it plays a role in dopaminergic neuron development and 
maintenance in the adult brain.  Furthermore these studies have documented at least 
some of the roles that GDF-5 plays in dopaminergic development.  GDF-5 increases the 
numbers of dopaminergic neurons in cultures of E14 rat VM.  This increase in 
dopaminergic neuron numbers is achieved by increasing the conversion of Nurr-1-
positive, TH-negative dopaminergic precursor cells to Nurr-1-positive TH-positive 
dopaminergic neurons.  Furthermore GDF-5 increases the branching and neurite length 
of these neurons, suggesting that it plays a role in their morphological development of 
these neurons (O’Keeffe et al. 2004b).   
It will be important to determine the precise mechanisms involved in these 
processes.  The activation of intracellular smad proteins by GDF-5 implies that the 
effects of GDF-5 treatment on dopaminergic neurons are (at least in part) mediated by 
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smad signaling.  The presence of Ror2, which is a novel receptor for GDF-5, in the VM 
at E14 makes it possible that GDF-5 can use alternative signaling pathways other than 
the smad pathway.  Some pilot data has also shown that GDF-5 can activate Erk-MAPK 
kinase in cultures of E14 rat VM (O’Keeffe et al. unpublished observations).  As this 
pathway has been shown to inhibit smad signaling (Kretzchmar et al. 1997), it will be 
important to determine the relationship between these signaling pathways.   
As well as the application of this research to a practical problem, that is 
generating dopaminergic neurons from NPCs, it also raises a fascinating point regarding 
how cell fate in specified in the nervous system.  These findings show that BMP-2, 
which to date has been shown to induce a dorsal fate in proliferating ventral cells, can 
also induce a ventral cell fate, in the presence of EGF.  It will be important to fully 
explore the relationship between the EGF signalling pathway and the signalling 
pathways activated by BMPs or GDFs, in order to fully understand how the same ligand 
can induce a dorsal or ventral cell fate in the neural tube.    Although BMPs are 
classically known as factors that induce a dorsal fate in NPCs during neural tube 
development, it is the opinion of this author that under certain circumstances that they 
may be involved in the induction of a ventral cell fate in the developing of the neural 
tube.  The species differences observed in these studies regarding the expression of 
BMPR-Ib, which is being expressed in the ventral midbrain in the rat but not in the 
mouse, implies that care must be taken when interpreting the findings of mouse genetic 
studies examining the roles of these receptors during CNS development (for example 
see Panchision et al. 2002). 
 
What is clear from these studies is that the effects of GDF-5 on dopaminergic 
neurons make it a very suitable candidate neurotrophin to use as an adjunct to neural 
transplantation of embryonic dopaminergic neurons in the treatment of PD.  GDF-5 is 
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perhaps a more suitable neurotrophin than GDNF for use in supporting grafted 
embryonic rat dopaminergic neurons, as the expression of GDF-5 in the VM is maximal 
on E14 the day that the neurons are routinely harvested for transplantation studies 
(O’Keeffe et al. 2004a), unlike that of GDNF whose expression increases in the 
postnatal period (O’Keeffe et al. unpublished observations).  Furthermore the increase in 
dopaminergic neuron numbers as well as the improvements seen in the morphological 
development of these neurons make suggest that GDF-5 may improve integration of the 
grafted dopaminergic neurons into the host brain by inducing axonal outgrowth from the 
transplanted cells and the establishment of functional connections with the host brain 
(for a summary of roles of GDF-5 during rat VM development see Figure 10.1). 
 
 Neurotransplantation for the treatment of PD is limited, due to ethical and 
practical concerns regarding the use of human embryonic tissue.  One of the most 
limiting problems is the requirement for 6-8 embryos to treat a single patient.  The 
widespread adoption of clinical neurotransplantation for the treatment of PD is unlikely 
unless alternative sources of dopaminergic neurons are found.  As NPCs can be grown 
efficiently in large numbers and differentiated into the required neuronal phenotype, 
they are an ideal source of cells for use in transplantation approaches to 
neurodegenerative disease.    
One of the studies presented here show that the gestational age of the donor 
tissue used to generate the NPCs is a key factor in determining the cell types generated.  
It was found that NPCs expanded from the rat E12 VM for 6 DIV and differentiated for 
6 DIV could generate dopaminergic neurons, whereas those from later ages could not.  
However, the ability to generate dopaminergic neurons was only observable on the first 
passage and subsequently lost with increasing time in culture.  These studies have 
shown that GDF-5 (and BMP-2) induce the expression of nurr-1 and TH in proliferating 
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NPCs from the E12 rat VM.  This makes these factors candidates for further studies 
aimed at examining whether they could be used to efficiently generate dopaminergic 
neurons from NPCs for use in transplantation approaches to PD.   
Transplantation of expanded NPCs (or cells derived from these) is the most 
hopeful course for generating dopaminergic neurons for transplantation approaches to 
PD.  Although NPCs can be isolated from a variety of brain regions, it is the opinion of 
this author that the NPCs should be isolated from regions of the embryonic brain that 
give rise to the types of neurons which are affected by the disease process.  For example, 
for transplantation approaches to PD, NPCs should be isolated from the embryonic VM, 
while for transplantation approaches to Huntingtons disease, they should be isolated 
from the embryonic striatum.  At the present time not enough is understood about NPCs 
(or other stem cell sources) to begin clinical transplantation.  Centres and clinical trials 
that offer transplants of stem cells to patients in the current day are extremely damaging 
to the field of transplantation as these simply are not effective.  Not enough is known 
about the basic biology of the stem cell and how it differentiates to generate a mature 
neuronal cell.  For example, although much is know about how VM dopaminergic 
neurons develop in vivo, much more remains to elucidated.  The generation of mature 
fully functional dopaminergic neurons during normal VM development is likely to 
require and be controlled by a multitude of different factors and signaling pathways.  
Whether we can ever simulate such a complex process in a culture dish to differentiate 
NPCs to mature, fully functional dopaminergic neurons remains to be seen.  This 
problem is highlighted by a recent report presented at a stem cell meeting in Boston.  
Dopaminergic neurons were efficiently generated from human ES cells in vitro, but 
when these cells were transplanted to the striatum in animal models of PD, none of them 
survived.  Much more research needs to be carried out to determine how these neurons 
develop, mature, become electrically active and maintain a dopaminergic phenotype.  
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Only when scientists can show that dopaminergic neurons generated from NPCs or other 
stem cell sources have all the properties of mature fully functional midbrain 
dopaminergic neurons isolated directly from the midbrain should such cells be 
considered for transplantation.  Until that point is reached, medical, pharmacological 
and surgical treatment for PD should be pursued.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.1:  
Schematic representation showing functions of GDF-5 during rate VM 
development. GDF-5 increases the conversion of Nurr-1-positive, TH-negative 
precursors to Nurr-1-positive, TH-positive dopaminergic neurons. GDF-5 also 
improves the morphological development of dopaminergic neurons. The results 
of the present study taken with those of a previous study (Brederlau et a. 2002) 
show that GDF-5 promotes differentiation of GRPs to an astroglial fate at the 
expense of an oligodendroglial fate.  
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12.0 APPENDICES 
 
12.1 APPENDIX A (GENERAL APPENDIX) 
 
Antibodies used in western blotting 
Antibody      Working dilution  
GDF-5 (P3/66) (Monoclonal; Biopharm)  1:1,000 
-III tubulin (Monoclonal; Promega)   1:50,000 
GFAP (Monoclonal; Sigma)    1:1,000 
GFAP (Polyclonal-rb
*
; DAKO)   1:1,000 
TH (Polyclonal-rb; Chemicon)   1:1,000 
Actin (Polyclonal-gt; Santa-cruz)   1:10,000 
(
*
 -rb = polyclonal antibody raised in rabbit, -gt = polyclonal antibody raised in goat). 
 
10% (
w
/v) ammonium persulphate (APS) 
0.1g  of APS was dissolved in 1ml of distilled water.  Fresh APS was made up for each 
new western blot. 
 
Biotinylated molecular weight markers (Amersham): 
25l of the molecular weight markers were mixed with 225l of the sample bufferfor 
the molecular weight markers (see below). 10l aliquots were stored at –20C.  10l 
molecular weight markers were boiled for 5 mins before being loaded onto the gel. 
 
1% (
w
/v)  Bromophenol blue 
0.1g bromophenol blue (Sigma) was dissolved in 10ml of distilled water.  Solution was 
stored at room temperature. 
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Coomassie blue staining 
Coomassie dye (Sigma)    2.5g 
Ethanol (AGB)     500ml 
Glacial acetic acid     100ml 
Distilled water     200ml 
Destaining solution: 
Ethanol (AGB)     250ml 
Glacial acetic acid     70ml 
Distilled water     680ml 
The gel was incubated in staining solution overnight at 4C.  Excessive staining was 
removed by incubating the stained gel in destaining solution with gentle agitation until 
an appropriate contrast was reached. 
 
Gel recipes      
Percentage Gels  5%   10%   12% 
Distilled water  5.7ml   4.1ml   3.4ml 
*
Acrylamide   1.7ml   3.3ml   4.0ml 
*
0.5M Tris pH 6.8  2.5ml   2.5ml   2.5ml 
*
1.5M Tris pH8.8  2.5ml   2.5ml   2.5ml 
10% SDS (Sigma)  100l   100l   100l 
10% APS (Sigma)  50l   50l   50l 
TEMED (Sigma)  10l   10l   10l 
(*Bio-Rad) 
 
Homogenate buffer for cell/tissue lysis 
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1M Tris pH7.4 (Bio-rad)  1ml 
NaCl (Sigma)    0.18g 
Glycerol (Sigma)   2ml 
Triton X-100 (Sigma)   200l 
0.5M EDTA (Sigma)   40l 
PMSF 100μg/ml 
Bacitracin 1μg/ml 
Pepstatin A 1μg/ml 
Aprotinin 1μg/ml 
Leupeptin 1μg/ml 
Antipain 1μg/ml 
Distilled water Made up to 20ml   
 
10x PBS (100mM) 
Sodium chloride     33.64g  
Di-sodium hydrogen orthophosphate   11.86g 
Di-sodium hydrogen orthophosphate di-hydrate 46.0g 
Distilled water     Made up to 1 liter 
To make a 1x PBS solution (10mM), 100ml was added to 900ml of distilled water.  
Solution was stored at room temperature. 
 
PBST (1x) 
1 liter of 10mM PBS + 1ml of tween 20 (Sigma). Solution was stored at room 
temperature. 
  
PBS-Tx (1x) 
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1 liter of 10mM PBS + 1ml of 20% Triton-X 100 (Sigma).  Solution was stored at room 
temperature. 
 
Ponceau S staining of the PVDF membrane 
10 x Ponceau S staining solution: 
Ponceau S (Sigma)     2g 
Acetic Acid      50ml 
Distilled water     50ml 
PVDF membranes were stained by placing them in 1 x Ponceau S solution (1ml 10x 
stock + 9ml distilled water) for 10 mins.  Following this blots were washed in several 
changes of distilled water to remove the Ponceau S staining. 
 
Running buffer (5x) 
Tris-base (Sigma)     15.15g 
Glycine (Sigma)     72.50g 
SDS (Sigma)      5g 
Distilled Water     Made up to 1 liter 
A 1x solution was mage by diluting the 5x stock with distilled water (100ml 5x stock + 
400ml distilled water) 
 
Sample buffer for cell/tissue samples 
Urea (Sigma)      8.4g 
sodium-phosphate (Sigma)    0.02g 
SDS (Sigma)      0.2g 
1% bromophenol blue (Sigma)   200l   
dithiothreitol (Sigma)     0.31g 
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Distilled water     Made up to 20ml 
 
Sample buffer for molecular weight markers 
0.5M Tris pH 6.8 (Bio-rad)    1ml   
Glycerol (Sigma)     0.8ml 
10% SDS (Sigma)     1.6ml 
-metacarpoethanol(Sigma)    0.4ml 
1%(
w
/v) bromophenol blue(Sigma)    0.2ml 
Distilled water     4ml 
 
10% (
w
/v) SDS solution: 
10g of SDS (Sigma) was dissolved in 100ml of distilled water.  Solution was stored at 
room temperature. 
 
Transfer buffer (1x) 
Tris-base (Sigma)     5.82g 
Glycine (Sigma)     2.93g 
Methanol (Sigma)     50ml 
Distilled water     Made up to 1 liter 
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12.2 APPENDIX B (CELL CULTURE) 
 
12.2.1 Poly-D-lysine coating of culture dishes 
A 0.1mg/ml solution of poly-d-lysine (Sigma) was made by dissolving 5 mg of poly-d-
lysine in 50 ml of distilled water.  This solution was applied to the 13mm coverslips or 
the wells of the 3cm 4 well dishes.  It was left covering the surfaces for 20 mins, before 
being removed.  The coverslips and dishes were washed (3 x 10 mins) in distilled water.  
Coverslips/culture dishes were allowed to dry at 37C for one h before use.  Any unused 
poly-d-lysine solution was aliquoted into 5 ml aliquoted and stored at –20C. 
 
12.2.2 Culture media 
GDF5-CHO cell line serum medium 
MEM       450ml 
FCS       50ml 
L-glutamine       2mM 
Methotrexate      400nM   
Penicillin      100U/ml  
Streptomycin      100g/ml  
 
GDF5-CHO cell line serum-free medium 
DMEM/Ham’s F12 (1:1) with 15mM HEPES  
and sodium bicarbonate (Sigma)   500ml 
Aprotinin      10 KIU  
Sodium butyrate     1mM   
Sodium selenate     6.7ng/ml  
Transferrin      5.5g/ml  
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Ethanolamine      2g/ml  
Insulin       9g/ml  
Penicillin      100U/ml   
Streptomycin      100g/ml 
 
Complete medium for cultures of rat neural cells 
DMEM/Ham’s F12 (1:1) with 15mM HEPES  
and sodium bicarbonate (Sigma)   500ml  
L-glutamine (Sigma; 100x)    5ml  
Pen/Strep/Fungizone (Sigma; 100x)   5ml 
*D-glucose (Sigma)     3g 
(* 3g of D-Glucose were dissolved in 10 ml of DMEM/F12 and sterile filtered into the 
remaining 490ml of DMEM/F12) 
Complete medium was stored in the original bottle, wrapped in tin foil and stored at 
4C. 
 
Plating medium for cultures of E14 rat VM 
Complete medium     9.7ml    
B27 (Gibco; 50x)     200l 
Foetal calf serum (Sigma; FCS)   100l 
 
Serum-free medium for cultures of E12 and E14 rat VM 
Complete medium     9.46ml    
B27 (Gibco; 50x)     200l 
BSA (Sigma; 7.5%)  333l 
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Expansion medium for neural progenitor cell culture 
Complete medium     9.9ml    
N2 (Gibco; 100x)     100l 
EGF (20g/ml stock; Sigma)    10l 
FGF-2 (20g/ml stock; RnD Systems)   10l 
 
Differentiation medium for neural progenitor cell culture 
Complete medium     9.9ml    
N2 (Gibco; 100x)     100l 
FCS (Sigma)      100l 
 
DAPI: 
Stock solution of DAPI was prepared by dissolving 10mg of DAPI powder (Sigma) in 
10mM PBS.  500 l aliquots were stored in the dark at -20C.  A working solution was 
prepared by diluting the stock 1:100 in 10mM PBS to give a final working concentration 
of 10g/ml. 
                                                                       
 
12.2.3 Buffers for reconstitution of growth factors 
Sodium citrate buffer: 
Sodium citrate (Sigma)    0.02g 
Sodium chloride (Sigma)    0.09g 
Distilled water     Made up to 10ml 
 
 
100mM DTT stock: 
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0.31g of DTT (Sigma) was dissolved in 20ml of 10mM PBS.  The solution was sterile 
filtered and stored at 4C. 
50 mg/ml Heparin: 
50 mg of heparin (Sigma) was dissolved in 1 ml of 10mM PBS.  The solution was 
sterile filtered and stored at 4C. 
 
Reconstitution of growth factors: 
GDF-5 (Biopharm): 
100g of recombinant human GDF-5 was reconstituted using 0.2 M filtered sterile 
sodium-citrate buffer to give a stock solution of 100g/ml.  20l aliquots were prepared 
and stored at 
–20C. 
EGF (Sigma): 
25g of EGF was reconstituted using 0.2 M filtered sterile 10mM acetic acid 
containing 0.1% BSA (Sigma) to give a stock solution of 20g/ml. 20l aliquots were 
prepared and stored at –20C. 
FGF-2 (R &D systems): 
25g of FGF-2 was reconstituted using 0.2 M filtered sterile 10mM PBS containing 
0.1% BSA (Sigma), 1mM DTT (Sigma) and heparin (Sigma) at a final concentration of 
5g/ml, to give a stock solution of 20g/ml. 20l aliquots were prepared and stored at –
20C. 
Shh (R &D systems): 
25g of recombinant human Shh was reconstituted using 0.2 M filtered sterile 10mM 
PBS containing 0.1% BSA (Sigma) to give a stock solution of 50g/ml. 20l aliquots 
were prepared and stored at –20C. 
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FGF-2 (R &D systems): 
25g of recombinant mouse FGF-2 was reconstituted using 0.2 M filtered sterile 
10mM PBS containing 0.1% BSA (Sigma) to give a stock solution of 50g/ml. 20l 
aliquots were prepared and stored at –20C. 
BMP-2: 
25g of recombinant human BMP-2 was reconstituted using 0.2 M filtered sterile 
4mM HCl containing 0.1% BSA (Sigma) to give a stock solution of 10g/ml. 20l 
aliquots were prepared and stored at –20C. 
 
Blocking solution for immunocyotchemistry: 
Normal horse serum (Sigma)    1ml 
20% Triton X-100     200l 
10mM PBS pH 7.4     18.8ml 
Solution was stored at 4C for up 7 days before fresh blocking solution was prepared. 
 
Primary antibodies used in immunocytochemistry: 
Antibody:     Working dilution for immunocyotchemistry: 
GDF-5/MP-52 (Monoclonal; Biopharm)  1:50 
-III tubulin (Monoclonal; Promega)   1:200 
MAP-2ab (Monoclonal; Sigma)   1:100 
GFAP (Monoclonal; Sigma)    1:200 
GFAP (Polyclonal-rb
*
; DAKO)   1:400 
PCNA (Monoclonal; Sigma)    1:100 
Nestin (Monoclonal; Chemicon)   1:200 
Nurr1 (Polyclonal-gt
*
; Santa-cruz)   1:1000 
Nurr1 (Polyclonal-rb; Chemicon)   1:1000 
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TH (Polyclonal-rb; Chemicon)   1:200 
BMPR-II (Polyclonal-gt
*
; Santa-cruz)  1:10 
BMPR-Ia (Polyclonal-gt; Santa-cruz)  1:10 
BMPR-Ib (Polyclonal-gt; Santa-cruz)  1:10 
 (
*
 -rb = polyclonal antibody raised in rabbit, -gt = polyclonal antibody raised in goat). 
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12.3 APPENDIX C (CHAPTER 6) 
 
12.3.1 COUNTS OF TH-POSITIVE CELLS IN E14VM CULTURES AFTER TREATMENT WITH GDF-5 FOR 6 DIV 
 
Control    1ng/ml GDF-5  10ng/ml GDF-5 
   
c.slip no. / field no.                      TH (+) cells/field Average   TH (+) cells/field  Average   TH (+) cells/field  Average 
 
1.1  1   14   20  
1.2  10   17   9  
1.3  11   20   12  
1.4  7   12   11  
1.5  4   14   17  
1.6  6   13   15  
1.7  3   21   18  
1.8  13 6.9  19 16.3  14 15 
2.1  7   13   10  
2.2  8   13   13  
2.3  9   14   15  
2.4  5   11   19  
2.5  8   30   14  
2.6  4   9   13  
2.7  7   19   11  
2.8  2 6.3  10 14.8  13 14 
3.1  0   11   17  
3.2  5   15   15  
3.3  5   7   14  
3.4  10   13   16  
3.5  6   27   15  
3.6  2   21   24  
3.7  1   18   18  
3.8  6 4.4  17 16.2  7 15.8 
4.1  6   16   9  
4.2  4   17   22  
4.3  6   15   17  
4.4  7   19   11  
4.5  5   18   21  
4.6  5   25   11  
4.7  4   17   12  
4.8  6 5.4  9 17  13 15 
5.1  3   12   10  
5.2  6   16   19  
5.3  6   21   16  
5.4  2   16   11  
5.5  3   12   20  
5.6  8   13   11  
5.7  6   10   10  
5.8  6 5  15 14.4  12 13.7 
6.1  2   16   15  
6.2  4   21   24  
6.3  7   19   21  
6.4  4   16   14  
6.5  5   15   14  
6.6  3   14   18  
6.7  6   14   13  
6.8  4 4.4  12 15.9  14 16.7 
7.1  3   7   8  
7.2  2   9   6  
7.3  2   18   11  
7.4  8   11   11  
7.5  3   21   6  
7.6  5   14   8  
7.7  2   10   11  
7.8  4 3.6  12 12.8  3 8 
8.1  2   9   5  
8.2  2   6   3  
8.3  3   17   10  
8.4  8   19   10  
8.5  3   18   5  
8.6  2   14   6  
8.7  4   14   5  
8.8  3 3.4  10 13.4  7 6.4 
9.1  2   9   6  
9.2  3   7   8  
9.3  4   8   6  
9.4  5   14   7  
9.5  2   14   10  
9.6  4   14   11  
9.7  3   7   9  
9.8  3 3.3  10 10.4  6 7.9 
10.1  3   9   7  
10.2  2   14   5  
10.3  5   12   11  
10.4  8   13   9  
10.5  4   15   5  
10.6  3   20   6  
10.7  1   16   11  
10.8  1 3.4  8 13.4  8 7.8 
 
MEAN   4.6   14.4   11.9 
SD   1.3   2.0   3.9 
SE   0.4   0.6   1.2 
 
 
12.3.2 COUNTS OF GFAP-POSITIVE CELLS AFTER TREATMENT WITH GDF-5 FOR 6 DIV 
 
Control    1ng/ml GDF-5  10ng/ml GDF-5 
   
c.slip no. / field no.                      GFAP (+) cells/field Average   GFAP (+) cells/field  Average   GFAP (+) cells/field  Average 
1.1  8   16   24  
1.2  5   13   18  
1.3  8   18   56  
1.4  9 7.5  11 14.5  34 33 
2.1  4   14   73  
2.2  9   10   36  
2.3  6   15   62  
2.4  7 6.5  17 14  41 53 
3.1  8   17   74  
3.2  9   13   71  
3.3  8   18   38  
3.4  5 7.5  25 18.3  29 53 
4.1  10   12   61  
4.2  6   18   42  
4.3  10   16   43  
4.4  8 8.5  25 17.8  74 55 
5.1  10   32   41  
5.2  8   8   42  
5.3  11   15   50  
5.4  7 9  14 17.3  29 40.5 
6.1  7   20   32  
6.2  6   13   61  
6.3  4   14   57  
6.4  6 5.8  10 14.3  66 54 
7.1  4   10   63  
7.2  4   13   20  
7.3  5   26   47  
7.4  3 4  20 17.3  50 45 
8.1  5   22   48  
8.2  6   18   26  
8.3  6   9   63  
8.4  8 6.3  13 15.5  27 41 
9.1  9   33   30  
9.2  11   5   42  
9.3  15   16   40  
9.4  11 11.5  13 16.8  30 35.5 
10.1  10   13   33  
10.2  15   21   37  
10.3  10   21   45  
10.4  6 10.3  9 16  41 39 
11.1  18   36   43  
11.2  15   34   63  
11.3  11   18   44  
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11.4  8 13  13 25.3  44 48.5 
12.1  10   41   32  
12.2  4   27   39  
12.3  11   26   47  
12.4  6 7.8  38 33  69 46.8 
 
MEAN  8.1    18.3   45.4 
SD  2.5    5.5   7.6 
SE  0.7    1.6   2.2 
 
 
 
 
12.3.3 COUNTS OF TH-POSITIVE CELLS AFTER TREATMENT WITH GDF-5 FOR 24 HS AT 1 OR 6 DIV 
 
1DIV      7DIV 
 
Control  10ng/ml GDF-5     Control  10ng/ml GDF-5 
    
c.slip no. / field no.                      TH (+) cells/field TH (+) cells/field Average/field Average/field  TH (+) cells/field TH (+) cells/field Average/field Average/field 
   
1.1  16 18    81 88   
1.2  31 23    70 86   
1.3  23 21    76 77   
1.4  16 21 21.5 20.75  44 76 67.75 81.75 
2.1  26 20    93 91   
2.2  13 33    103 74   
2.3  22 33    64 82   
2.4  12 46 18.25 33  40 79 75 81.5 
3.1  29 18    83 81   
3.2  9 19    50 89   
3.3  60 19    63 107   
3.4  34 30 33 21.5  68 67 66 86 
4.1  24 28    70 93   
4.2  26 41    56 64   
4.3  11 27    71 96   
4.4  31 22 23 29.5  62 62 64.75 78.75 
5.1  25 29    71 93   
5.2  29 11    73 82   
5.3  33 22    70 97   
5.4  33 27 30 22.25  60 71 68.5 85.75 
6.1  4 32    54 73   
6.2  18 14    57 88   
6.3  22 22    42 83   
6.4  50 17 23.5 21.25  59 122 53 91.5 
MEAN    24.9 24.7    65.9 84.2 
SD    5.5 5.2    7.2 4.5 
SE    3.9 3.7    5.1 3.2 
 
 
 
 
 
12.3.4 MEASUREMENT OF NEURITE LENGTH 
 
Control  Number of intercepts at different levels of neurite field  Neurite length in m at different levels of neurite field  
 
 c slip no. Primary Sec Ter Quat Total Primary Sec Ter Quat Total 
 
Neuron 1 1 5 0 0 0 5 57.1 0.0 0.0 0.0 57.1 
Neuron 2 1 5 4 0 0 9 57.1 45.7 0.0 0.0 102.8 
Neuron 3 1 6 6 0 0 12 68.5 68.5 0.0 0.0 137.1 
Neuron 4 1 8 0 0 0 8 91.4 0.0 0.0 0.0 91.4 
Neuron 5 2 2 7 3 0 12 22.8 80.0 34.3 0.0 137.1 
Neuron 6 2 6 0 0 0 6 68.5 0.0 0.0 0.0 68.5 
Neuron 7 2 4 2 0 0 6 45.7 22.8 0.0 0.0 68.5 
Neuron 8 3 2 6 1 0 9 22.8 68.5 11.4 0.0 102.8 
Neuron 9 3 4 1 0 0 5 45.7 11.4 0.0 0.0 57.1 
Neuron 10 3 8 2 0 0 10 91.4 22.8 0.0 0.0 114.2 
Neuron 11 3 11 0 0 0 11 125.7 0.0 0.0 0.0 125.7 
Neuron 12 4 4 7 0 0 11 45.7 80.0 0.0 0.0 125.7 
Neuron 13 4 5 4 0 0 9 57.1 45.7 0.0 0.0 102.8 
Neuron 14 4 13 1 0 0 14 148.5 11.4 0.0 0.0 159.9 
Neuron 15 4 4 2 0 0 6 45.7 22.8 0.0 0.0 68.5 
Neuron 16 5 10 2 0 0 12 114.2 22.8 0.0 0.0 137.1 
Neuron 17 5 8 0 0 0 8 91.4 0.0 0.0 0.0 91.4 
Neuron 18 5 3 7 0 0 10 34.3 80.0 0.0 0.0 114.2 
Neuron 19 5 11 0 0 0 11 125.7 0.0 0.0 0.0 125.7 
Neuron 20 5 1 4 0 0 5 11.4 45.7 0.0 0.0 57.1 
Neuron 21 6 20 0 0 0 20 228.5 0.0 0.0 0.0 228.5 
Neuron 22 6 3 4 0 0 7 34.3 45.7 0.0 0.0 80.0 
Neuron 23 6 8 0 0 0 8 91.4 0.0 0.0 0.0 91.4 
Neuron 24 6 12 0 0 0 12 137.1 0.0 0.0 0.0 137.1 
Neuron 25 6 4 0 0 0 4 45.7 0.0 0.0 0.0 45.7 
Neuron 26 7 8 5 0 0 13 91.4 57.1 0.0 0.0 148.5 
Neuron 27 8 8 0 0 0 8 91.4 0.0 0.0 0.0 91.4 
Neuron 28 8 6 0 0 0 6 68.5 0.0 0.0 0.0 68.5 
Neuron 29 9 5 4 0 0 9 57.1 45.7 0.0 0.0 102.8 
Neuron 30 9 4 0 0 0 4 45.7 0.0 0.0 0.0 45.7 
Neuron 31 9 9 0 0 0 9 102.8 0.0 0.0 0.0 102.8 
Neuron 32 10 9 0 0 0 9 102.8 0.0 0.0 0.0 102.8 
Neuron 33 11 8 3 0 0 11 91.4 34.3 0.0 0.0 125.7 
Neuron 34 11 5 2 0 0 7 57.1 22.8 0.0 0.0 80.0 
Neuron 35 11 3 6 0 0 9 34.3 68.5 0.0 0.0 102.8 
Neuron 36 11 12 7 0 0 19 137.1 80.0 0.0 0.0 217.1 
Neuron 37 12 9 5 0 0 14 102.8 57.1 0.0 0.0 159.9 
Neuron 38 12 10 7 0 0 17 114.2 80.0 0.0 0.0 194.2 
Neuron 39 12 7 1 4 0 12 80.0 11.4 45.7 0.0 137.1 
Neuron 40 13 5 0 0 0 5 57.1 0.0 0.0 0.0 57.1 
Neuron 41 13 8 1 2 0 11 91.4 11.4 22.8 0.0 125.7 
Neuron 42 13 9 0 0 0 9 102.8 0.0 0.0 0.0 102.8 
Neuron 43 14 8 2 0 0 10 91.4 22.8 0.0 0.0 114.2 
Neuron 44 14 8 0 0 0 8 91.4 0.0 0.0 0.0 91.4 
Neuron 45 14 10 0 0 0 10 114.2 0.0 0.0 0.0 114.2 
Neuron 46 14 16 0 0 0 16 182.8 0.0 0.0 0.0 182.8 
Neuron 47 15 9 2 0 0 11 102.8 22.8 0.0 0.0 125.7 
Neuron 48 15 9 2 0 0 11 102.8 22.8 0.0 0.0 125.7 
Neuron 49 15 18 0 0 0 18 205.6 0.0 0.0 0.0 205.6 
Neuron 50 15 5 4 0 0 9 57.1 45.7 0.0 0.0 102.8 
 
MEAN       85.7 25.1 2.3 0.0 113.1 
SD       44.9 28.4 8.6 0.0 42.6 
SE       6.3 4.0 1.2 0.0 6.0 
 
 
          
 
1ng/ml GDF-5 Number of intercepts at different levels of neurite field  Neurite length in m at different levels of neurite field 
   
 c slip no. Primary Sec Ter Quat Total Primary Sec Ter Quat Total 
 
Neuron 1 1 4 6 0 0 10 45.7 68.5 0.0 0.0 114.2 
Neuron 2 1 16 3 2 0 21 182.8 34.3 22.8 0.0 239.9 
Neuron 3 1 11 5 8 0 24 125.7 57.1 91.4 0.0 274.2 
Neuron 4 1 23 5 0 0 28 262.8 57.1 0.0 0.0 319.9 
Neuron 5 2 6 4 0 0 10 68.5 45.7 0.0 0.0 114.2 
Neuron 6 2 6 13 2 0 21 68.5 148.5 22.8 0.0 239.9 
Neuron 7 2 25 0 0 0 25 285.6 0.0 0.0 0.0 285.6 
Neuron 8 2 3 9 0 0 12 34.3 102.8 0.0 0.0 137.1 
Neuron 9 3 7 5 0 0 12 80.0 57.1 0.0 0.0 137.1 
Neuron 10 3 7 13 0 0 20 80.0 148.5 0.0 0.0 228.5 
Neuron 11 3 6 10 0 0 16 68.5 114.2 0.0 0.0 182.8 
Neuron 12 3 11 7 2 3 23 125.7 80.0 22.8 34.3 262.8 
Neuron 13 4 13 5 0 0 18 148.5 57.1 0.0 0.0 205.6 
Neuron 14 4 14 14 5 0 33 159.9 159.9 57.1 0.0 377.0 
Neuron 15 4 8 9 0 0 17 91.4 102.8 0.0 0.0 194.2 
Neuron 16 5 26 0 0 0 26 297.0 0.0 0.0 0.0 297.0 
Neuron 17 5 17 7 0 0 24 194.2 80.0 0.0 0.0 274.2 
Neuron 18 5 8 22 0 0 30 91.4 251.3 0.0 0.0 342.7 
Neuron 19 6 20 9 0 0 29 228.5 102.8 0.0 0.0 331.3 
Neuron 20 6 6 10 6 0 22 68.5 114.2 68.5 0.0 251.3 
Neuron 21 6 4 11 7 0 22 45.7 125.7 80.0 0.0 251.3 
Neuron 22 6 12 8 12 0 32 137.1 91.4 137.1 0.0 365.6 
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Neuron 23 7 3 14 6 0 23 34.3 159.9 68.5 0.0 262.8 
Neuron 24 7 7 5 0 0 12 80.0 57.1 0.0 0.0 137.1 
Neuron 25 7 2 9 4 0 15 22.8 102.8 45.7 0.0 171.4 
Neuron 26 7 10 5 0 0 15 114.2 57.1 0.0 0.0 171.4 
Neuron 27 8 9 7 0 0 16 102.8 80.0 0.0 0.0 182.8 
Neuron 28 8 5 6 0 0 11 57.1 68.5 0.0 0.0 125.7 
Neuron 29 8 9 16 0 0 25 102.8 182.8 0.0 0.0 285.6 
Neuron 30 9 10 7 2 0 19 114.2 80.0 22.8 0.0 217.1 
Neuron 31 9 12 2 1 0 15 137.1 22.8 11.4 0.0 171.4 
Neuron 32 10 6 8 0 0 14 68.5 91.4 0.0 0.0 159.9 
Neuron 33 10 10 11 0 0 21 114.2 125.7 0.0 0.0 239.9 
Neuron 34 10 15 9 9 0 33 171.4 102.8 102.8 0.0 377.0 
Neuron 35 11 4 8 0 0 12 45.7 91.4 0.0 0.0 137.1 
Neuron 36 11 13 5 0 0 18 148.5 57.1 0.0 0.0 205.6 
Neuron 37 11 4 14 4 0 22 45.7 159.9 45.7 0.0 251.3 
Neuron 38 11 8 7 0 0 15 91.4 80.0 0.0 0.0 171.4 
Neuron 39 12 13 13 4 0 30 148.5 148.5 45.7 0.0 342.7 
Neuron 40 12 5 13 0 0 18 57.1 148.5 0.0 0.0 205.6 
Neuron 41 12 7 15 0 0 22 80.0 171.4 0.0 0.0 251.3 
Neuron 42 12 7 13 4 0 24 80.0 148.5 45.7 0.0 274.2 
Neuron 43 13 15 8 0 0 23 171.4 91.4 0.0 0.0 262.8 
Neuron 44 13 10 6 0 0 16 114.2 68.5 0.0 0.0 182.8 
Neuron 45 13 13 19 8 0 40 148.5 217.1 91.4 0.0 457.0 
Neuron 46 14 12 4 8 0 24 137.1 45.7 91.4 0.0 274.2 
Neuron 47 14 24 8 0 0 32 274.2 91.4 0.0 0.0 365.6 
Neuron 48 14 5 8 0 0 13 57.1 91.4 0.0 0.0 148.5 
Neuron 49 15 4 13 0 0 17 45.7 148.5 0.0 0.0 194.2 
Neuron 50 15 9 12 4 1 26 102.8 137.1 45.7 11.4 297.0 
 
MEAN       115.2 100.5 22.4 0.9 239.0 
SD       67.4 51.7 35.3 5.1 79.3 
SE       9.5 7.3 5.0 0.7 11.2 
 
 
10ng/ml GDF-5 Number of intercepts at different levels of neurite field  Neurite length in m at different levels of neurite field 
   
 c slip no. Primary Sec Ter Quat Total Primary Sec Ter Quat Total 
 
Neuron 1 1 12 6 14 0 32 137.1 68.5 159.9 0.0 365.6 
Neuron 2 1 7 4 3 0 14 80.0 45.7 34.3 0.0 159.9 
Neuron 3 1 8 2 3 3 16 91.4 22.8 34.3 34.3 182.8 
Neuron 4 1 4 12 5 0 21 45.7 137.1 57.1 0.0 239.9 
Neuron 5 2 10 8 0 0 18 114.2 91.4 0.0 0.0 205.6 
Neuron 6 2 7 8 0 0 15 80.0 91.4 0.0 0.0 171.4 
Neuron 7 2 9 3 0 0 12 102.8 34.3 0.0 0.0 137.1 
Neuron 8 3 4 7 0 0 11 45.7 80.0 0.0 0.0 125.7 
Neuron 9 3 8 6 0 0 14 91.4 68.5 0.0 0.0 159.9 
Neuron 10 3 12 0 0 0 12 137.1 0.0 0.0 0.0 137.1 
Neuron 11 3 7 15 0 0 22 80.0 171.4 0.0 0.0 251.3 
Neuron 12 3 10 10 1 0 21 114.2 114.2 11.4 0.0 239.9 
Neuron 13 4 14 5 0 0 19 159.9 57.1 0.0 0.0 217.1 
Neuron 14 4 18 13 0 0 31 205.6 148.5 0.0 0.0 354.1 
Neuron 15 4 10 0 0 0 10 114.2 0.0 0.0 0.0 114.2 
Neuron 16 5 2 14 6 0 22 22.8 159.9 68.5 0.0 251.3 
Neuron 17 5 4 4 0 0 8 45.7 45.7 0.0 0.0 91.4 
Neuron 18 5 12 11 0 0 23 137.1 125.7 0.0 0.0 262.8 
Neuron 19 5 5 8 0 0 13 57.1 91.4 0.0 0.0 148.5 
Neuron 20 6 23 0 0 0 23 262.8 0.0 0.0 0.0 262.8 
Neuron 21 6 8 5 0 0 13 91.4 57.1 0.0 0.0 148.5 
Neuron 22 6 3 18 0 0 21 34.3 205.6 0.0 0.0 239.9 
Neuron 23 6 12 2 0 0 14 137.1 22.8 0.0 0.0 159.9 
Neuron 24 7 25 7 0 0 32 285.6 80.0 0.0 0.0 365.6 
Neuron 25 7 7 11 4 0 22 80.0 125.7 45.7 0.0 251.3 
Neuron 26 7 20 0 0 0 20 228.5 0.0 0.0 0.0 228.5 
Neuron 27 8 4 24 0 0 28 45.7 274.2 0.0 0.0 319.9 
Neuron 28 8 13 4 0 0 17 148.5 45.7 0.0 0.0 194.2 
Neuron 29 8 29 0 0 0 29 331.3 0.0 0.0 0.0 331.3 
Neuron 30 8 34 12 0 0 46 388.4 137.1 0.0 0.0 525.5 
Neuron 31 9 14 4 0 0 18 159.9 45.7 0.0 0.0 205.6 
Neuron 32 9 24 4 0 0 28 274.2 45.7 0.0 0.0 319.9 
Neuron 33 9 12 0 0 0 12 137.1 0.0 0.0 0.0 137.1 
Neuron 34 9 15 8 0 0 23 171.4 91.4 0.0 0.0 262.8 
Neuron 35 10 32 0 0 0 32 365.6 0.0 0.0 0.0 365.6 
Neuron 36 10 14 10 15 0 39 159.9 114.2 171.4 0.0 445.5 
Neuron 37 11 6 13 7 0 26 68.5 148.5 80.0 0.0 297.0 
Neuron 38 11 5 11 16 5 37 57.1 125.7 182.8 57.1 422.7 
Neuron 39 11 16 14 0 0 30 182.8 159.9 0.0 0.0 342.7 
Neuron 40 12 10 6 0 0 16 114.2 68.5 0.0 0.0 182.8 
Neuron 41 12 11 34 0 0 45 125.7 388.4 0.0 0.0 514.1 
Neuron 42 12 8 6 0 0 14 91.4 68.5 0.0 0.0 159.9 
Neuron 43 13 3 9 5 0 17 34.3 102.8 57.1 0.0 194.2 
Neuron 44 13 12 20 0 0 32 137.1 228.5 0.0 0.0 365.6 
Neuron 45 13 15 4 5 0 24 171.4 45.7 57.1 0.0 274.2 
Neuron 46 14 21 16 0 0 37 239.9 182.8 0.0 0.0 422.7 
Neuron 47 14 20 14 16 0 50 228.5 159.9 182.8 6.0 571.2 
Neuron 48 15 6 10 0 0 16 68.5 114.2 0.0 0.0 182.8 
Neuron 49 15 10 7 2 0 19 114.2 80.0 22.8 0.0 217.1 
Neuron 50 15 16 4 0 0 20 182.8 45.7 0.0 0.0 228.5 
 
MEAN       139.6 94.4 23.3 1.9 259.1 
SD       86.3 76.7 49.6 9.3 112.4 
SE       12.2 10.8 7.0 1.3 15.9 
 
 
12.3.5 MEASUREMENT OF NEURITE BRANCHING 
 
Control  Number of nodes at different levels of neurite field  
  
 c slip no. Primary Sec Ter Quat Total 
 
Neuron 1 1 3 0 0 0 3 
Neuron 2 1 1 1 1 0 3 
Neuron 3 1 4 1 0 0 5 
Neuron 4 1 2 0 0 0 2 
Neuron 5 2 4 1 2 0 7 
Neuron 6 2 2 0 0 0 2 
Neuron 7 2 2 1 0 0 3 
Neuron 8 3 3 3 1 0 7 
Neuron 9 3 3 1 0 0 4 
Neuron 10 3 3 1 0 0 4 
Neuron 11 3 4 0 0 0 4 
Neuron 12 4 3 1 0 0 4 
Neuron 13 4 2 2 0 0 4 
Neuron 14 4 5 1 0 0 6 
Neuron 15 4 2 1 0 0 3 
Neuron 16 5 3 1 0 0 4 
Neuron 17 5 2 0 0 0 2 
Neuron 18 5 2 2 0 0 4 
Neuron 19 5 1 0 0 0 1 
Neuron 20 5 2 1 1 0 4 
Neuron 21 6 2 0 0 0 2 
Neuron 22 6 2 1 0 0 3 
Neuron 23 6 3 0 0 0 3 
Neuron 24 6 3 0 0 0 3 
Neuron 25 6 2 0 0 0 2 
Neuron 26 7 2 1 0 0 3 
Neuron 27 8 2 0 0 0 2 
Neuron 28 8 2 0 0 0 2 
Neuron 29 9 2 1 0 0 3 
Neuron 30 9 3 0 0 0 3 
Neuron 31 9 3 0 0 0 3 
Neuron 32 10 2 0 0 0 2 
Neuron 33 11 3 1 0 0 4 
Neuron 34 11 2 1 0 0 3 
Neuron 35 11 2 1 0 0 3 
Neuron 36 11 2 1 0 0 3 
Neuron 37 12 2 1 0 0 3 
Neuron 38 12 1 1 0 0 2 
Neuron 39 12 4 1 1 0 6 
Neuron 40 13 2 0 0 0 2 
Neuron 41 13 2 1 1 0 4 
Neuron 42 13 2 0 0 0 2 
Neuron 43 14 3 1 0 0 4 
Neuron 44 14 2 0 0 0 2 
Neuron 45 14 3 0 0 0 3 
Neuron 46 14 4 0 0 0 4 
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Neuron 47 15 2 1 0 0 3 
Neuron 48 15 3 1 0 0 4 
Neuron 49 15 3 0 0 0 3 
Neuron 50 15 2 2 0 0 4 
 
MEAN  2.5 0.7 0.1 0.0 3.3 
SD  0.8 0.7 0.4 0.0 1.3 
SE  0.1 0.1 0.1 0.0 0.2 
 
 
 
 
1ng/ml GDF-5 Number of nodes at different levels of neurite field 
      
 c slip no. Primary Sec Ter Quat Total 
Neuron 1 1 2 1 1 0 4 
Neuron 2 1 5 1 1 0 7 
Neuron 3 1 5 1 1 0 7 
Neuron 4 1 6 2 0 0 8 
Neuron 5 2 5 2 0 0 7 
Neuron 6 2 4 3 1 0 8 
Neuron 7 2 4 0 0 0 4 
Neuron 8 2 3 3 0 0 6 
Neuron 9 3 2 1 0 0 3 
Neuron 10 3 4 3 0 0 7 
Neuron 11 3 2 2 0 0 4 
Neuron 12 3 3 2 1 1 7 
Neuron 13 4 4 1 0 0 5 
Neuron 14 4 5 3 1 0 9 
Neuron 15 4 3 1 0 0 4 
Neuron 16 5 2 0 0 0 2 
Neuron 17 5 4 1 0 0 5 
Neuron 18 5 5 3 0 0 8 
Neuron 19 6 2 3 0 0 5 
Neuron 20 6 3 2 1 0 6 
Neuron 21 6 2 2 1 0 5 
Neuron 22 6 4 1 1 2 8 
Neuron 23 7 3 2 2 1 8 
Neuron 24 7 4 1 0 0 5 
Neuron 25 7 2 2 1 0 5 
Neuron 26 7 3 1 0 0 4 
Neuron 27 8 3 1 0 0 4 
Neuron 28 8 3 1 0 0 4 
Neuron 29 8 2 2 0 0 4 
Neuron 30 9 5 2 1 0 8 
Neuron 31 9 5 1 1 0 7 
Neuron 32 10 4 2 0 0 6 
Neuron 33 10 2 2 0 0 4 
Neuron 34 10 2 2 1 0 5 
Neuron 35 11 6 1 0 0 7 
Neuron 36 11 2 1 0 0 3 
Neuron 37 11 4 2 2 0 8 
Neuron 38 11 6 1 0 0 7 
Neuron 39 12 2 2 1 0 5 
Neuron 40 12 5 2 0 0 7 
Neuron 41 12 2 2 0 0 4 
Neuron 42 12 2 2 1 1 6 
Neuron 43 13 3 2 0 0 5 
Neuron 44 13 3 1 0 0 4 
Neuron 45 13 2 3 1 0 6 
Neuron 46 14 4 1 1 0 6 
Neuron 47 14 4 1 0 0 5 
Neuron 48 14 3 2 0 0 5 
Neuron 49 15 3 2 0 0 5 
Neuron 50 15 3 2 2 1 8 
 
MEAN  3.4 1.7 0.5 0.1 5.7 
SD  1.2 0.8 0.6 0.4 1.7 
SE  0.2 0.1 0.1 0.1 0.2 
 
 
 
10ng/ml GDF-5 Number of nodes at different levels of neurite field 
      
 c slip no. Primary Sec Ter Quat Total 
Neuron 1 1 3 2 2 0 7 
Neuron 2 1 4 1 1 0 6 
Neuron 3 1 4 1 1 1 7 
Neuron 4 1 3 3 2 0 8 
Neuron 5 2 4 2 0 0 6 
Neuron 6 2 2 1 0 0 3 
Neuron 7 2 2 1 0 0 3 
Neuron 8 3 2 4 0 0 6 
Neuron 9 3 4 1 1 0 6 
Neuron 10 3 3 0 0 0 3 
Neuron 11 3 2 2 0 0 4 
Neuron 12 3 4 2 1 0 7 
Neuron 13 4 3 1 0 0 4 
Neuron 14 4 5 2 0 0 7 
Neuron 15 4 2 0 0 0 2 
Neuron 16 5 3 2 2 0 7 
Neuron 17 5 4 1 0 0 5 
Neuron 18 5 4 2 0 0 6 
Neuron 19 5 3 2 0 0 5 
Neuron 20 6 2 0 0 0 2 
Neuron 21 6 2 1 0 0 3 
Neuron 22 6 3 2 0 0 5 
Neuron 23 6 2 1 0 0 3 
Neuron 24 7 2 2 0 0 4 
Neuron 25 7 4 2 1 0 7 
Neuron 26 7 2 0 0 0 2 
Neuron 27 8 2 2 0 0 4 
Neuron 28 8 3 1 0 0 4 
Neuron 29 8 2 0 0 0 2 
Neuron 30 8 3 1 0 0 4 
Neuron 31 9 4 1 0 0 5 
Neuron 32 9 3 1 0 0 4 
Neuron 33 9 1 0 0 0 1 
Neuron 34 9 3 1 0 0 4 
Neuron 35 10 2 0 0 0 2 
Neuron 36 10 4 2 2 0 8 
Neuron 37 11 2 2 1 0 5 
Neuron 38 11 2 2 1 1 6 
Neuron 39 11 4 1 0 0 5 
Neuron 40 12 3 1 0 0 4 
Neuron 41 12 4 2 0 0 6 
Neuron 42 12 4 2 0 0 6 
Neuron 43 13 4 2 1 0 7 
Neuron 44 13 2 2 0 0 4 
Neuron 45 13 4 1 1 0 6 
Neuron 46 13 5 2 0 0 7 
Neuron 47 14 6 3 2 0 11 
Neuron 48 14 3 2 0 0 5 
Neuron 49 15 3 2 1 0 6 
Neuron 50 15 2 2 0 0 4 
 
MEAN  3.1 1.5 0.4 0.0 5.0 
SD  1.0 0.9 0.7 0.2 2.0 
SE  0.1 0.1 0.1 0.0 0.3 
 
 
 
12.3.6  MEASUREMENT OF SOMAL AREA 
 Control    1ng/ml GDF-5  10ng/ml GDF-5  
     
 c slip no.                     Points                  Somal area (m
2
)   Points                    Somal area (m
2
)    Points                    Somal area (m
2
)  
      
Neuron 1 1 7 242.9  7 242.9  8 277.6 
Neuron 2 1 6 208.2  7 242.9  9 312.3 
Neuron 3 1 6 208.2  9 312.3  8 277.6 
Neuron 4 1 7 242.9  13 451.1  10 347 
Neuron 5 2 7 242.9  8 277.6  9 312.3 
Neuron 6 2 7 242.9  9 312.3  8 277.6 
Neuron 7 2 8 277.6  10 347  11 381.7 
Neuron 8 3 4 138.8  9 312.3  8 277.6 
Neuron 9 3 7 242.9  10 347  9 312.3 
Neuron 10 3 7 242.9  8 277.6  10 347 
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Neuron 11 3 7 242.9  10 347  10 347 
Neuron 12 4 7 242.9  12 416.4  10 347 
Neuron 13 4 8 277.6  10 347  8 277.6 
Neuron 14 4 8 277.6  13 451.1  12 416.4 
Neuron 15 4 7 242.9  9 312.3  8 277.6 
Neuron 16 5 6 208.2  10 347  11 381.7 
Neuron 17 5 7 242.9  11 381.7  12 416.4 
Neuron 18 5 8 277.6  8 277.6  11 381.7 
Neuron 19 5 7 242.9  11 381.7  9 312.3 
Neuron 20 5 8 277.6  10 347  13 451.1 
Neuron 21 6 7 242.9  11 381.7  10 347 
Neuron 22 6 6 208.2  14 485.8  10 347 
Neuron 23 6 7 242.9  10 347  8 277.6 
Neuron 24 6 7 242.9  9 312.3  14 485.8 
Neuron 25 6 8 277.6  11 381.7  10 347 
Neuron 26 7 7 242.9  8 277.6  8 277.6 
Neuron 27 8 5 173.5  11 381.7  14 485.8 
Neuron 28 8 5 173.5  7 242.9  11 381.7 
Neuron 29 9 7 242.9  13 451.1  15 520.5 
Neuron 30 9 4 138.8  10 347  9 312.3 
Neuron 31 9 6 208.2  9 312.3  9 312.3 
Neuron 32 10 7 242.9  8 277.6  10 347 
Neuron 33 11 8 277.6  10 347  9 312.3 
Neuron 34 11 8 277.6  12 416.4  9 312.3 
Neuron 35 11 6 208.2  12 416.4  11 381.7 
Neuron 36 11 7 242.9  11 381.7  12 416.4 
Neuron 37 12 9 312.3  12 416.4  10 347 
Neuron 38 12 9 312.3  12 416.4  10 347 
Neuron 39 12 7 242.9  10 347  11 381.7 
Neuron 40 13 8 277.6  9 312.3  12 416.4 
Neuron 41 13 6 208.2  10 347  13 451.1 
Neuron 42 13 10 347  9 312.3  9 312.3 
Neuron 43 14 8 277.6  10 347  13 451.1 
Neuron 44 14 9 312.3  9 312.3  10 347 
Neuron 45 14 8 277.6  16 555.2  8 277.6 
Neuron 46 14 10 347  14 485.8  7 242.9 
Neuron 47 15 7 242.9  10 347  12 416.4 
Neuron 48 15 6 208.2  8 277.6  9 312.3 
Neuron 49 15 8 277.6  8 277.6  10 347 
Neuron 50 15 7 242.9  10 347  11 381.7 
 
MEAN   247.1   351.9   352.6 
SD   43.0   67.2   63.6 
SE   6.1   9.5   9.0 
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12.4 APPENDIX D (CHAPTER 7) 
 
12.4.1 COUNTS OF TH-, TUJ-1- and DAPI-POSITIVE CELLS AFTER GDF-5 TREATMENT FOR 3 DIV IN E14 VM CULTURES. 
 
TH-positive cells/field Average no./field TUJ-1-positive cells/field Average no./field DAPI-positive cells/field Average no./field 
 
 
Control 10ng.ml GDF-5    Control 10ng.ml GDF-5    Control 10ng.ml GDF-5 
         
1.1 1 1   24 8   30 10   
1.2 2 4   13 23   24 33   
1.3 0 2   25 13   30 17   
1.4 1 2   19 35   22 37   
1.5 0 3 0.8 2.4 15 12 19.2 18.2 20 17 25.2 22.8 
2.1 0 1   20 14   29 17   
2.2 2 3   18 15   29 19   
2.3 1 2   16 20   29 30   
2.4 2 2   15 29   28 38   
2.5 0 1 1 1.8 20 10 17.8 17.6 37 14 30.4 23.6 
3.1 1 1   17 16   25 21   
3.2 6 6   30 20   33 28   
3.3 0 1   20 18   26 25   
3.4 0 2   18 6   25 10   
3.5 2 1 1.8 2.2 16 10 20.2 14 26 15 27 19.8 
4.1 0 3   10 14   12 16   
4.2 1 1   12 7   24 11   
4.3 1 1   14 10   24 11   
4.4 0 3   5 24   25 37   
4.5 1 2 0.6 2 17 20 11.6 15 26 22 22.2 19.4 
5.1 2 1   8 9   17 14   
5.2 0 4   22 9   28 13   
5.3 1 1   9 20   14 24   
5.4 1 4   20 12   22 23   
5.5 0 2 0.8 2.4 15 12 14.8 12.4 20 26 20.2 20 
6.1 2 2   22 21   26 26   
6.2 0 4   13 25   16 36   
6.3 1 5   7 23   11 29   
6.4 0 1   12 13   15 19   
6.5 3 0 1.2 2.4 27 11 16.2 18.6 33 15 20.2 25 
7.1 2 1   43 33   48 36   
7.2 2 3   46 56   49 59   
7.3 3 3   64 64   68 68   
7.4 2 5   47 41   49 44   
7.5 2 4 2.2 3.2 41 58 48.2 50.4 45 67 51.8 54.8 
8.1 1 5   33 54   39 58   
8.2 1 3   37 41   41 45   
8.3 2 4   68 41   76 44   
8.4 1 5   45 59   52 69   
8.5 1 2 1.2 3.8 40 29 44.6 44.8 43 31 50.2 49.4 
9.1 1 4   41 43   45 47   
9.2 1 3   57 81   65 88   
9.3 1 2   41 44   48 49   
9.4 1 5   68 57   75 61   
9.5 1 3 1 3.4 31 36 47.6 52.2 34 39 53.4 56.8 
 
MEAN   1.2 2.6   26.7 27.0   33.4 32.4 
S.D.   0.5 0.7   15.3 16.8   14.2 16.2 
S.E.   0.3 0.4   8.8 9.7   8.2 9.3  
 
 
 
 
12.4.2 PERCENTAGE OF TUJ-1- and DAPI-POSITIVE CELLS THAT EXPRESS TH AFTER GDF-5 TREATMENT FOR 3 DIV IN E14 VM CULTURES. 
 
%TH OF TUJ-1-positive cells   %TH-DAPI-positive cells 
 
Control 10ng/ml GDF-5    Control 10ng/ml GDF-5     
  
1.1 4.2 12.5   3.3 10.0   
1.2 15.4 17.4   8.3 12.1   
1.3 0.0 15.4   0.0 11.8   
1.4 5.3 5.7   4.5 5.4   
1.5 0.0 25.0 5.0 15.2 0.0 17.6 3.2 11.4 
2.1 0.0 7.1   0.0 5.9   
2.2 11.1 20.0   6.9 15.8   
2.3 6.3 10.0   3.4 6.7   
2.4 13.3 6.9   7.1 5.3   
2.5 0.0 10.0 6.1 10.8 0.0 7.1 3.5 8.1 
3.1 5.9 6.3   4.0 4.8   
3.2 20.0 30.0   18.2 21.4   
3.3 0.0 5.6   0.0 4.0   
3.4 0.0 33.3   0.0 20.0   
3.5 12.5 10.0 7.7 17.0 7.7 6.7 6.0 11.4 
4.1 0.0 21.4   0.0 18.8   
4.2 8.3 14.3   4.2 9.1   
4.3 7.1 10.0   4.2 9.1   
4.4 0.0 12.5   0.0 8.1   
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4.5 5.9 10.0 4.3 13.6 3.8 9.1 2.4 10.8 
5.1 25.0 11.1   11.8 7.1   
5.2 0.0 44.4   0.0 30.8   
5.3 11.1 5.0   7.1 4.2   
5.4 5.0 33.3   4.5 17.4   
5.5 0.0 16.7 8.2 22.1 0.0 7.7 4.7 13.4 
6.1 9.1 9.5   7.7 7.7   
6.2 0.0 16.0   0.0 11.1   
6.3 14.3 21.7   9.1 17.2   
6.4 0.0 7.7   0.0 5.3   
6.5 11.1 0.0 6.9 11.0 9.1 0.0 5.2 8.3 
7.1 4.7 3.0   4.2 2.8   
7.2 4.3 5.4   4.1 5.1   
7.3 4.7 4.7   4.4 4.4   
7.4 4.3 12.2   4.1 11.4   
7.5 4.9 6.9 4.6 6.4 4.4 6.0 4.2 5.9 
8.1 3.0 9.3   2.6 8.6   
8.2 2.7 7.3   2.4 6.7   
8.3 2.9 9.8   2.6 9.1   
8.4 2.2 8.5   1.9 7.2   
8.5 2.5 6.9 2.7 8.3 2.3 6.5 2.4 7.6 
9.1 2.4 9.3   2.2 8.5   
9.2 1.8 3.7   1.5 3.4   
9.3 2.4 4.5   2.1 4.1   
9.4 1.5 8.8   1.3 8.2   
9.5 3.2 8.3 2.3 6.9 2.9 7.7 2.0 6.4 
 
MEAN   5.3 12.4   3.7 9.3 
SD   2.1 5.1   1.4 2.6 
SE   1.2 3.0   0.8 1.5 
 
 
 
 
12.4.3 PERCENTAGE OF TUJ-1-POSITIVE CELLS THAT EXPRESS TH AFTER GDF-5, WNT-5A OR GDF-5 AND WNT-5A TREATMENT FOR 3 DIV IN E14 VM CULTURES. 
 
%TH OF TUJ-1-positive cells    
 
C.SLIP NO./ Control 10ng/ml  1:100 1:100 GDF-5 (10ng/ml) GDF-5 (10ng/ml) Average 
FIELD NO.  GDF-5  Wnt-5a Wnt-5a control + Wnt-5a (1:100) + Wnt-5a control percentage 
 
1.1 4.2 12.5 8.0 11.1 16.7 0.0       
1.2 15.4 17.4 14.3 0.0 5.0 13.3       
1.3 0.0 15.4 3.6 0.0 28.6 40.0       
1.4 5.3 5.7 7.7 5.6 12.5 21.4       
1.5 0.0 25.0 28.6 7.7 10.0 16.7 5.0 15.2 12.4 4.9 14.5 18.3 
2.1 0.0 7.1 11.1 20.0 33.3 6.7       
2.2 11.1 20.0 13.6 0.0 33.3 8.3       
2.3 6.3 10.0 9.7 9.5 11.8 6.7       
2.4 13.3 6.9 10.0 0.0 13.3 13.3       
2.5 0.0 10.0 9.5 5.0 5.9 0.0 6.1 10.8 10.8 6.9 19.5 7.0 
3.1 5.9 6.3 22.2 0.0 30.0 11.4       
3.2 20.0 30.0 9.1 0.0 10.0 7.1       
3.3 0.0 5.6 7.1 0.0 14.3 18.2       
3.4 0.0 33.3 5.9 4.8 8.3 5.6       
3.5 12.5 10.0 10.0 13.8 5.6 0.0 7.7 17.0 10.9 3.7 13.6 8.5 
4.1 0.0 21.4 7.7 9.1 23.5 4.3       
4.2 8.3 14.3 16.7 0.0 12.5 22.2       
4.3 7.1 10.0 9.5 8.3 12.5 6.7       
4.4 0.0 12.5 19.0 20.0 15.4 22.2       
4.5 5.9 10.0 0.0 0.0 11.1 6.7 4.3 13.6 10.6 7.5 15.0 12.4 
5.1 25.0 11.1 16.7 8.3 20.0 16.7       
5.2 0.0 44.4 5.6 33.3 26.9 5.6       
5.3 11.1 5.0 6.7 6.7 44.4 33.3       
5.4 5.0 33.3 25.0 0.0 0.0 0.0       
5.5 0.0 16.7 16.7 0.0 3.7 4.3 8.2 22.1 14.1 9.7 19.0 12.0 
6.1 9.1 9.5 8.3 12.5 20.0 8.7       
6.2 0.0 16.0 9.1 10.5 0.0 5.9       
6.3 14.3 21.7 20.0 22.2 7.7 0.0       
6.4 0.0 7.7 4.2 0.0 5.3 4.5       
6.5 11.1 0.0 17.6 0.0 0.0 0.0 6.9 11.0 11.8 9.0 6.6 3.8 
7.1 4.7 3.0           
7.2 4.3 5.4           
7.3 4.7 4.7           
7.4 4.3 12.2           
7.5 4.9 6.9     4.6 6.4     
8.1 3.0 9.3           
8.2 2.7 7.3           
8.3 2.9 9.8           
8.4 2.2 8.5           
8.5 2.5 6.9     2.7 8.3     
9.1 2.4 9.3           
9.2 1.8 3.7           
9.3 2.4 4.5           
9.4 1.5 8.8           
9.5 3.2 8.3     2.3 6.9     
        
MEAN       5.3 12.4 12.6 6.0 12.6 8.9 
SD       2.1 5.1 2.5 3.4 7.0 6.0 
SE       1.2 3.0 1.8 2.4 5.0 4.3 
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12.4.4 PERCENTAGE OF DAPI-POSITIVE CELLS THAT EXPRESS TH AFTER GDF-5, WNT-5A OR GDF-5 AND WNT-5A TREATMENT FOR 3 DIV IN E14 VM CULTURES. 
 
%TH OF TUJ-1-positive cells    
 
C.SLIP NO./ Control 10ng/ml  1:100 1:100 GDF-5 (10ng/ml) GDF-5 (10ng/ml) Average 
FIELD NO.  GDF-5  Wnt-5a Wnt-5a control + Wnt-5a (1:100) + Wnt-5a control percentage 
 
1.1 3.3 10.0 6.7 6.7 13.0 0.0       
1.2 8.3 12.1 10.0 0.0 4.2 10.5       
1.3 0.0 11.8 3.1 0.0 18.2 32.0       
1.4 4.5 5.4 5.6 4.2 5.3 18.8       
1.5 0.0 17.6 22.2 4.3 8.7 13.3 3.2 11.4 9.5 3.0 9.9 14.9 
2.1 0.0 5.9 8.3 14.3 22.2 5.9       
2.2 6.9 15.8 10.3 0.0 9.1 6.3       
2.3 3.4 6.7 8.8 7.4 11.1 4.8       
2.4 7.1 5.3 7.1 0.0 11.8 11.1       
2.5 0.0 7.1 6.5 3.8 5.0 0.0 3.5 8.1 8.2 5.1 11.8 5.6 
3.1 4.0 4.8 20.0 0.0 17.6 12.1       
3.2 18.2 21.4 8.3 0.0 6.7 6.3       
3.3 0.0 4.0 6.3 0.0 13.3 18.2       
3.4 0.0 20.0 4.5 4.3 5.9 4.0       
3.5 7.7 6.7 6.7 11.8 4.5 0.0 6.0 11.4 9.2 3.2 9.6 8.1 
4.1 0.0 18.8 7.1 6.3 18.2 3.3       
4.2 4.2 9.1 12.5 0.0 7.1 18.2       
4.3 4.2 9.1 7.4 5.6 5.0 4.8       
4.4 0.0 8.1 13.3 11.8 14.3 14.8       
4.5 3.8 9.1 0.0 0.0 10.0 5.0 2.4 10.8 8.1 4.7 10.9 9.2 
5.1 11.8 7.1 14.8 5.6 15.0 14.3       
5.2 0.0 30.8 3.6 12.5 19.4 4.0       
5.3 7.1 4.2 5.9 5.6 34.8 22.0       
5.4 4.5 17.4 20.0 0.0 0.0 0.0       
5.5 0.0 7.7 8.3 0.0 3.1 4.2 4.7 13.4 10.5 4.7 14.5 8.9 
6.1 7.7 7.7 6.7 7.1 13.3 6.5       
6.2 0.0 11.1 5.9 8.3 0.0 4.8       
6.3 9.1 17.2 9.1 16.0 6.7 0.0       
6.4 0.0 5.3 2.8 0.0 3.7 4.2       
6.5 9.1 0 15 0 0 0 5.2 8.3 7.9 6.3 4.7 3.1 
7.1 4.2 2.8           
7.2 4.1 5.1           
7.3 4.4 4.4           
7.4 4.1 11.4       15.0 0.0 0.0 0.0 
7.5 4.4 6.0     4.2 5.9     
8.1 2.6 8.6           
8.2 2.4 6.7           
8.3 2.6 9.1           
8.4 1.9 7.2           
8.5 2.3 6.5     2.4 7.6     
9.1 2.2 8.5           
9.2 1.5 3.4           
9.3 2.1 4.1           
9.4 1.3 8.2           
9.5 2.9 7.7     2.0 6.4  
    
MEAN       3.7 9.3 9.8 3.9 8.8 7.1 
SD       1.4 2.6 2.5 2.0 4.9 4.8 
SE       0.8 1.5 1.8 1.4 3.4 3.4 
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12.5 APPENDIX E (CHAPTER 8) 
 
12.5.1 AVERAGE VALUES OF NEUROSPHERE DIAMETER AT 2, 4, 6 DIV   (MAGNIFICATION = x 232.5) 
 
 
2 DIV 2 DIV 2 DIV  4 DIV 4 DIV 4 DIV  6 DIV 6 DIV 6 DIV 
FLASK NO./ 
FIELD NO. E12 E13 E14  E12 E13 E14  E12 E13 E14 
 
 
1.1 1.75 1.20 1.15  2.88 4.55 1.62  3.18 3.07 1.65 
1.2 1.33 1.43 0.87  2.68 4.87 2.00  3.04 3.28 1.68 
1.3 1.55 1.44 0.95  3.30 4.13 1.95  2.94 2.73 1.70 
1.4 1.80 1.90 1.15  2.80 4.38 1.77  2.98 2.52 2.17 
1.5 1.53 1.26 1.07  4.23 3.67 1.48  2.80 2.92 1.97 
1.6 1.04 1.80 1.02  2.78 3.72 1.62  3.48 2.63 2.10 
2.1 2.05 1.15 0.83  3.70 2.47 1.38  3.10 2.45 2.10 
2.2 1.42 1.08 0.83  3.87 2.75 1.55  2.80 2.33 2.07 
2,3 1.57 1.25 1.05  4.67 3.23 1.58  3.16 2.43 2.07 
2.4 1.87 2.00 0.93  4.25 2.28 1.65  2.46 2.03 1.92 
2.5 1.75 1.28 0.93  4.00 2.50 1.55  2.94 2.40 1.62 
2.6 2.02 1.02 1.50  4.78 2.87 1.53  2.40 2.47 1.73 
3.1 2.95 1.63 0.73  3.53 5.52   3.20 2.32 1.27 
3.2 1.43 1.37 0.83  2.63 4.33   3.42 3.45 1.52 
3.3 1.59 1.28 0.92  3.81 3.65   2.62 3.13 1.47 
3.4 1.76 1.55 0.88  3.72 4.90   2.90 3.67 1.53 
3.5 1.46 1.65 0.85  3.98 3.88   2.73 2.77 1.68 
3.6 1.45 1.48 1.05  4.65 4.45   2.89 3.47 1.55 
 
MEAN D (cm) 1.68 1.43 0.98  3.68 3.79 1.64  2.95 2.78 1.77 
MEAN D (m) 16831.75 14324.07 9750.00  36806.88 37861.11 16402.78  29461.90 27814.81 17657.41 
ACTUAL D (m) 72.39 61.61 41.94  158.31 162.84 70.55  316.79 299.08 189.86 
            
SD (cm) 0.40 0.28 0.17  0.71 0.94 0.18  0.29 0.47 0.26 
SD (m) 4025.23 2786.89 1749.18  7085.10 9433.68 1819.45  2924.00 4679.22 2639.24 
ACTUAL SD (m) 17.31 11.99 7.52  30.47 40.57 7.83  31.44 50.31 28.38 
            
ACTUAL SEM (m) 10.00 6.92 4.34  17.59 23.43 5.53  18.15 29.05 16.38 
   
 
 
ACTUAL D =  (SD(cm) x 10,000) / MAGNIFICATION 
       
ACTUAL SD =  (MEAN D(cm) x 10,000) / MAGNIFICATION 
    
ACTUAL SEM   =  ACTUAL SD / 3 
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12.5.2 AVERAGE VALUES OF NEUROSPHERE VOLUME AT 2, 4, 6 DIV   (MAGNIFICATION = x 232.5) 
  2 DIV 2 DIV 2 DIV  4 DIV 4 DIV 4 DIV  6 DIV 6 DIV 6 DIV 
FLASK NO./ 
FIELD NO. E12 E13 E14  E12 E13 E14  E12 E13 E14 
 
1.1 2.40 1.13 1.04  6.49 16.25 2.05  7.94 7.38 2.14 
1.2 1.40 1.61 0.59  5.62 18.59 3.14  7.25 8.46 2.22 
1.3 1.89 1.63 0.71  8.55 13.41 2.98  6.79 5.86 2.27 
1.4 2.54 2.83 1.04  6.15 15.08 2.45  6.97 4.97 3.69 
1.5 1.83 1.25 0.89  14.01 10.55 1.73  6.15 6.68 3.04 
1.6 0.85 2.54 0.81  6.07 10.84 2.05  9.52 5.44 3.46 
2.1 3.30 1.04 0.55  10.75 4.78 1.50  7.54 4.71 3.46 
2.2 1.58 0.92 0.55  11.74 5.94 1.89  6.15 4.27 3.35 
2.3 1.93 1.23 0.87  17.13 8.21 1.97  7.84 4.65 3.35 
2.4 2.74 3.14 0.68  14.18 4.09 2.14  4.74 3.25 2.88 
2.5 2.40 1.29 0.68  12.56 4.91 1.89  6.79 4.52 2.05 
2.6 3.19 0.81 1.77  17.96 6.45 1.85  4.52 4.78 2.36 
3.1 6.83 2.09 0.42  9.80 23.89 0.00  8.04 4.21 1.26 
3.2 1.60 1.47 0.55  5.41 14.74 0.00  9.18 9.34 1.81 
3.3 1.97 1.29 0.66  11.42 10.46 0.00  5.37 7.71 1.69 
3.4 2.42 1.89 0.61  10.86 18.85 0.00  6.60 10.55 1.85 
3.5 1.67 2.14 0.57  12.46 11.84 0.00  5.84 6.01 2.22 
3.6 1.65 1.73 0.87  16.97 15.54 0.00  6.54 9.43 1.89 
 
MEAN V (cm
3
) 2.34 1.67 0.77  11.01 11.91 1.42  6.88 6.24 2.50 
MEAN V (m
3
) 23440.89 16682.38 7689.24  110069.25 119124.84 14239.15  68772.17 62355.89 24991.47 
ACTUAL V (m
3
) 100.82 71.75 33.07  473.42 512.36 61.24  739.49 670.49 268.73 
            
SD (cm
3
) 1.28 0.66 0.30  4.07 5.60 1.11  1.35 2.12 0.74 
SD (m
3
) 12827.31 6607.38 3042.26  40736.66 56048.74 11086.78  13506.21 21195.57 7351.22 
ACTUAL SD (m
3
) 55.17 28.42 13.08  175.21 241.07 47.69  58.09 91.16 31.62 
            
ACTUAL SEM(m
3
)31.85 16.41 7.55  101.16 139.18 27.53  33.54 52.63 18.25 
 
 
 
ACTUAL V =  (MEAN V(cm
3
) x 10,000) / MAGNIFICATION 
       
ACTUAL SD =  (MEAN D(cm
3
) x 10,000) / MAGNIFICATION 
    
ACTUAL SEM   =  ACTUAL SD / 3 
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12.5.3 CULTURE CHARACTERISATION OF DIFFERENTIATING NEUROSPHERES AFTER 6 DIV (TUJ-1-1) 
 
E12    E13    E14 
C.SLIP NO./ TUJ-1(+) cells/ DAPI/ %TUJ-1/ MEAN TUJ-1(+) cells/ DAPI/ %TUJ-1/ MEAN  TUJ-1(+) cells/ DAPI/ %TUJ-1/ MEAN 
FIELD NO. field field DAPI % field field DAPI % field field DAPI % 
 
1.1 11 83 13.3  15 99 15.2  1 79 1.3  
1.2 10 57 17.5  18 100 18.0  1 76 1.3  
1.3 22 103 21.4  10 114 8.8  0 69 0.0  
1.4 14 53 26.4 19.6 15 106 14.2 14.0 2 52 3.8 1.6 
2.1 22 98 22.4  12 73 16.4  3 110 2.7  
2.2 21 109 19.3  12 83 14.5  2 107 1.9  
2.3 13 70 18.6  18 120 15.0  5 105 4.8  
2.4 13 63 20.6 20.2 14 75 18.7 16.1 2 77 2.6 3.0 
3.1 20 65 30.8  15 106 14.2  1 63 1.6  
3.2 24 84 28.6  10 62 16.1  3 94 3.2  
3.3 21 106 19.8  7 77 9.1  0 88 0.0  
3.4 19 128 14.8 23.5 8 83 9.6 12.3 4 104 3.8 2.2 
4.1 12 97 12.4  12 90 13.3  2 97 2.1  
4.2 22 110 20.0  13 84 15.5  0 74 0.0  
4.3 21 115 18.3  14 86 16.3  2 110 1.8  
4.4 16 113 14.2 16.2 17 130 13.1 14.5 3 88 3.4 1.8 
5.1 13 120 10.8  12 119 10.1  3 65 4.6  
5.2 21 84 25.0  6 53 11.3  7 51 13.7  
5.3 5 44 11.4  13 119 10.9  3 74 4.1  
5.4 23 101 22.8 17.5 5 68 7.4 9.9 7 50 14.0 9.1 
6.1 13 103 12.6  11 82 13.4  9 84 10.7  
6.2 25 130 19.2  12 86 14.0  2 45 4.4  
6.3 25 127 19.7  11 80 13.8  10 111 9.0  
6.4 23 107 21.5 18.3 10 94 10.6 12.9 7 82 8.5 8.2 
7.1 20 97 20.6  5 83 6.0  7 81 8.6  
7.2 24 103 23.3  14 87 16.1  4 69 5.8  
7.3 16 96 16.7  11 82 13.4  6 40 15.0  
7.4 17 121 14.0 18.7 12 110 10.9 11.6 4 95 4.2 8.4 
8.1 21 97 21.6  8 72 11.1  4 54 7.4  
8.2 23 108 21.3  5 76 6.6  6 84 7.1  
8.3 16 114 14.0  12 121 9.9  5 81 6.2  
8.4 18 92 19.6 19.1 13 80 16.3 11.0 5 50 10.0 7.7 
9.1 30 157 19.1  12 63 19.0  8 51 15.7  
9.2 17 97 17.5  15 70 21.4  20 80 25.0  
9.3 27 103 26.2  8 85 9.4  8 66 12.1  
9.4 30 120 25.0 22.0 12 66 18.2 17.0 3 41 7.3 15.0 
10.1 20 113 17.7  4 47 8.5  3 49 6.1  
10.2 19 133 14.3  8 56 14.3  5 70 7.1  
10.3 21 140 15.0  6 50 12.0  6 57 10.5  
10.4 24 116 20.7 16.9 10 67 14.9 12.4 4 53 7.5 7.8 
11.1 19 80 23.8  9 62 14.5  5 62 8.1  
11.2 19 112 17.0  7 41 17.1  5 54 9.3  
11.3 27 126.0 21.4  8 60 13.3  5 46 10.9  
11.4 20 98.0 20.4 20.6 9 70 12.9 14.4 7 91 7.7 9.0 
12.1 18 85.0 21.2  10 72 13.9  7 78 9.0  
12.2 23 109.0 21.1  8 46 17.4  3 38 7.9  
12.3 20 103.0 19.4  10 75 13.3  4 62 6.5  
12.4 13 84.0 15.5 19.3 12 48 25.0 17.4 6 47 12.8 9.0 
 
 
MEAN    19.3    13.6    6.9 
SD    2.1    2.4    4.0 
SE    0.6    0.7    1.2 
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12.5.4 CULTURE CHARACTERISATION OF DIFFERENTIATING NEUROSPHERES AFTER 6 DIV (MAP-2ab) 
 
E12    E13    E14 
C.SLIP NO./ MAP2(+) cells/ DAPI/ %MAP2/ MEAN MAP2(+) cells/ DAPI/ %MAP2/ MEAN  MAP2(+) cells/ DAPI/ %MAP2/ MEAN 
FIELD NO. field field DAPI % field field DAPI % field field DAPI % 
 
1.1 10 67 14.9  5 110 4.5  1 110 0.9  
1.2 26 133 19.5  18 89 20.2  3 103 2.9  
1.3 17 110 15.5  12 93 12.9  2 57 3.5  
1.4 7 57 12.3 15.6 8 70 11.4 12.3 4 57 7.0 3.6 
2.1 21 140 15.0  13 89 14.6  1 114 0.9  
2.2 16 105 15.2  16 108 14.8  2 104 1.9  
2.3 18 94 19.1  18 83 21.7  3 99 3.0  
2.4 20 140 14.3 15.9 15 80 18.8 17.5 2 83 2.4 2.1 
3.1 10 97 10.3  9 127 7.1  1 121 0.8  
3.2 24 142 16.9  14 118 11.9  2 84 2.4  
3.3 22 150 14.7  12 100 12.0  2 106 1.9  
3.4 12 61 19.7 15.4 15 105 14.3 11.3 4 83 4.8 2.5 
4.1 17 96 17.7  18 131 13.7  2 68 2.9  
4.2 16 72 22.2  14 114 12.3  3 72 4.2  
4.3 22 108 20.4  9 110 8.2  3 96 3.1  
4.4 19 141 13.5 18.4 15 96 15.6 12.5 2 108 1.9 3.0 
5.1 20 103 19.4  5 64 7.8  2 56 3.6  
5.2 9 76 11.8  8 120 6.7  5 109 4.6  
5.3 20 102 19.6  10 84 11.9  3 28 10.7  
5.4 16 104 15.4 16.6 9 66 13.6 10.0 1 68 1.5 5.1 
6.1 25 108 23.1  12 81 14.8  3 63 4.8  
6.2 20 83 24.1  10 87 11.5  1 44 2.3  
6.3 18 132 13.6  11 93 11.8  2 32 6.3  
6.4 30 148 20.3 20.3 10 105 9.5 11.9 5 112 4.5 4.4 
7.1 28 160 17.5  13 71 18.3  3 56 5.4  
7.2 14 116 12.1  9 69 13.0  3 71 4.2  
7.3 31 180 17.2  7 90 7.8  4 55 7.3  
7.4 13 101 12.9 14.9 8 110 7.3 11.6 1 54 1.9 4.7 
8.1 28 132 21.2  18 116 15.5  1 21 4.8  
8.2 25 192 13.0  14 105 13.3  1 67 1.5  
8.3 15 97 15.5  16 111 14.4  1 64 1.6  
8.4 10 107 9.3 14.8 11 80 13.8 14.3 3 82 3.7 2.9 
9.1 9 38 23.7  13 111 11.7      
9.2 35 197 17.8  7 101 6.9      
9.3 33 147 22.4  11 93 11.8      
9.4 25 150 16.7 20.1 6 59 10.2 10.2     
10.1 21 110 19.1  10 96 10.4      
10.2 20 103 19.4  9 107 8.4      
10.3 28 143 19.6  5 90 5.6      
10.4 27 167 16.2 18.6 11 80 13.8 9.5     
11.1 22 132 16.7  9 87 10.3      
11.2 21 84 25.0  10 105 9.5      
11.3 21 130 16.2  13 88 14.8      
11.4 27 143 18.9 19.2 8 101 7.9 10.6     
12.1 21 120 17.5  13 81 16.0      
12.2 24 140 17.1  12 105 11.4      
12.3 29 180 16.1  10 81 12.3      
12.4 21 131 16.0 16.7 4 62 6.5 11.6     
 
MEAN    17.2    11.9    3.5 
SD    2.0    2.2    1.1 
SE    0.6    0.6    0.4 
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12.5.5 CULTURE CHARACTERISATION OF DIFFERENTIATING NEUROSPHERES AFTER 6 DIV (GFAP) 
 
E12    E13    E14 
C.SLIP NO./ GFAP(+) cells/ DAPI/ %GFAP/ MEAN GFAP(+) cells/ DAPI/ %GFAP/ MEAN  GFAP(+) cells/ DAPI/ %GFAP/ MEAN 
FIELD NO. field field DAPI % field field DAPI % field field DAPI % 
 
1.1 10 156 6.4  26 66 39.4  10 46 21.7  
1.2 10 128 7.8  22 98 22.4  20 50 40.0  
1.3 18 126 14.3  35 100 35.0  16 40 40.0  
1.4 19 93 20.4 12.2 36 93 38.7 33.9 15 75 20.0 30.4 
2.1 15 143 10.5  46 106 43.4  22 55 40.0  
2.2 6 156 3.8  30 110 27.3  47 82 57.3  
2.3 17 131 13.0  35 96 36.5  25 72 34.7  
2.4 2 80 2.5 7.5 30 86 34.9 35.5 39 83 47.0 44.8 
3.1 8 106 7.5  32 97 33.0  45 99 45.5  
3.2 13 118 11.0  27 99 27.3  36 84 42.9  
3.3 11 102 10.8  24 97 24.7  30 93 32.3  
3.4 7 77 9.1 9.6 35 76 46.1 32.8 21 45 46.7 41.8 
4.1 8 160 5.0  27 88 30.7  29 90 32.2  
4.2 9 121 7.4  26 91 28.6  59 101 58.4  
4.3 8 176 4.5  28 71 39.4  22 66 33.3  
4.4 19 114 16.7 8.4 37 115 32.2 32.7 52 91 57.1 45.3 
5.1 10 140 7.1  23 56 41.1  36 67 53.7  
5.2 15 163 9.2  31 68 45.6  19 36 52.8  
5.3 8 110 7.3  30 60 50.0  42 66 63.6  
5.4 8 123 6.5 7.5 41 80 51.3 47.0 17 43 39.5 52.4 
6.1 14 140 10.0  23 46 50.0  16 40 40.0  
6.2 9 190 4.7  43 77 55.8  24 65 36.9  
6.3 10 150 6.7  25 47 53.2  28 76 36.8  
6.4 9 143 6.3 6.9 34 59 57.6 54.2 23 58 39.7 38.4 
7.1 20 165 12.1  48 77 62.3  21 45 46.7  
7.2 8 178 4.5  51 60 85.0  29 64 45.3  
7.3 6 137 4.4  48 68 70.6  17 42 40.5  
7.4 13 167 7.8 7.2 62 82 75.6 73.4 17 41 41.5 43.5 
8.1 18 136 13.2  26 52 50.0  20 42 47.6  
8.2 9 151 6.0  44 73 60.3  19 38 50.0  
8.3 8 89 9.0  36 51 70.6  13 45 28.9  
8.4 8 131 6.1 8.6 32 68 47.1 57.0 27 83 32.5 39.8 
9.1 7 36 19.4  53 94 56.4  26 54 48.1  
9.2 11 101 10.9  38 63 60.3  24 47 51.1  
9.3 6 128 4.7  25 75 33.3  23 45 51.1  
9.4 6 50 12.0 11.8 38 97 39.2 47.3 31 42 73.8 56.0 
10.1 9 56 16.1  33 59 55.9  26 47 55.3  
10.2 3 56 5.4  39 49 79.6  21 61 34.4  
10.3 3 70 4.3  61 99 61.6  29 67 43.3  
10.4 16 110 14.5 10.1 26 64 40.6 59.4 37 54 68.5 50.4 
11.1 6 50 12.0  64 97 66.0  15 38 39.5  
11.2 10 140 7.1  50 98 51.0  16 50 32.0  
11.3 7 53 13.2  54 88 61.4  33 56 58.9  
11.4 7 50 14.0 11.6 67 100 67.0 61.3 16 39 41.0 42.9 
12.1 14 60 23.3  51 86 59.3  19 56 33.9  
12.2 10 120 8.3  54 98 55.1  25 68 36.8  
12.3 8 93 8.6  31 90 34.4  28 57 49.1  
12.4 8 103 7.8 12.0 40 88 45.5 48.6 20 41 48.8 42.1 
 
MEAN    9.4    48.6    44.0 
SD    2.0    13.1    6.8 
SE    0.6    3.8    2.0 
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12.5.6 CULTURE CHARACTERISATION OF DIFFERENTIATING NEUROSPHERES AFTER 6 DIV (MBP) 
 
E12    E13    E14 
 
C.SLIP NO./ MBP(+) cells/ DAPI/ %MBP/ MEAN MBP(+) cells/ DAPI/ %MBP/ MEAN  MBP(+) cells/ DAPI/ %MBP/ MEAN 
FIELD NO. field field DAPI % field field DAPI % field field DAPI % 
 
1.1 4 96 4.2  7 80 8.8  8 121 6.6  
1.2 9 125 7.2  11 73 15.1  8 88 9.1  
1.3 6 94 6.4  6 74 8.1  7 68 10.3  
1.4 3 101 3.0 5.2 1 57 1.8 8.4 5 56 8.9 8.7 
2.1 4 106 3.8  8 70 11.4  10 93 10.8  
2.2 8 117 6.8  4 55 7.3  9 87 10.3  
2.3 5 87 5.7  6 103 5.8  10 123 8.1  
2.4 8 130 6.2 5.6 9 72 12.5 9.3 15 130 11.5 10.2 
3.1 15 167 9.0  4 62 6.5  5 93 5.4  
3.2 4 101 4.0  6 101 5.9  3 94 3.2  
3.3 4 73 5.5  3 72 4.2  8 96 8.3  
3.4 5 103 4.9 5.8 10 77 13.0 7.4 18 100 18.0 8.7 
4.1 5 137 3.6  5 72 6.9  7 85 8.2  
4.2 2 37 5.4  5 110 4.5  5 110 4.5  
4.3 4 77 5.2  3 53 5.7  7 100 7.0  
4.4 4 85 4.7 4.7 4 56 7.1 6.1 5 64 7.8 6.9 
5.1 9 230 3.9  3 69 4.3  10 58 17.2  
5.2 6 180 3.3  2 73 2.7  16 86 18.6  
5.3 9 207 4.3  4 85 4.7  12 82 14.6  
5.4 3 130 2.3 3.5 3 107 2.8 3.6 8 55 14.5 16.3 
6.1 3 87 3.4  1 87 1.1  17 60 28.3  
6.2 2 95 2.1  2 93 2.2  9 71 12.7  
6.3 4 139 2.9  3 101 3.0  6 25 24.0  
6.4 9 130 6.9 3.8 4 107 3.7 2.5 6 46 13.0 19.5 
7.1 7 203 3.4  3 110 2.7  5 38 13.2  
7.2 4 155 2.6  6 96 6.3  11 75 14.7  
7.3 1 100 1.0  4 72 5.6  8 68 11.8  
7.4 2 117 1.7 2.2 1 80 1.3 3.9 5 55 9.1 12.2 
8.1 1 70 1.4  3 78 3.8  6 31 19.4  
8.2 11 210 5.2  1 59 1.7  10 60 16.7  
8.3 2 68 2.9  3 81 3.7  12 63 19.0  
8.4 6 86 7.0 4.1 1 31 3.2 3.1 9 48 18.8 18.5 
9.1 2 69 2.9  11 85 12.9  7 43 16.3  
9.2 2 78 2.6  6 87 6.9  7 29 24.1  
9.3 1 87 1.1  5 110 4.5  5 27 18.5  
9.4 2 101 2.0 2.1 2 85 2.4 6.7 16 53 30.2 22.3 
10.1 2 140 1.4  5 101 5.0  12 57 21.1  
10.2 2 73 2.7  5 72 6.9  11 81 13.6  
10.3 2 86 2.3  4 82 4.9  8 63 12.7  
10.4 3 95 3.2 2.4 3 57 5.3 5.5 6 68 8.8 14.0 
11.1 1 70 1.4  7 87 8.0  4 40 10.0  
11.2 2 83 2.4  2 81 2.5  6 38 15.8  
11.3 2 108 1.9  3 80 3.8  5 50 10.0  
11.4 2 60 3.3 2.3 5 72 6.9 5.3 3 40 7.5 10.8 
12.1 2 80 2.5  2 89 2.2  2 30 6.7  
12.2 4 82 4.9  3 63 4.8  8 44 18.2  
12.3 1 88 1.1  4 85 4.7  9 65 13.8  
12.4 1 128 0.8 2.3 5 110 4.5 4.1 8 44 18.2 14.2 
 
MEAN    3.7    5.5    13.5 
SD    1.4    2.1    4.8 
SE    0.4    0.6    1.4 
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12.5.7 CULTURE CHARACTERISATION OF DIFFERENTIATING NEUROSPHERES AFTER 6 DIV (NESTIN) 
 
E12    E13    E14 
 
C.SLIP NO./ NESTIN(+) cells/ DAPI/ %NESTIN/ MEAN NESTIN(+) cells/ DAPI/ %NESTIN/ MEAN  NESTIN(+) cells/ DAPI/ %NESTIN/ MEAN 
FIELD NO. field field DAPI % field field DAPI % field field DAPI % 
 
1.1 34 60 56.7  39 123 31.7  42 76 55.3  
1.2 39 50 78.0  33 104 31.7  40 78 51.3  
1.3 22 36 61.1  37 124 29.8  32 64 50.0  
1.4 36 100 36.0 57.9 39 100 39.0 33.1 41 97 42.3 49.7 
2.1 40 65 61.5  38 101 37.6  28 51 54.9  
2.2 50 87 57.5  31 97 32.0  65 80 81.3  
2.3 38 83 45.8  34 95 35.8  13 62 21.0  
2.4 66 120 55.0 54.9 61 141 43.3 37.2 15 51 29.4 46.6 
3.1 75 97 77.3  44 117 37.6  40 61 65.6  
3.2 50 85 58.8  37 97 38.1  32 73 43.8  
3.3 80 85 94.1  36 98 36.7  37 78 47.4  
3.4 90 95 94.7 81.2 44 106 41.5 38.5 32 59 54.2 52.8 
4.1 100 107 93.5  29 120 24.2  54 85 63.5  
4.2 62 97 63.9  34 108 31.5  15 74 20.3  
4.3 43 61 70.5  37 131 28.2  45 73 61.6  
4.4 40 61 65.6 73.4 25 103 24.3 27.0 23 52 44.2 47.4 
5.1 46 86 53.5  46 103 44.7  26 44 59.1  
5.2 27 51 52.9  39 99 39.4  26 51 51.0  
5.3 25 50 50.0  32 84 38.1  14 37 37.8  
5.4 10 36 27.8 46.1 32 81 39.5 40.4 8 30 26.7 43.6 
6.1 98 113 86.7  33 83 39.8  15 37 40.5  
6.2 35 71 49.3  35 105 33.3  4 29 13.8  
6.3 17 34 50.0  27 75 36.0  17 35 48.6  
6.4 38 80 47.5 58.4 31 85 36.5 36.4 17 35 48.6 37.9 
7.1 30 60 50.0  26 52 50.0  29 51 56.9  
7.2 8 15 53.3  22 64 34.4  18 83 21.7  
7.3 53 107 49.5  22 68 32.4  31 79 39.2  
7.4 25 51 49.0 50.5 18 59 30.5 36.8 19 56 33.9 37.9 
8.1 62 82 75.6  37 111 33.3  25 41 61.0  
8.2 65 129 50.4  25 69 36.2  21 42 50.0  
8.3 77 155 49.7  29 84 34.5  22 48 45.8  
8.4 81 110 73.6 62.3 33 89 37.1 35.3 20 40 50.0 51.7 
9.1 73 95 76.8  34 59 57.6      
9.2 19 36 52.8  20 78 25.6      
9.3 21 52 40.4  36 76 47.4      
9.4 33 69 47.8 54.5 33 98 33.7 41.1     
10.1 52 75 69.3  54 81 66.7      
10.2 68 93 73.1  49 79 62.0      
10.3 35 64 54.7  44 82 53.7      
10.4 44 70 62.9 65.0 67 101 66.3 62.2     
11.1 62 90 68.9  47 66 71.2      
11.2 69 107 64.5  33 67 49.3      
11.3 37 67 55.2  29 55 52.7      
11.4 32 46 69.6 64.5 54 82 65.9 59.8     
12.1 111 131 84.7  40 86 46.5      
12.2 50 95 52.6  66 97 68.0      
12.3 90 120 75.0  42 101 41.6      
12.4 35 77 45.5 64.5 51 103 49.5 51.4  
    
MEAN    61.1    41.6    46.0 
SD    9.7    10.7    5.7 
SE    2.8    3.1    2.0 
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12.5.8 CULTURE CHARACTERISATION OF DIFFERENTIATING NEUROSPHERES AFTER 6 DIV (TH) 
 
E12     
 
C.SLIP NO./ NESTIN(+) cells/ DAPI/ %NESTIN/ MEAN  
FIELD NO. field field DAPI %  
 
1.1 27 1000 2.7  
1.2 17 584 2.9  
1.3 24 576 4.2  
1.4 5 810 0.6 2.6 
2.1 10 512 2.0  
2.2 6 764 0.8  
2.3 23 720 3.2  
2.4 21 613 3.4 2.3 
3.1 20 510 3.9  
3.2 5 572 0.9  
3.3 17 820 2.1  
3.4 5 612 0.8 1.9 
4.1 4 645 0.6  
4.2 5 616 0.8  
4.3 15 960 1.6  
4.4 2 610 0.3 0.8 
5.1 7 573 1.2  
5.2 19 692 2.7  
5.3 14 627 2.2  
5.4 15 726 2.1 2.1 
6.1 6 555 1.1  
6.2 12 658 1.8  
6.3 6 539 1.1  
6.4 9 721 1.2 1.3 
7.1 5 654 0.8  
7.2 6 711 0.8  
7.3 9 681 1.3  
7.4 12 723 1.7 1.1 
8.1 15 653 2.3  
8.2 9 576 1.6  
8.3 4 457 0.9  
8.4 19 650 2.9 1.9 
9.1 16 710 2.3  
9.2 10 612 1.6  
9.3 6 519 1.2  
9.4 13 645 2.0 1.8 
 
MEAN    1.8 
SD    0.6 
SE    0.2 
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12.6 APPENDIX F (CHAPTER 9) 
 
12.6.1 CULTURE CHARACTERISATION OF E12 VM AFTER 1 DIV 
 
C.SLIP NO./ TUJ-1(+) cells/ DAPI/ %TUJ-1/ MEAN TH(+) cells/ DAPI/ %TH/ MEAN  Brd-U(+) cells/ BRD-U/ %BRD-U/ MEAN 
FIELD NO. field field DAPI % field field DAPI % field field DAPI % 
 
1.1 48 70 68.6  2 81 2.47  16 57 28.1  
1.2 55 82 67.1  2 119 1.68  25 65 38.5  
1.3 41 67 61.2  3 133 2.26  11 49 22.4  
1.4 36 87 41.4 59.6 1 124 0.81 1.80 11 56 19.6 27.2 
2.1 28 53 52.8  2 112 1.79  27 71 38.0  
2.2 30 48 62.5  3 114 2.63  26 69 37.7  
2.3 33 54 61.1  3 82 3.66  24 121 19.8  
2.4 46 85 54.1 57.6 2 149 1.34 2.35 48 149 32.2 31.9 
3.1 36 58 62.1  2 120 1.67  19 83 22.9  
3.2 48 82 58.5  2 130 1.54  14 72 19.4  
3.3 47 78 60.3  5 145 3.45  18 57 31.6  
3.4 53 91 58.2 59.8 1 101 0.99 1.91 11 58 19.0 23.2 
4.1 44 86 51.2  1 105 0.95  17 53 32.1  
4.2 46 70 65.7  2 134 1.49  14 72 19.4  
4.3 42 69 60.9  4 142 2.82  27 102 26.5  
4.4 39 60 65.0 60.7 2 84 2.38 1.91 17 46 37.0 28.7 
5.1 29 140 20.7  4 121 3.31  21 87 24.1  
5.2 45 96 46.9  3 97 3.09  13 90 14.4  
5.3 63 109 57.8  1 133 0.75  21 82 25.6  
5.4 61 92 66.3 47.9 2 129 1.55 2.18 20 56 35.7 25.0 
6.1 30 60 50.0  2 88 2.27  15 47 31.9  
6.2 50 85 58.8  2 96 2.08  26 111 23.4  
6.3 43 80 53.8  1 131 0.76  13 62 21.0  
6.4 45 88 51.1 53.4 4 157 2.55 1.92 20 91 22.0 24.6 
7.1 40 72 55.6  3 114 2.63      
7.2 48 90 53.3  2 164 1.22      
7.3 61 112 54.5  2 131 1.53      
7.4 44 89 49.4 53.2 3 129 2.33 1.93     
8.1 70 112 62.5  1 145 0.69      
8.2 59 120 49.2  2 131 1.53      
8.3 41 87 47.1  4 179 2.23      
8.4 60 91 65.9 56.2 3 121 2.48 1.73  
    
MEAN    56.0    1.97    26.8 
SD    4.3    0.20    3.2 
SE    1.5    0.07    1.3 
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12.6.2 COUNTS OF TH-POSITIVE CELLS IN E12VM CULTURES AFTER TREATMENT WITH GDF-5 FOR 1 DIV 
 
Control  10ng/ml GDF-5 
   
c.slip no. / field no.                      TH (+) cells/field TH (+) cells/field   Average/field   Average/field 
 
1.1  3 9    
1.2  3 3    
1.3  6 6    
1.4  7 5  4.8 5.8 
2.1  2 3    
2.2  2 9    
2.3  2 8    
2.4  5 9  2.8 7.3 
3.1  5 7    
3.2  10 10    
3.3  1 8    
3.4  2 9  4.5 8.5 
4.1  4 8    
4.2  2 8    
4.3  2 12    
4.4  4 6  3.0 8.5 
5.1  7 10    
5.2  9 13    
5.3  10 33    
5.4  14 26  10.0 20.5 
6.1  3 23    
6.2  5 11    
6.3  10 10    
6.4  15 15  8.3 14.8 
7.1  9 9    
7.2  12 8    
7.3  8 7    
7.4  2 10  7.8 8.5 
8.1  16 12    
8.2  10 15    
8.3  7 9    
8.4  9 11  10.5 11.8 
9.1  7 9    
9.2  7 4    
9.3  4 9    
9.4  4 9  5.5 7.8 
 
MEAN     6.3 10.4 
SD     2.9 4.6 
SE     1.0 1.5 
 
 
 
 
12.6.3 COUNTS OF APOPTOTIC CELLS IN E12VM CULTURES AFTER TREATMENT WITH GDF-5 FOR 1 DIV 
 
Control  10ng/ml GDF-5 
   
c.slip no. / field no.                      Apoptotic cells/field Apoptotic cells/field   Average/field   Average/field 
 
1.1  7 20    
1.2  30 8    
1.3  20 20    
1.4  3 11  15.0 14.8 
2.1  3 11    
2.2  5 16    
2.3  16 5    
2.4  15 3  9.8 8.8 
3.1  20 6    
3.2  9 14    
3.3  6 8    
3.4  6 6  10.3 8.5 
4.1  25 12    
4.2  13 20    
4.3  14 16    
4.4  26 14  19.5 15.5 
5.1  5 3    
5.2  12 2    
5.3  2 15    
5.4  3 7  5.5 6.8 
6.1  12 9    
6.2  7 10    
6.3  5 20    
6.4  9 8  8.3 11.8 
7.1  15 10    
7.2  5 9    
7.3  11 8    
7.4  23 10  13.5 9.3 
8.1  4 16    
8.2  15 8    
8.3  10 12    
8.4  8 12  9.3 12.0 
9.1  12 19    
9.2  12 12    
9.3  8 12    
9.4  4 8  9.0 12.8 
 
MEAN     11.1 11.1 
SD     4.2 3.0 
SE     1.4 1.0 
 
12.6.4 COUNTS OF TOTAL CELLS IN E12VM CULTURES AFTER TREATMENT WITH GDF-5 FOR 1 DIV 
 
Control  10ng/ml GDF-5 
   
c.slip no. / field no.                      Total cells/field Total cells/field   Average/field   Average/field 
 
1.1  57 42    
1.2  65 65    
1.3  49 61    
1.4  56 50  56.8 54.5 
2.1  71 43    
2.2  69 76    
2.3  121 85    
2.4  149 85  102.5 72.3 
3.1  83 96    
3.2  72 121    
3.3  57 26    
3.4  58 93  67.5 84.0 
4.1  53 84    
4.2  72 90    
4.3  102 50    
4.4  46 47  68.3 67.8 
5.1  87 96    
5.2  90 113    
5.3  82 54    
5.4  56 86  78.8 87.3 
6.1  47 101    
6.2  111 110    
6.3  62 73    
6.4  91 90  77.8 93.5 
 
MEAN     75.3 76.5 
SD     15.6 14.4 
SE     6.4 5.9 
 
 
 
 
 
12.6.5 COUNTS OF BrdU-POSITIVE CELLS IN E12VM CULTURES AFTER TREATMENT WITH GDF-5 FOR 1 DIV 
 
Control  10ng/ml GDF-5 
   
c.slip no. / field no.                      BrdU(+) cells/field BrdU(+) cells/field   Average/field   Average/field 
 
1.1  16 8    
1.2  25 17    
1.3  11 24    
1.4  11 13  15.8 15.5 
2.1  27 8    
2.2  26 23    
 198 
2.3  24 22    
2.4  48 22  31.3 18.8 
3.1  19 19    
3.2  14 18    
3.3  18 6    
3.4  11 21  15.5 16.0 
4.1  17 13    
4.2  14 31    
4.3  27 20    
4.4  17 12  18.8 19.0 
5.1  21 18    
5.2  13 33    
5.3  21 16    
5.4  20 20  18.8 21.8 
6.1  15 24    
6.2  26 16    
6.3  13 19    
6.4  20 19  18.5 19.5 
 
MEAN     19.8 18.4 
SD     5.8 2.3 
SE     2.4 1.0 
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